The interactomes of ALS/FTD associated poly-GR/PR link protein translation to disease pathogenesis by Hartmann, Hannelore
 
 
 
Aus dem Deutschen Zentrum für neurodegenerative Erkrankungen und dem Adolf-Butenandt-Institut 
im Biomedizinischen Zentrum der Ludwig-Maximilians-Universität München 
Lehrstuhl: Stoffwechselbiochemie 
Vorstand: Prof. Dr. rer. nat. Dr. h. c. Christian Haass 
 
 
The interactomes of ALS/FTD associated 
poly-GR/PR link protein translation to 
disease pathogenesis  
 
Dissertation zum Erwerb des Doktorgrades der Naturwissenschaften 
an der Medizinischen Fakultät der Ludwig-Maximilians-Universität 
München im Jahr 2019 
 
 
vorgelegt von M.Sc. 
Hannelore Hartmann 
geboren am 22. Oktober 1988 in Iaşi 
 
 
 
 
  
II 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Gedruckt mit der Genehmigung der Medizinischen Fakultät der Universität München  
 
Betreuer:     Prof. Dr. rer. nat. Dr. h. c. Christian Haass 
 
Zweitgutachterin:    PD Dr. Florence Bareyre 
Dekan:      Prof. Dr. med. dent. Reinhard Hickel 
Datum der mündlichen Prüfung:  03. Dezember 2019 
 
III 
 
Eidesstattliche Versicherung 
Hartmann, Hannelore 
Name, Vorname 
Ich erkläre hiermit an Eides statt, 
dass ich die vorliegende Dissertation mit dem Thema „The interactomes of ALS/FTD associated poly-
GR/PR link protein translation to disease pathogenesis“ selbständig verfasst, mich außer der 
angegebenen keiner weiteren Hilfsmittel bedient und alle Erkenntnisse, die aus dem Schrifttum ganz 
oder annähernd übernommen sind, als solche kenntlich gemacht und nach ihrer Herkunft unter 
Bezeichnung der Fundstelle einzeln nachgewiesen habe.  
Ich erkläre des Weiteren, dass die hier vorgelegte Dissertation nicht in gleicher oder in ähnlicher Form 
bei einer anderen Stelle zur Erlangung eines akademischen Grades eingereicht wurde. 
 
 
München, den 28.02.2020__     Hannelore Hartmann____________ 
         
 
 
 
 
 
 
 
 
 
  
Unterschrift Doktorandin/Doktorand Ort, Datum 
IV 
 
 
SUMMARY 
 
The (GGGGCC)n repeat expansion within the first intron of the C9orf72 gene is the most common 
known genetic cause of amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD). So far, 
three non-exclusive potential mechanisms underlying C9orf72-mediated neurodegeneration are 
described. First, reduced expression of the mutated C9orf72 allele may impair the physiological 
function of the C9orf72 protein. Second, the repeat-containing RNA accumulates in nuclear foci and 
sequesters RNA-binding proteins, which might trigger a loss-of-function mechanism. And third, 
unconventional repeat associated non-ATG (RAN) translation of the expanded repeat results in 
aggregation-prone dipeptide repeat (DPR) proteins, namely, poly-GA, poly-GP, poly-GR, poly-PR, and 
poly-PA, which are potentially toxic. These DPR proteins are found in cytoplasmic inclusions 
throughout the patient brain. While poly-GA is the most abundant species, poly-GR and poly-PR 
expression is most toxic in many model systems. Although extensive in vitro work has been done on 
the characterization of DPR proteins, their role in disease pathogenesis remains unclear. In order to 
elucidate potential toxic mechanisms underlying the arginine-rich DPR proteins poly-GR and poly-PR, I 
analyzed their interactome in primary neurons and HEK293 cells and validated the results in patient 
tissue.  
I identified close to 600 GFP-(GR)149 and (PR)175-GFP interacting proteins in primary neurons with 
significant overlap, particularly in RNA-binding proteins. Analysis revealed that interactors are 
especially enriched for components of stress granules, the nucleolus, the ribosome, and the splicing 
machinery. Stress granules are cellular membrane-less compartments which form upon cellular stress 
and mainly contain stalled translation pre-initiation complexes. The nucleolus represents the site of 
ribosome biogenesis, while the ribosome itself is a complex molecular machinery responsible for 
protein synthesis. The interactomes of poly-GR and poly-PR in HEK293 corroborate the pathways and 
compartments identified in neurons. 
In order to validate individual interactors, I performed overexpression experiments with over 30 
interacting proteins. I mainly tested interactors associated with stress granules, the nucleolus, and the 
ribosome and their effect on poly-GR/poly-PR localization as well as expression and vice versa. Under 
control conditions, poly-GR is expressed in the nucleolus and diffusely distributes in the cytoplasm, 
whereas poly-PR mainly localizes to the nucleolus in HEK293 cells. In neurons, poly-GR is mainly found 
in the cytoplasm and poly-PR exclusively localizes to the nucleolus. To assess the role of stress granules, 
I co-expressed the poly-GR/PR interacting stress granule proteins STAU1, STAU2, and YBX1 together 
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with poly-GR/poly-PR in both cell systems. Interestingly, all tested stress granule proteins rerouted 
poly-GR/PR into large cytoplasmic granules which were positive for the stress granule marker G3BP1. 
Importantly, STAU2 colocalizes with poly-GR in C9orf72 patient brains suggesting it is a disease-
relevant interactor. Moreover, closer examination of the nucleolus revealed that poly-PR expression 
disrupts uniform distribution of nucleolar proteins such as NOP56 and Fibrillarin suggesting that also 
nucleolar functions, such as assembly of ribosomes, might be comprised. In addition, expression of the 
nucleolar component NPM1 recruited otherwise cytoplasmic poly-(GR)149 into the nucleolus. 
Regarding the ribosome, expression of toxic nucleolar poly-(PR)175, but not cytoplasmic poly-(GR)149, 
significantly reduced levels of several ribosomal subunits which was accompanied by a comparable 
reduction in overall protein synthesis. Surprisingly, truncated poly-GR versions localized to the 
nucleolus and inhibited translation – like poly-PR. In accordance, boosting protein synthesis by 
overexpression of MEK1 blunted poly-GR/PR toxicity. Most importantly, I detected ribosomal proteins 
in poly-GR/PR inclusions in C9orf72 ALS/FTD brains. This direct interaction between poly-GR/PR and 
the ribosome was confirmed in vitro. 
In summary, this study provides the first poly-PR/GR interactome in primary neurons and 
identifies ribosomes as a direct link between the toxicity of poly-GR/PR in vitro and in C9orf72 patients. 
It shows that the two arginine-rich DPR proteins alter stress granule formation, disrupt nucleolar 
organization and reduce ribosomal subunits as well as protein synthesis. Together these findings 
suggest that impaired ribosome biogenesis and/or function may drive acute neurotoxicity underlying 
poly-GR and poly-PR expression in vitro and contribute to chronic toxicity in vivo. These intriguing 
findings might pave ways for new therapeutic strategies targeting C9orf72-mediated ALS/FTD.  
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ZUSAMMENFASSUNG 
 
Eine Verlängerung der (GGGGCC)n Repeatsequenz im nicht-kodierenden Bereich des C9orf72-Gens ist 
als die häufigste genetische Ursache Amyotropher Lateralsklerose (ALS) und Frontotemporaler 
Demenz (FTD) bekannt. Umfangreiche Forschungsarbeiten konnten bisher drei mögliche nicht-
exklusive Mechanismen der C9orf72-assoziierten Neurodegeneration aufdecken. Erstens, wird das 
mutierte C9orf72 Allel geringer exprimiert, so dass die physiologische C9orf72-Funktion beeinträchtigt 
sein könnte. Zweitens, könnte die Akkumulation der Repeat-RNA in nukleäre Foci, durch die 
Sequestrierung von RNA-bindenden Proteinen, zu Neurodegeneration führen. Drittens, entstehen 
durch unkonventionelle Translation der Repeatsequenz fünf aggregationsanfällige Dipeptid Repeat 
(DPR)-Proteine, genauer poly-GA, poly-GP, poly-GR, poly-PR und poly-PA, welche neuronale 
zytoplasmatische Einschlüsse bilden und ebenfalls zu neuronalem Zelltod beitragen könnten. Während 
poly-GA die am häufigsten vorkommende DPR-Protein-Spezies ist, gelten poly-GR und poly-PR 
allgemein als die toxischsten Aggregat-Typen in vielen Modelsystemen. Obwohl intensiv an der 
Charakterisierung von DPR-Proteinen und deren Auswirkungen gearbeitet wird, bleibt ihre exakte 
Rolle im Krankheitsverlauf weiterhin unklar. Um den Beitrag der Arginin-reichen DPR Proteine poly-GR 
und poly-PR zur zellulären Toxizität zu entschlüsseln, habe ich in dieser Arbeit umfangreiche 
Interaktom-Studien in primären Neuronen und HEK293 Zellen durchgeführt und die Ergebnisse in 
Patientengewebe validiert.  
Ich konnte nahezu 600 GFP-(GR)149- und (PR)175-GFP-interagierende Proteine in primären 
Neuronen identifizieren und zeigen, dass die beiden DPR-Proteine zahlreiche RNA-bindende 
Interaktoren gemeinsam haben, darunter Splicing-, Stress Granule-, Nukleoli- und 
Ribosomkomponenten. Sogenannte Stress Granules sind zelluläre membranlose Kompartimente, 
welche sich aufgrund von zellulärem Stress bilden und hauptsächlich aus blockierten 
Translationskomplexen bestehen. Der Nukleolus stellt den Ort der Ribosombiogenese dar und das 
Ribosom ist die molekulare Maschine, welche für die Proteinsynthese zuständig ist. In den poly-GR/PR-
Interaktomen von HEK293-Zellen waren Proteine mit Funktionen in ähnlichen zellulären Vorgängen 
und Kompartimenten angereichert.  
Um verschiedene Interaktoren individuell zu validieren, führte ich Überexpressionsexperimente 
mit über 30 poly-GR- und poly-PR-bindenden Proteinen durch. Dabei untersuchte ich hauptsächlich 
Proteine aus Stress Granules, dem Nukleolus und Ribosomen. Unter Kontroll-Bedingungen war poly-
GR in HEK293-Zellen im Nukleolus und diffus im Zytoplasma zu finden, während poly-PR primär im 
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Nukleolus lokalisierte. In Neuronen verteilte sich poly-GR gleichmäßig im Zytoplasma. Poly-PR 
lokalisierte ausschließlich im Nukleolus. Um die Rolle der Stress Granules in poly-GR/PR-vermittelter 
Toxizität aufzudecken, ko-exprimierte ich die Stress Granule-Proteine STAU1, STAU2 und YBX1 
zusammen mit poly-GR/poly-PR in beiden Zellsystemen. Interessanterweise führte dies zu der Bildung 
großer zytoplasmatischer Einschlüsse, in welchen nicht nur die jeweiligen Stress Granule-Proteine, 
sondern auch poly-GR und poly-PR akkumulierten. Darüber hinaus kolokalisierte STAU2 mit poly-GR-
Einschlüssen in C9orf72-ALS/FTD-Patienten und wurde so auch im menschlichen Gewebe als Interaktor 
validiert. Weiterhin ergab die Untersuchung des Nukleolus in Neuronen, dass poly-PR die ansonsten 
gleichmäßige Verteilung nukleolärer Proteine wie NOP56 oder Fibrillarin erheblich stört und somit 
auch nukleoläre Funktionen, wie die Zusammensetzung der Ribosomen, beeinträchtig sein könnten. 
Zudem wurde zytoplasmatisches poly-(GR)149 von NPM1, einem Protein, welches Aufgaben in der 
Ribosombiogenese übernimmt, in den Nukleolus rekrutiert. Anschließend ergab die detaillierte 
Analyse ribosomaler Proteine, dass die Expression des toxischen, nukleolären poly-(PR)175, aber nicht 
die des zytoplasmatischen poly-(GR)149, die Proteinmenge von mehreren ribosomalen Untereinheiten 
in Neuronen herabsetzt und dies mit vergleichbarer Reduktion der Proteinsynthese einhergeht. 
Interessanterweise wurden ähnliche Effekte mit einer verkürzten poly-GR-Version erzielt, welche im 
Nukleolus lokalisierte und nachweislich toxisch war. Steigerung der Proteinsynthese durch MEK1 
reduzierte die zelluläre DPR-Toxizität. Die bedeutendste Beobachtung dieser Arbeit jedoch ist, dass 
ribosomale Untereinheiten in poly-GR/PR Einschlüssen in C9orf72-ALS/FTD Gehirnen zu finden sind. 
Diese direkte Interaktion konnte ich auch in vitro bestätigen. 
Insgesamt enthält diese Arbeit die erste poly-PR/GR-Interaktom-Studie in primären Neuronen 
und identifiziert Ribosomen als direkte Verbindung zwischen poly-GR/PR-Toxizität in vitro und in 
C9orf72-Patienten. Sie zeigt, dass die beiden Arginin-reichen DPR-Proteine Stress Granules 
beeinflussen, die Organisation des Nukleolus stören und sowohl Ribosom-Menge als auch 
Proteinsynthese reduzieren. Zusammen implizieren diese Beobachtungen, dass eine beeinträchtigte 
Ribosombiogenese und/oder -funktion die Ursache von poly-GR- und poly-PR-vermittelter 
Neurotoxizität sind. Diese Erkenntnisse könnten zu neuen Therapiestrategien für C9orf72-ALS/FTD 
führen.  
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1. INTRODUCTION 
 
 Amyotrophic lateral sclerosis and frontotemporal dementia  
 
Amyotrophic lateral sclerosis (ALS) and frontotemporal lobar dementia (FTD) are two devastating 
neurodegenerative diseases with no available cure or causal therapy so far. Both diseases are rapidly 
progressing with a typical onset at ~55 and <65 years, respectively (Chio et al., 2013; Vieira et al., 2013). 
With an incidence of 5.4/100,000 per year, ALS is considered the most common neurological disorder 
affecting the upper and lower motor neurons (Chio et al., 2013). FTD occurs with an incidence of 2.7-
4.1 per 100,000 and represents the third most common form of dementia following Alzheimer’s 
disease and Lewy bodies-associated dementia (Onyike and Diehl-Schmid, 2013; Vieira et al., 2013). 
Over the years it became clear that ALS and FTD are linked by overlapping clinical symptoms, pathology 
and genetics and thereby represent two extremes in a disease spectrum. 
 Clinical features of ALS and FTD  
In 1869, Jean-Martin Charcot described ALS as a separate disease for the first time. The French 
neurologist observed progressive paralysis with and without contractures as well as muscle atrophy in 
affected individuals and linked these symptoms to motor neurons in the brain and spinal cord (Kumar 
et al., 2011). Today, hyperreflexia, spasticity, progressive muscle weakness and atrophy are considered 
the major symptoms of ALS. Disease often starts in the limbs, rapidly spreads to other muscle groups 
and ultimately leads to respiratory failure (Van Damme and Robberecht, 2009) defining ALS as a 
relentlessly progressive disease (Talbot, 2009). After symptom onset, 50% of patients die within 30 
months and about 20% of patients survive 5 years. After 10 years, only a small percentage of patients 
is alive. 
 In FTD, first described by Arnold Pick, three different variants are distinguished based on the 
predominant clinical symptoms, namely behavioral variant FTD (bvFTD) and primary progressive 
aphasia (PPA). The latter is subdivided in semantic dementia (SD) and progressive non-fluent aphasia 
(PNFA). The most common form of FTD, bvFTD, is characterized by changes in social conduct and 
personality expressed by apathy, inappropriate or ritualistic behaviors, inertia or loss of sympathy 
emerging from degeneration in the frontal lobe. (Bang et al., 2015). The most pronounced symptoms 
of SD are impaired naming and word comprehension resulting from early asymmetrical degeneration 
of anterior temporal lobes and amygdala (Josephs et al., 2008; Seeley et al., 2005). Lastly, patients with 
PNFA show slow, effortful and halted speech production as well as agrammatism. Over time, all three 
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FTD syndromes converge and lead to global cognitive impairment. The bed-ridden patients usually die 
from pneumonia or secondary infections (Bang et al., 2015).  
Interestingly, 15% of FTD diagnosed patients are estimated are estimated to develop 
symptoms consistent with a typical definition of ALS (Goldman et al., 2005; Rosso et al., 2003) and vice 
versa, up to 50% of ALS patients present some FTD-like symptoms (Abrahams et al., 2004; Mackenzie 
and Feldman, 2005) providing evidence that ALS and FTD are two distinct ends of a broad disease 
spectrum. Therefore, patients representing both ALS and FTD symptoms are referred to as ALS/FTD 
patients.  
 Pathological features and genetics of ALS/FTD 
Pathologically, ALS shows loss of upper motor neurons, located in the cerebral cortex, and lower motor 
neurons, found in the brainstem and spinal cord while FTD is associated with degeneration of the 
frontal and temporal lobe. Nonetheless, in both disorders, common pathological protein inclusions are 
found in different areas of the brain which are thought to eventually cause cell death (Ferrari et al., 
2011). In ALS, the pathological hallmarks are mainly transactive response (TAR) DNA binding protein 
(TDP-43), superoxide dismutase (SOD1) and Fused in sarcoma (FUS) inclusions being present in 97%, 
2% and <1% of patient brains, respectively (Ling et al., 2013). In FTD, 45% of cases display TDP-43 
aggregates and another 45% have mainly hyperphosphorylated TAU inclusions. FUS aggregates 
account for 9% of FTD cases, the remaining 1% show aggregates that can only be stained with markers 
for the ubiquitin proteasome system. Together, TDP-43 and FUS pathological inclusions are most 
abundant in both ALS and FTD (Figure 1-1A and B).  
However, ALS and FTD do not only share similar types of neuropathological inclusions, but also 
show overlapping genetic features. Although most ALS and FTD cases are sporadic, familial ALS (fALS) 
and FTD (fFTD) caused by mutations in various genes, account for approximately 10% and 40% of 
patients, respectively, and are mostly inherited in an autosomal-dominant manner (Boylan, 2015; 
Rohrer et al., 2009). In the last years, a variety of genes was linked to either pure ALS, pure FTD or 
mixed ALS/FTD. SOD1 is the gene which is most strongly associated with pure ALS and is found to be 
mutated in up to 20% of familial and up to 2% of sporadic cases (Al-Chalabi et al., 2012). Also mutations 
in the genes TARDBP, encoding for TDP-43, and FUS are connected specifically to ALS in 9% of familial 
patients (Renton et al., 2014). As both TDP-43 and FUS harbor RNA-binding domains and have 
important functions in RNA processing, genetics suggests that RNA homeostasis might be 
dysfunctional in ALS disease pathogenesis.  
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Genes associated with pure FTD are microtubule-associated protein Tau (MAPT) and progranulin (GRN) 
as well as charged multivesicular body protein 2b (CHMP2B) and triggered receptor expressed on 
myeloid cells 2 (TREM2) (Borroni et al., 2014; Isaacs et al., 2011; Le Ber, 2013; Rayaprolu et al., 2013). 
Beyond the mutations linked to either ALS or FTD, several genes provide a direct molecular link 
between the two disorders. Among others, mutations in sequestosome 1 (SQSTM1), optineurin (OPT), 
valosin-containing protein (VCP) and ubiquilin 2 (UBQLN2) were identified in both diseases. Since all of 
the commonly affected proteins are involved in major clearance pathways of the cell, impairment of 
protein homeostasis is suggested to be a shared toxic mechanism of ALS and FTD. Most importantly, 
mutations in chromosome 9 open reading frame 72 (C9orf72) were discovered to be highly abundant 
in patients with ALS, FTD, and ALS/FTD. The C9orf72 mutation can explain up to 40% of fALS and 25% 
of fFTD (Majounie et al., 2012) thereby representing the most common known causal mutation in both 
neurological disorders (Figure 1-1C). 
45%
45%
97%
 
TAU
 
FTDALS
ALS
FTD
5%
5% 30%
30%
MAPT
FUS SQSTM1
VCP
OPT
TDP-43
SOD1
GRN
CMP2B
TREM2
UBQLN1
C9orf72
Figure 1-1: ALS and FTD are two ends of a disease spectrum - schematic illustration of neuropathological inclusions and genes 
associated with ALS and FTD.  
(A, B) Neuropathological inclusions found in ALS and FTD classified according to the main accumulated protein. TDP-43 and 
FUS represent common inclusions (C) The ALS and FTD phenotypes are presented along the Y- and X-axis. Genetic mutations 
in SOD1, TDP-43 and FUS result in a pure ALS phenotype, TREM2, CHMP2B, GRN and MAPT in a pure FTD one. Genes depicted 
in violet result in ALS/FTD. The more the gene is located towards the end of the axis, the more frequent the mutation is. The 
most frequent gene mutated in both ALS and FTD is C9orf72. Adapted from Ling et al. (2013). 
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 The C9orf72 nucleotide repeat expansion 
 
The hexanucleotide GGGGCC repeat expansion within the non-coding region of the C9orf72 gene was 
first discovered in 2011 (DeJesus-Hernandez et al., 2011; Renton et al., 2011). Depending on which of 
the three C9orf72 transcript variants is formed, the repeat is located either in the first intron between 
exon 1a and 1b or in the promoter region of the gene. While the sequence only harbors up to 23 
repeats in healthy individuals, the repeat in C9orf72-mediated ALS/FTD cases is expanded to hundreds 
or even thousands of base pairs (DeJesus-Hernandez et al., 2011; Renton et al., 2011). However, the 
exact repeat length is not inherited as it has been shown that the GGGGCC sequence is unstable at a 
length above 20 repeats and might shrink or expand during germline or somatic transmission (Beck et 
al., 2013). Since most people harbor either very short (2-3) or very long repeats (>400), an exact cutoff 
for pathogenicity is not known. Surprisingly, there is no strong correlation between repeat length and 
clinical phenotype (Beck et al., 2013; Gijselinck et al., 2016).  
 Clinical and pathological representation of C9orf72-mediated ALS/FTD 
Nonetheless, independent of repeat length, patients carrying the C9orf72 mutation show an earlier 
age of onset, shorter survival and a higher decline of cognitive and behavior functions compared to 
ALS/FTD cases without C9orf72 expansion (Byrne et al., 2012; Chio et al., 2012) underlining the 
importance of the expansion in disease progression. Although patients harboring the C9orf72 repeat 
expansion initially present highly heterogeneous clinical symptoms, the mutation typically leads to ALS 
and FTD in the end – an observation which differs from non-C9orf72 ALS and FTD patients (Byrne et 
al., 2012; Stewart et al., 2012).  
Nearly all C9orf72 mutation carriers show TDP-43 cytoplasmic inclusions in the frontal and 
temporal or motor cortex, as well as the spinal cord reflecting the main regions of neurodegeneration 
(Hsiung et al., 2012; Stewart et al., 2012). In addition to TDP-43 pathology, other neuronal cytoplasmic 
inclusions were found which are positive for markers of the UPS system, such as p62, but are TDP-43 
negative. These inclusions are present in the cerebellar cortex, hippocampus and, all neocortical 
regions and are unique to patient brains with the C9orf72 mutation (Al-Sarraj et al., 2011). The nature 
of these p62-positive/TDP-43-negative inclusions will be discussed in more detail in 1.2.4.2. 
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 Toxic mechanisms underlying the C9orf72 repeat expansion 
Currently, three main non-exclusive mechanisms are suspected to cause C9orf72-associated 
neurodegeneration. The first potential pathomechanism implies that the C9orf72 protein loses its 
function due to decreased transcription and therefore expression of the repeat containing gene 
(haploinsufficiency). The second mechanism infers that the (GGGGCC)n expansion might gain toxic 
function upon transcription and accumulation of repeat RNA which potentially sequesters RNA-binding 
proteins (RBPs)(RNA mediated toxicity). Finally, it has been shown that unconventional bi-directional 
transcription and translation of the C9orf72 repeat leads to expression of aggregation-prone dipeptide 
repeat (DPR) proteins. These proteins are toxic in various model systems and may interfere with 
several cellular pathways (protein mediated toxicity) (Fehler! Verweisquelle konnte nicht gefunden 
werden.). In the following chapters, these three mechanisms are described in more detail.  
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Figure 1-2: Postulated pathomechanisms underlying C9orf72-mediated ALS/FTD.  
Schematic illustrations with overview of three potential mechanisms how the C9orf72 repeat might cause neurodegeneration. 
The C9orf72 repeat is depicted in grey, the non-coding region in blue and the coding region in violet. (A) The C9orf72 repeat 
expansion hinders transcription of the gene which may impair C9orf72 protein function (haploinsufficiency). (B) Two gain of 
function mechanisms are postulated: The repeat RNA is forming secondary structures and binds RNA-binding proteins (RBPs, 
in red) (RNA mediated gain of function) or the repeat RNA is translated (in sense and antisense direction) into aggregation-
prone DPR proteins, namely poly-GA, poly-GP, poly-GR, poly-PR and poly-PA (DPR protein mediated gain of function). 
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 C9orf72 loss of function 
Alternative splicing of the C9orf72 transcript results in three transcript variants with variant 1 encoding 
a short protein isoform and variants 2 and 3 encoding the full-length isoform (Figure 1-3). Already the 
initial report of the C9orf72 mutation showed that the repeat expansion leads to reduced variant 2 
C9orf72 transcript levels in the frontal cortex and lymphoblast cells of individuals harboring the repeat 
(DeJesus-Hernandez et al., 2011).  
 
 
 
Figure 1-3: Scheme of genomic C9orf72 structure and its pre-mRNA splicing products. 
Transcript variant 1 encodes for the short C9orf72 isoform, whereas transcript variant 2 and 3 encode for the long C9orf72 
isoforms. Blue boxes represent noncoding and violet boxes represent coding exons. Positions of the (GGGGCC)n repeat 
(grey), the start codon (ATG) and the 3’UTR are indicated. 
 
Others confirmed decreased C9orf72 transcript as well as protein levels in affected brain tissues and 
cultured cells of mutation carriers (Belzil et al., 2013; Frick et al., 2018; Gijselinck et al., 2016; Renton 
et al., 2011). This reduction in C9orf72 expression suggests haploinsufficiency may play a role in disease 
pathogenesis. However, the exact function of the C9orf72 protein is just emerging.  
C9orf72 is most closely related to the DENN (differentially expressed in normal and neoplastic 
cells) domain containing proteins. Therefore, it is predicted to have functions as a GDP/GTP exchange 
factor (GEF) that activates Rab-GTPases (Levine et al., 2013; Zhang et al., 2012). In line with this, it was 
reported that C9orf72 activates Rab1a thereby mediating trafficking of the ULK1 autophagy initiation 
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complex to the phagophore (Webster et al., 2016; Yang et al., 2016). In addition, C9orf72 forms a 
complex with SMRC8 and WDR41 directly linking it to the autophagy pathway (Jung et al., 2017; Sellier 
et al., 2016; Yang et al., 2016). Concomitantly, depletion of C9orf72 in vitro mitigates autophagy 
leading to build-up of p62-positive inclusions as well as TDP-43 (Sellier et al., 2016; Webster et al., 
2016) suggesting that loss of C9orf72 plays a role in disease development. Knockdown of C9orf72 in 
zebrafish, for example, mediated by injection with antisense morpholino oligonucleotides, leads to 
altered axonal branching and locomotion impairment further strengthening this hypothesis (Ciura et 
al., 2013). Furthermore, Shi and colleagues confirm that reduced C9orf72 protein levels are sufficient 
to cause neurodegeneration by accumulation of glutamate receptors leading to excitotoxicity (Shi et 
al., 2018) 
Conversely, in mice, neither knockdown nor knockout of C9orf72 results in neurodegeneration 
or ALS/FTD-related phenotype such as TDP-43 pathology (Atanasio et al., 2016; Burberry et al., 2016; 
O'Rourke et al., 2016). Instead, these mice show enlarged spleens and lymph nodes linking the C9orf72 
protein to the immune system (Atanasio et al., 2016). Also, C9orf72 knockout in mice leads to an 
altered immune response of microglia (O'Rourke et al., 2016). However, instead of showing a more 
severe phenotype, the clinical symptoms of a patient homozygous for the C9orf72 repeat expansion 
does not differ from the ones in heterozygote patients (Fratta et al., 2013). Taken together, the 
observations made in mice and diseased human individuals strongly indicate that loss of C9orf72 is not 
sufficient to trigger full disease pathology including neurodegeneration.  
 C9orf72 gain of function 
A second way how the C9orf72 nucleotide repeat expansion might contribute to disease pathogenesis 
is through gain of toxic function of repeat containing RNA or dipeptide repeat proteins. 
 RNA mediated toxicity 
One pathological feature typical for many diseases associated with repeat expansions is the formation 
of RNA foci containing the repeat RNA. Also in myotonic dystrophy, RNA foci emerging from the CTG 
nucleotide repeat are toxic as they interfere with normal cellular functions of several RNA binding 
factors, such as the muscleblind-like proteins (Miller et al., 2000). An initial study shows that these foci 
also accumulate in nuclei within the cortex and spinal cord of C9orf72-associated FTD patients 
(DeJesus-Hernandez et al., 2011). Subsequently, RNA foci, which form after transcription of the sense 
and antisense strand, were found in neurons, but also astrocytes, microglia and oligodendrocytes of 
ALS/FTD patients as well as cell culture models expressing the repeat (Cooper-Knock et al., 2015; 
Donnelly et al., 2013; Gendron et al., 2013; Lagier-Tourenne et al., 2013; Mizielinska et al., 2013; Mori 
et al., 2013a; Sareen et al., 2013; Zu et al., 2013). Here, RNA foci predominantly localize to the nucleus 
INTRODUCTION 
21 
 
but are also found in the cytoplasm of patient derived fibroblasts (Donnelly et al., 2013; Lagier-
Tourenne et al., 2013; Sareen et al., 2013). Generally, these RNA foci are highly stable as they form 
secondary and tertiary structures, which may include G-quadruplexes and hairpins.  
The repeat containing RNA foci might cause toxicity similar to sequestration of muscleblind-
like protein 1 (MBNL1) by (CUG)n RNA in myotonic dystrophy type 1. The (GGGCC)n repeat may 
sequester essential RNA-binding proteins (RBPs) leading to impairment of their normal function in 
various molecular cascades such as RNA processing, RNA localization or translation. One major protein 
family trapped by the GGGGCC and CCCCGG repeat are the heterogeneous nuclear ribonucleoproteins 
(hnRNPs) (Cooper-Knock et al., 2015; Cooper-Knock et al., 2014; Lee et al., 2013; Mori et al., 2013b). 
Additional proteins which are found to colocalize with C9orf72 RNA foci including the splicing factors 
ALYREF (Cooper-Knock et al., 2015; Cooper-Knock et al., 2014) and SRSF2 (Cooper-Knock et al., 2015; 
Cooper-Knock et al., 2014), the transcriptional regulator Pur-α (Sareen et al., 2013; Xu et al., 2013), the 
nucleolar protein Nucleolin (NCL) (Haeusler et al., 2014) and RanGAP1 (Zhang et al., 2015), a protein 
involved in nucleocytoplasmic transport. Although dysregulation of splicing and alternative 
polyadenylation have been reported in C9orf72 patient brains (Conlon et al., 2016; Prudencio et al., 
2015), none of the RNA interactors have been connected to neuronal injury and it remains to be 
elucidated whether loss of one or more of the sequestered RBPs contributes to disease pathology.  
 Protein mediated toxicity 
As mentioned earlier, abundant p62-positive/TDP-43-negative inclusions are found in C9orf72 patient 
brains. These inclusions remained uncharacterized until it was found that the repeat is being 
transcribed and translated. The ability of repeat containing RNA to form secondary structures such as 
hairpins enables the transcript to undergo so-called repeat-associated non-ATG (RAN) translation. This 
type of unconventional translation was first identified in the microsatellite expansion disease 
spinocerebellar ataxia type 8 (SCA8) and was found to occur in absence of an ATG start codon (Zu et 
al., 2011).  
RAN translation of the hexanucleotide repeat in C9orf72 gives rise to five different dipeptide 
repeat (DPR) protein species from six different reading frames. Translation of the sense transcript 
results in poly-glycine-proline (poly-GP), poly-glycine-alanine (poly-GA) and poly-glycine-arginine 
(poly-GR) peptides and translation of the antisense strand leads to poly-proline-arginine (poly-PR), 
poly-proline-alanine (PA) and further poly-glycine-proline (poly-GP) peptides (Ash et al., 2013; Mori et 
al., 2013a; Mori et al., 2013c; Zu et al., 2013). The DPR proteins are prone to aggregation and 
accumulate throughout the brain of C9orf72 mutation carriers showing highest abundance in the 
cerebellum, hippocampus, thalamus, amygdala, and the motor, temporal and frontal cortex (Figure 
1-4). They show only moderate pathology in subcortical areas and are infrequent in lower motor 
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neurons of the spinal cord (Ash et al., 2013; Mackenzie et al., 2013; Mori et al., 2013a; Zu et al., 2013). 
This neuroanatomical distribution is highly consistent among C9orf72 positive cases irrespective of 
clinical symptoms. Notably, there is no correlation observed between DPR expression and areas of 
neurodegeneration (Mackenzie et al., 2013). However, one has to keep in mind that DPR proteins are 
also present in soluble forms and may, therefore, be difficult to visualize in patient tissue. Additionally, 
highly toxic DPRs might not be detectable anymore due to loss of degenerating neurons. 
DPR proteins form typical star- or dot-shaped neuronal inclusions positive for p62 but show 
little colocalization with phospho-TDP-43 aggregates (Mackenzie et al., 2013; Mann et al., 2013; Mori 
et al., 2013a; Mori et al., 2013c). Furthermore, it has been shown that although the majority of DPR 
proteins is found in large cytoplasmic inclusions in post-mortem tissue they can also be sparsely 
detected in p62-negative para-nucleolar aggregates (Schludi et al., 2015a). 
How individual DPR species contribute to cellular toxicity and thereby neurodegeneration is 
still under intense debate. In the following sections, the specific DPR proteins are examined in more 
detail.  
 Poly-GA is the most abundant DPR species in patients 
Among the five DPR species in C9orf72-ALS/FTD, only poly-GA is found in nearly all TDP-43 negative 
inclusions. Short poly-GA peptides form amyloid-like structures containing characteristic cross-β 
sheets (Chang et al., 2016). Cryo-electron tomography of poly-GA inclusions in cultured neurons 
revealed densely packed twisted ribbons that are highly enriched in 26S proteasome, linking poly-GA 
to impaired proteasomal degradation (Guo et al., 2018). Supporting this connection, poly-GA also 
sequesters several proteasome-linked proteins in vitro, with p62 and UBQLN1 among them (May et 
al., 2014; Schludi et al., 2015a). Thus, disruption of the ubiquitin-proteasome system (UPS) might 
trigger the toxicity seen in cell culture and flies upon poly-GA expression (May et al., 2014; Mizielinska 
et al., 2014; Yamakawa et al., 2015; Zhang et al., 2014). Consistent with the toxicity observed in cellular 
models, mice expressing GFP-(GA)50 show neuronal loss and astrogliosis along with motor and 
cognitive deficits (Zhang et al., 2016). Furthermore, poly-GA expression shortens life span in transgenic 
flies (Mizielinska et al., 2014)  
poly-GRpoly-PRpoly-GA
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Figure 1-4: Dipeptide repeat proteins in the human cortex of C9orf72 brains tissue  
Immunofluorescence images of three different dipeptide repeat protein species in the human brain of C9orf72 patients. Poly-
GA, poly-PR and poly-GR aggregates are depicted in green. The nuclei are stained with DAPI in blue.  
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Besides UPS impairment, poly-GA aggregation causes mislocalization of nuclear pore 
components such as Pom121 and RanGAP1 in vivo (Zhang et al., 2016). In addition, we have shown 
that poly-GA expression hinders nuclear import of a fluorescent reporter containing the TDP-43 
nuclear localization (NLS) signal. Importantly, expression of poly-(GA)175 significantly shifted 
predominantly nuclear TDP-43 into small cytoplasmic TDP-43 granules in primary neurons further 
indicating that poly-GA impairs nucleocytoplasmic transport (Khosravi et al., 2017). Importantly, with 
these findings, we and others could causally connect two major aggregating proteins, namely TDP-43 
and poly-GA, in C9orf72-mediated ALS/FTLD disease.  
Taken together, poly-GA is the most abundant DPR protein species in brains and spinal cord of 
C9orf72 mutation carriers and may contribute to human disease by inhibiting the UPS or 
nucleocytoplasmic transport.  
 Poly-GR and poly-PR are the most toxic DPR species in model systems  
Although there is a general agreement that poly-GA is toxic in several biological systems (May et al., 
2014; Zhang et al., 2014), the arginine-rich DPR proteins poly-GR and poly-PR show significantly higher 
toxicity in side by side comparisons. In fact, they induce toxicity in multiple cell culture and animal 
models including U2OS cells, human astrocytes (Kwon et al., 2014), HEK293T cells, NSC34 cells 
(Kanekura et al., 2016; Tao et al., 2015), primary cortical and motor neurons (Wen et al., 2014), 
neurons derived from induced pluripotent stem cells (iPSCs) (Lopez-Gonzalez et al., 2016; Wen et al., 
2014) and Drosophila (Boeynaems et al., 2016; Freibaum et al., 2015; Lee et al., 2016a; Mizielinska et 
al., 2014; Wen et al., 2014). In the majority of cellular systems, both poly-GR and poly-PR localize to 
the nucleolus, the assembly site of ribosomes. However, in C9orf72-ALS/FTD patient brains poly-GR 
and poly-PR are predominantly found in compact cytoplasmic inclusions and to a lesser extent in para-
nucleolar compartments. When looking at the overall distribution of the two DPR species within the 
brain, poly-GR and poly-PR are most abundant in the frontal, occipital and motor cortex as well as the 
thalamus, hippocampus, and the cerebellar regions. Of note, poly-PR inclusions have been noted to be 
extremely rare and represent about 1% of DPR protein inclusions (Mackenzie et al., 2013; Schludi et 
al., 2015a).  
So far, little is known about the effects of poly-GR and poly-PR on cellular function and the 
mechanisms underlying poly-GR/PR toxicity are just emerging. Initial reports describe how the two 
arginine-rich DPR protein species might interfere with the physiology of the cell in different cell culture 
systems. These findings are described in the next paragraphs.  
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Poly-GR/PR expression impairs the dynamics of membrane-less organelles  
In order to approach the mechanisms contributing to poly-GR and poly-PR associated 
neurodegeneration, Lee and colleagues performed a proteomic study in poly-GR and poly-PR 
expressing HEK293 cells. Analysis revealed that poly-GR/PR interactors are enriched in RNA-binding 
proteins containing low complexity domains (LCDs). While only 35.8% of human proteins harbor LCDs, 
up to 67.9% of poly-GR/PR interactors contained low complexity sequences (Lee et al., 2016a). LCDs 
show low amino acid diversity and often harbor mainly glycine and serine interspersed with aromatic 
and charged residues (Uversky et al., 2015). Proteins with LCDs can undergo low-affinity interactions 
which are important for them to become rapidly and reversibly concentrated in discrete spots within 
the cell. These interactions are crucial in the formation and function of membrane-less organelles such 
as nuclear speckles, the nuclear pore complex (NPC), stress granules, and the nucleolus which 
represent sites of splicing, nucleocytoplasmic transport, stalled translation complexes, and ribosome 
biogenesis, respectively. Under certain conditions, these intermolecular biophysical interactions, 
however, drive phase separation of the LCD containing proteins and clustering in liquid droplets which 
have the property to propagate into hydrogels comprised of amyloid-like fibers. This process is called 
liquid-liquid phase separation (LLPS).  
Liquid phase transition has been shown to occur in a variety of poly-GR and poly-PR interactors 
with NPM1, TIA1 or FUS being among them (Lee et al., 2016a; Lin et al., 2016). Moreover, the ALS-
linked RBPs hnRNPA1 and TDP-43 are able to assemble into protein-rich droplets by LLPS (Molliex et 
al., 2015). Thus, several proteins aggregating in ALS/FTD patients are found to undergo LLPS in vitro. 
As disease-causing mutations in these genes are mostly located within LCDs (Taylor et al., 2016) and 
have the ability to disturb their biophysical properties it is proposed that LLPS is a general disease 
mechanism.  
Both poly-GR and poly-PR are highly charged, basic and polar due to the incorporation of 
arginine residues and have a disordered nature. Thus, they are expected to form flexible structures 
that remain soluble. In vitro, the two DPR species induce liquid droplet formation of NPM1, hnRNPA1, 
and TIA1, proteins found in the nucleolus and SGs, when applied in the right ratios suggesting that 
poly-GR/PR disturb low-affinity interactions. Also, poly-(GR)20 and poly-(PR)20 do phase separate by 
themselves in vitro following the addition of a molecular crowder (Boeynaems et al., 2017).  
Thus, a complementary mechanism how poly-GR and poly-PR might contribute to C9orf72 
pathogenesis is by disruption of the assembly and dynamics of membrane-less organelles such as 
nuclear speckles, the NPC, stress granules or the nucleolus through disturbance of the LLPS properties 
of their resident proteins. However, all approaches so far were performed in vitro, with pure proteins 
and/or in high molecular ranges and no co-aggregation was reported in patient tissue. Consequently, 
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further experiments are needed in order to prove that these relations occur under physiological 
conditions.  
 
Poly-GR and poly-PR lead to aberrant splicing in cell culture systems 
Another putative mechanism by which the two DPR species might lead to toxicity is their effect on 
mRNA splicing. The first study describing altered splicing in vitro was by Kwon and colleagues who 
exposed human astrocytes to PR20 synthetic peptide and subsequently analyzed the extracted RNA by 
deep sequencing. Analysis revealed ~5,000 mis-spliced RNA transcripts resulting from altered RNA 
processing such as exon skipping or intron retention (Kwon et al., 2014). In concordance, classification 
analysis of the interactome of poly-PR20 in treated NSC34 cells revealed mRNA splicing as the second 
most enriched gene ontology category (Kanekura et al., 2016). This was also true for a more recent 
study with GR20 or PR20 peptides in which mostly the U2 snRNP complex was enriched. In line with the 
findings in vitro, also in C9orf72 patient cerebella and cortices, U2-dependent exons, mostly linked to 
mitochondrial functions, were preferentially mis-spliced (Yin et al., 2017). Together with the 
widespread transcriptome changes found in familial and sporadic ALS patient brains (Prudencio et al., 
2015) splicing could further be shown to be deregulated in C9orf72-mediated ALS/FTD, but it is not 
known whether poly-GR and poly-PR play a role in disruption of this process in patients.  
 
Poly-GR and poly-PR cause oxidative and ER stress in vitro 
Poly-GR and poly-PR have also been associated with toxic effects in mitochondria and the endoplasmic 
reticulum (ER). As mentioned above, transcripts of mitochondrial genes were found to undergo 
aberrant splicing, including COX16 and TIMM9 and the mitochondrial ribosomal proteins MRPL52 and 
MRPS31 suggesting that mitochondrial function may be comprised. And indeed, mitochondria in 
patient-derived C9orf72 iPSC motor neurons and neurons expressing poly-(GR)80 show increased 
membrane potential accompanied by elevated production of reactive oxygen species (ROS) and 
increase in DNA damage (Lopez-Gonzalez et al. 2016) suggesting a role of poly-GR in oxidative stress. 
Whether these defective mitochondria also show altered mitochondrial respiration or morphology has 
not been addressed. Additionally, these in vitro effects have not been validated in patient tissue.  
 Besides oxidative stress, also ER stress was linked to cellular toxicity in (GR)20/(PR)20 peptide 
treated human cells and mouse primary cortical neurons. In a CRISPR/Cas9 knockout screen, Kramer 
et al identified ER-resident proteins and almost all members of the ER-membrane to modulate poly-
GR/PR toxicity, with transmembrane thioredoxin protein (TMX2) being the strongest protective hit. 
Knock-down of TMX2, a protein enriched at the mitochondria-associated membrane of the ER, 
decreased Caspase 3/7 activity and increased ATP levels in poly-PR20 treated neuronal cells suggesting 
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a role of ER stress in DPR-mediated toxicity in cell culture (Kramer et al., 2018). Although IRE1 signaling 
positively correlates with TDP-43 pathology in familial C9orf72-ALS cases (Lee et al., 2016b), there is 
no evidence for a connection between ER stress and poly-GR/poly-PR in patients so far. 
Nucleocytoplasmic transport is comprised in poly-GR/PR expressing cells 
Recently, the nuclear pore complex was linked to poly-GR and poly-PR toxicity. Jovičić et al. identified 
modifier genes involved in nucleocytoplasmic transport in a gain and loss of function screen in yeast. 
In this study, poly-(PR)50 toxicity was mainly modified by nuclear import receptors, NPC components 
and regulators of the Ran-GTPase cycle (Jovicic et al., 2015). To validate hits in vivo, an RNAi screen 
was performed in Drosophila expressing a poly-PR version with 25 repeats. Also here, similar proteins 
were found to be modifiers of poly-PR toxicity (Boeynaems et al., 2016). In line with these findings, 
flies expressing 58 repeats of the GGGGCC expansion showed an abnormal nuclear envelope. Next to 
the defects in architecture of the nuclear envelope, disruption of the Ran-GTP gradient between 
nucleus and cytoplasm was observed in patient derived iPSC neurons. (Freibaum et al., 2015).  
 Overall, these data indicate that the nuclear pore is at least partly dysfunctional in cell culture 
systems harboring the hexanucleotide repeat. In C9orf72-associated ALS motor cortex, RanGAP1, a 
protein that stimulates Ran to hydrolase GTP to GDP, and Nup205, an extremely long-lived NPC 
scaffold protein, exhibit mislocalization (Zhang et al., 2015). However, if these phenotypes ultimately 
lead to nucleocytoplasmic trafficking defects also in patients and if DPR proteins are contributors to 
these findings has not been addressed.  
Poly-GR and poly-PR impair stress granule and nucleolus dynamics 
Stress granules (SGs) are membrane-less cytoplasmic compartments with a very dynamic nature which 
form in response to cellular stress. Upon stress, translational control allows for the regulation of mRNA 
expression and is the mechanism by which the cell protects itself from environmental changes. After 
phosphorylation of the translation initiation factor eIF2α, a variety of proteins, such as RNA-binding 
proteins, transcription factors, and RNA helicases, as well as mRNA accumulate. Binding of the RNPs 
to the mRNA transcripts subsequently prevents translation initiation. These translation inhibition 
complexes are routed into SGs and thus, translational programming is closely linked to SG assembly 
(Anderson and Kedersha, 2009). Importantly, cytoplasmic TDP-43 was found to be trapped in SGs. This 
was validated by colocalization with SG markers (TIA-1, eIF3) in postmortem brains from ALS and FTD 
patients linking SGs to disease (Liu-Yesucevitz et al., 2010). With the finding that mutations in TIA-1 
(Mackenzie et al., 2017) and Ataxin 2 (Elden et al., 2010), two important components of SGs, increase 
the risk for ALS, evidence exists linking C9orf72-mediated toxicity to stress granules also in vivo. 
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 Nucleoli are distinct subnuclear components associated with ribosome biogenesis that consist 
of three separate regions. The fibrillar center (FC) is surrounded by a dense fibrillar component (DFC) 
where pre-ribosomal RNA transcripts are spliced and modified. FC and DFC are both enclosed by the 
granular component (GC) where ribosomal proteins and the ribosomal RNA (rRNA) are assembled 
(Boisvert et al., 2007).  
Although SGs and the nucleolus are in a rapid dynamic equilibrium with the cytoplasm, poly-
GR, as well as poly-PR, have the property to impair this dynamic and stabilize molecular interactions 
as suggested by fluorescence recovery after photobleaching (FRAP) experiments (Figure 1-5A and B). 
Here, nucleolin (NCL), an important protein involved in pre-rRNA transcription and ribosome assembly 
and nucleophosmin 1 (NPM1), connected with ribosome biogenesis and nucleolar export, exhibit 
reduced mobility upon poly-(GR)20/(PR)20 expression (Lee et al., 2016a). Whether these poly-GR/PR 
dependent changes in dynamics affect SG and nucleolar function, such as translational control and 
ribosome assembly, respectively, has not been addressed.  
 
Figure 1-5: Scheme of the impact of poly-GR and poly-PR expression on SGs and the nucleolus in vitro. 
(A) The expression of poly-GR20 and poly-PR20 results in impaired stress granule dynamics as suggested by FRAP experiments 
with SG markers such as TIA-1, eIF3, Stau1 or G3BP. (B) The nucleolus is subdivided into three separate regions – the fibrillary 
center (FC), the dense fibrillar component (DFC) and the granular component. The letter contains several proteins involved in 
ribosome biogenesis or rRNA processing with NCL and NPM1 among them. These two proteins are less mobile upon poly-
GR/PR expression. (C) The pre-ribosomal 45S rRNA is processed into mature 5.8S, 18S and 28S rRNA in the nucleolus. Poly-GR 
and poly-PR expressing cells show reduced levels of mature rRNAs suggesting disturbed rRNA processing.  
 
Interestingly, overexpressed poly-PR exclusively localizes within the nucleolus and poly-GR is 
seen in both, nucleolus and cytoplasm in all in vitro model systems regardless of whether the DPR 
proteins are expressed from a vector or added as synthetic peptides (Boeynaems et al., 2017; Kramer 
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et al., 2018; Kwon et al., 2014; Lee et al., 2016a; Schludi et al., 2015a; Tao et al., 2015; Wen et al., 2014; 
Zhang et al., 2018b). Super-resolution fluorescent imaging revealed that GFP-(GR)50 is recruited to the 
GC and the DFC, while poly-(PR)50 is solely found in the GC (Lee et al., 2016a). Thus, both poly-GR and 
poly-PR are localized to the outer layer of the nucleolus where ribosome assembly takes place (Lee et 
al., 2016a). 
However, so far, none of the DPR protein species was detected in stress granules or the 
nucleolus in patients and therefore validation experiments are needed in order to link poly-GR/PR to 
the two compartments in C9orf72-ALS/FTD pathogenesis.  
 
Poly-GR and poly-PR alter rRNA processing 
One of the first studies linking DPR protein toxicity to the ribosome showed that administration of the 
PR20 peptide to human astrocytes alters RNAs encoding ribosomal proteins and indeed impairs 
processing of the pre-ribosomal 45S rRNA (Kwon et al., 2014). In eukaryotic cells, rRNA processing is a 
tightly regulated process in which the 45S rRNA precursor is first methylated and subsequently cleaved 
and processed into mature 18S, 5.8S, and 28S rRNA. These rRNAs then serve as a scaffold for the 
assembly of ribosomal proteins and execute catalytic functions in translation initiation, elongation, and 
termination (Henras et al., 2015). In poly-PR treated cells, the levels of 5.8S rRNA are reduced by 70% 
providing evidence that altered rRNA processing is underlying DPR toxicity (Kwon et al., 2014). 
Likewise, 18S and 28S rRNA is remarkably decreased upon poly-GR/PR expression in NSC-34 cells (Tao 
et al., 2015). Thus, these findings indicate, that poly-GR and poly-PR comprise rRNA processing in vitro 
(Figure 1-5C). However, many open questions remain: Does this reduction in rRNA processing products 
lead to overall impairment of ribosome biogenesis and if yes, is also protein synthesis altered? Would 
restorage of rRNA processing products rescue poly-GR/PR-mediated toxicity? Is the ribosome also 
affected in C9orf72-ALS/FTD? 
Taken together, the exact mechanism(s) by which the arginine-rich DPR proteins poly-GR and poly-PR 
induce toxicity in C9orf72 pathogenesis are still not quite understood. So far, alternative splicing, 
oxidative and ER stress, mitochondrial and NPC dysfunction, alterations in nucleolus and SG dynamics, 
as well as reduced rRNA processing, have been implicated, nevertheless, detailed analysis of these 
putative toxic mechanisms is missing. Most importantly, all experiments have been performed in 
cellular or animal models and thus, there is no evidence for the significance of these mechanisms in 
C9orf72-ALS/FTD patients yet. 
INTRODUCTION 
29 
 
 The role of poly-GP and poly-PA  
Poly-GP and poly-PA are two DPR species translated from the antisense C9orf72 transcript. While poly-
GP inclusions are highly abundant in C9orf72-associated ALS/FTD brains, poly-PA inclusions are rare. 
Under individual expression in vitro, poly-GP localization is mainly cytoplasmic and poly-PA is localized 
to the nucleus as well as the cytoplasm. Following poly-GP/PA expression or treatment, NCS-34 and 
HEK93 cells, cultured neurons and yeast as well as flies show similar survival as their respective controls 
(Jovicic et al., 2015; Lee et al., 2016a; May et al., 2014; Tao et al., 2015; Wen et al., 2014; Yamakawa 
et al., 2015). Only in zebrafish, poly-PA with a repeat length of 1000 shows an effect on larvae survival 
(Swaminathan et al., 2018). Due to their amino acid residues, these DPR proteins have an uncharged 
nature and might therefore not undergo strong interactions with endogenous cellular proteins (Lee et 
al., 2016a). Therefore, poly-GP and pol-PA are thought to contribute the least to toxicity.  
 Biomarkers in C9orf72-associated ALS/FTD 
Although there is general agreement that DPR proteins contribute to toxicity in cellular and animal 
models, their overall significance in C9orf72-mediated ALS/FTD remains unresolved. To better address 
their role in C9orf72-ALS/FTD pathogenesis it is crucial to monitor individual DPR proteins in patients 
over time. As studies in post mortem tissue cannot provide temporal information, a DPR dependent 
biomarker could serve as a useful tool. Interestingly, in patients with C9orf72-FTD, widespread 
accumulation of DPR proteins within neurons occurs much earlier than TDP-43 pathology (Baborie et 
al., 2015). Thus, it is possible that DPR proteins already exist early in disease or even before its onset 
and therefore might be used as pharmacodynamic biomarkers.  
 So far, poly-GP has been discovered as a potential biomarker candidate as it was shown to be 
readily detectable in the cerebrospinal fluid (CSF) in a small case series of symptomatic ALS patients 
harboring the C9orf72 mutation (Su et al., 2014). Recently, two larger studies built up on this finding 
and showed that poly-GP can indeed be detected in immunoassays and thus serve as a biomarker 
signaling the onset and progression of C9orf72-ALS/FTD. Importantly, poly-GP levels were already 
measurable in asymptomatic C9orf72 mutation carriers and thus can be used to detect target 
engagement of applied C9orf72-directed drugs (Gendron et al., 2017a; Lehmer et al., 2017). In 
contrast, phosphorylated neurofilament heavy chain (pNFH), a marker for axonal damage, was only 
elevated in the symptomatic patients and showed similar levels in ALS cases with or without C9orf72 
mutation. Nonetheless, pNFH levels predict disease progression of ALS patients over time (Gendron et 
al., 2017b) and thus serve as an additional, DPR-independent and prognostic biomarker.  
As poly-GR and poly-PR show far greater toxicity than poly-GP in vitro and in vivo, it is of great 
importance to develop immunoassays also monitoring their protein levels in patients. This may help 
to clarify the defined role of poly-GR and poly-PR in C9orf72-disease progression.  
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 C9orf72 repeat expansion-directed therapies  
Although the exact mechanisms underlying C9orf72-mediated ALS/FTD are not quite understood, gain-
of-function of the repeat-containing RNA is likely essential for pathogenesis as not only potentially 
toxic RNA foci, but also DPR proteins can emerge from it. Therefore, reduction of the repeat-containing 
RNA is a therapeutic option. However, lowering of global C9orf72 transcripts in order to treat RNA-
dependent toxic mechanisms might be disadvantageous in case haploinsufficiency significantly 
contributes to disease pathogenesis.  
 Therefore, antisense oligonucleotides (ASOs), which can be designed to target and inactivate 
specific mRNA sequences, are suitable for therapeutic treatment. Recently, ASOs have been proven to 
be safe in humans and are already applied for therapy of spinal muscular atrophy (Chiriboga et al., 
2016). In a study from April 2018, Liu and colleagues could show that their C9orf72-ASO sequence 
preferentially reduced repeat-containing transcripts in patient-derived iPSC neurons and fibroblasts 
and validated their promising results in C9orf72 BAC transgenic mice. Here, they observed a reduction 
of both RNA foci and DPR proteins without affecting total C9orf72 levels (Liu et al. 2018). Further 
investigation will be needed for their ASO treatment to be approved for therapy as correct targeting, 
efficacy, and efficiency remain to be confirmed also in patients. 
 Another therapeutic approach might emerge from targeting secondary structures occurring in 
repeat containing RNA or specifically inhibit RAN-translation by other means. Here, structure-specific 
small molecules recognize and bind to nucleotides with a defined RNA conformation, such as RNA 
hairpins or G-quadruplexes, as seen in the C9orf72 hexanucleotide repeat transcript. Most recently, it 
was shown that application of compounds binding to the C9orf72 repeat RNA reduced RNA foci and 
poly-GP expression in iPSC-derived spinal motor neurons, cortical neurons, and flies (Simone et al., 
2018). However, it remains an open question whether these compounds might also bind off target or 
inhibit ATG-initiated translation of regular repetitive RNA. Even so, Simone and colleagues pave the 
way for new C9orf72-associated treatment opportunities and provide a serious therapy option to ASOs 
which, in contrast to small molecules, require invasive application.  
 
Although ASOs, RNA-targeting small molecules or other compounds might be viable treatment options 
for C9orf72-ALS/FTD, only clinical trials can show their suitability and efficacy in patients. Ultimately, 
patients can only profit from the fast evolving C9orf72 research field which shows great interest in 
C9orf72-associated therapies.  
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 Translation deregulation in human disease 
 
The ribosome is one of the most accurately constructed and most complex molecular machines of the 
cell. It is the workplace for protein synthesis which itself is a finely tuned process. Translation factors, 
transfer RNAs (tRNAs) and ribosomes need to be coordinated precisely in order to translate the 
information contained in mRNA into a polypeptide chain. Thus, the ribosome, as well as the process of 
translation, are both highly susceptible to malfunction on multiple levels. Consequently, a variety of 
human diseases exist which are linked to ribosome structure and biogenesis, ribosome assembly, tRNA 
modifications, tRNA synthetases and other proteins involved in protein translation (Figure 1-6). 
 Ribosomopathies 
Alterations in ribosomal structure and function can lead to a heterogeneous class of disease termed 
ribosomopathies. Usually, the ribosome is built up of four rRNAs and a large number of ribosomal 
proteins forming a ribonucleoprotein. It comprises two subunits of different size that work as one: the 
small 40S subunit, which binds to the mRNA template, and the large 60S subunit, which binds to the 
tRNA and the amino acids. In eukaryotes, the biogenesis of ribosomes occurs in the nucleolus. For 
transcription of ribosomal proteins, ribosome maturation, rRNA modification, folding and processing 
(described in ‘Poly-GR and poly-PR alter rRNA processing’) as well as ribosome assembly, a plethora of 
factors are needed (Fromont-Racine et al., 2003; Henras et al., 2008; Kressler et al., 2010). Mutations 
in these factors or in ribosomal proteins themselves might result in genetic ribosomopathy.  
In 1999 for example, a mutation in the RPS19 gene was discovered to account for 25% of 
patients suffering from Diamond-Backfan Anemia (DBA) (Draptchinskaia et al., 1999). Since then, more 
mutations have been identified to lead to DBA – 50% to 70% of those affected genes encoding 
ribosomal proteins (Gerrard et al., 2013). The deficiencies in ribosomal proteins result in impaired 
ribosome assembly and decreased translation in cells of both hematopoietic and non-hematopoietic 
lineage, although the disease is characterized by low red cell count (Gazda et al., 2006). Similarly, also 
the 5q-syndrome, which shares clinical and pathologic features with DBA including anemia, is linked to 
haploinsufficiency of another ribosomal protein, namely RPS14 (Ebert et al., 2008). Mutations in DKC1 
and TCOF1, both involved in ribosome biogenesis, play a role in X-linked Dyskeratosis Congenita (Heiss 
et al., 1998) and the Treacher-Collins Syndrome (Dixon, 1996), respectively.  
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Figure 1-6: Scheme of translation deregulation in human disease. 
Translation deregulation in human disease can occur on multiple levels. Disrupted tRNA maturation, dysfunctional aminoacyl tRNA synthases 
or impaired ribosome assembly can all result in disease. Pontocerebellar hypoplasia, for example, is caused by defective tRNA splicing due 
to mutations in components of the tRNA-splicing endonuclease (TSEN) complex and in the polynucleotide kinase CLP1 (also part of TSEN). 
Uridine and adenosine bases are modified by the Elongator Complex and the KEOPS-EKC proteins, respectively. Mutations in these proteins 
cause familial dysautonomia and the Galloway-Mowat syndrome. Mutated ARSs result in disease in two ways: either by non-functional 
synthase activities (Charcot Marie Tooth disease) or non-functional proof-reading activities leading to amino acid (AA) misincorporation and 
misfolded proteins. Ribosomopathies like Diamond-Backfan anemia and the Treacher-Collins syndrome are defined by mutations in either 
ribosomal proteins themselves or proteins associated with ribosome biogenesis such as DKC1 and TCOF1.  
 
 Deregulation of tRNA function is often connected to neurodegenerative diseases 
tRNAs are the adaptor molecules between the information encoded by nucleic acids and the 
information on a protein level. They show a highly conserved as well as complex secondary and tertiary 
structure which is crucial to ensure efficient translation by correct codon-anticodon interactions. tRNA 
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biogenesis involves a multistep maturation process with a cascade of enzymatic reactions. Currently, 
93 post-transcriptional modifications are known (Cantara et al., 2011). These are executed by a variety 
of modulators such as endo- and exonucleases, ligases, kinases, and transferases. The functionality of 
these factors is of major importance as their modifications can lead to enormous tRNA structural 
rearrangements and with it tRNA dysfunction. Mutations in tRNA modifying factors lead to several 
human disorders.  
 For example, pontocerebellar hypoplasia (PCH) is a spectrum of early onset neurodegenerative 
diseases commonly characterized by impaired brain development, muscle weakness and motor 
deficits (Ryan et al., 2000). It is caused by mutations in proteins of the tRNA splicing endonuclease 
complex (TSEN) with TSEN54, TSEN34, TSEN15, and TSEN2 among them (Breuss et al., 2016; Budde et 
al., 2008). Also homozygous mutations in CLP1, an additional factor required for tRNA intron removal 
and ligation, are reported in individuals with PCH (Karaca et al., 2014; Schaffer et al., 2014). These 
mutations result in reduced affinity of individual components of the complex which leads to altered 
enzymatic activity and defects in tRNA splicing. Schaffer et al. suggest a subsequent accumulation of 
tRNA fragments including ‘half’ tRNAs which are known to inhibit protein translation (Sobala and 
Hutvagner, 2013). Further neurodegenerative diseases associated with dysfunctional tRNA include 
Familial Dysautonomia (mutation in the Elongator complex which is in charge of uridine modifications) 
(Anderson et al., 2001) and Galloway-Mowat syndrome (mutation in the KEOPS-EKC complex which is 
in charge of adenosine modifications) (Braun et al., 2017).  
 Mutant aminoacyl tRNA synthetases cause disease in multiple ways 
Aminoacyl tRNA synthetases (ARS) are the enzymes that ligate amino acids (AAs) to their 
corresponding tRNA. These multidomain proteins catalyze the covalent attachment of the AAs to the 
tRNA in a two-step reaction. To ensure the correct translation of mRNA, accurate function of the ARS 
catalytic, as well as editing, activity is necessary (Pang et al., 2014). Predominantly mutations in glycyl-
tRNA, tyrosyl-tRNA, and alanyl-tRNA synthetase have been reported to cause Charcot Marie Tooth 
(CMT) disease (Antonellis et al., 2003; Jordanova et al., 2006; Latour et al., 2010). CMT is the most 
common heritable disorder of the peripheral nervous system and patients suffer from progressive 
muscle weakness and wasting as well as loss of touch sensation. It is hypothesized that the common 
underlying pathogenic mechanism of ARS mutations is inhibition of translation (Storkebaum, 2016).  
 Not only translational inhibition but also misincorporation of false AAs into the nascent poly-
peptide chain can be an outcome of mutations in ARS. Lee et al. report a mutation within the active 
site of the alanyl-ARS editing domain. Normally, mischarged tRNAs would be cleared by the editing 
function of ARS, however, this ARS mutant shows proofreading defects. The subsequent AA 
misincorporation during protein synthesis leads to misfolded or unfolded proteins which accumulate 
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and stress the proteostasis system. Concomitant with the knowledge that protein aggregation 
commonly leads to neuron loss, the most prominent phenotype in their mouse model is 
neurodegeneration (Lee et al., 2006).  
 Evidence for protein translation defects in ALS and FTD 
Experiments in cellular models of ALS/FTD point to a role of in these diseases. TDP-43 knockdown, for 
example, results in alternative splicing of SKAR, an exon junction complex. Subsequently, S6 kinase 
activity is enhanced which in turn leads to increased translation and cell size. Thus, mutant TDP-43 
might regulate translation on a global level (Fiesel et al., 2012). Interestingly, the lysyl-ARS binds to 
mutant but not wild type SOD1, further connecting ALS to translation. In this scenario, lysyl-ARS might 
co-aggregate with mutant SOD1 and thereby be impaired in performing its normal function (Kunst et 
al., 1997). Whether also the DPR proteins poly-GR and poly-PR contribute to alterations in protein 
translation remains elusive. As so far only altered rRNA processing has been implicated, more evidence 
is needed to link the two arginine rich DPR protein species to translation deregulation.  
Taken together, disorders associated with deregulation of protein translation often belong to the 
group of neurodegenerative diseases. It would be rewarding for the ALS/FTD field to elucidate whether 
altered protein synthesis also contributes to neurodegeneration in these patients.  
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2. AIM OF THIS WORK 
 
Despite several proposed pathomechanisms, it is still largely unclear how the C9orf72 repeat 
expansion and in particular the individual dipeptide repeat (DPR) proteins mediate toxicity ultimately 
leading to neurodegeneration in patients. Several studies showed that poly-GA impairs the ubiquitin 
proteasome system and interferes with nucleocytoplasmic transport (Guo et al., 2018; Khosravi et al., 
2017; May et al., 2014; Mizielinska et al., 2014; Yamakawa et al., 2015). However, while poly-GA is the 
most abundant DPR species in patient brains, poly-GR and poly-PR are more toxic in cell culture and 
animal models (Kanekura et al., 2016; Kwon et al., 2014; Lee et al., 2016a; Lopez-Gonzalez et al., 2016; 
Tao et al., 2015; Wen et al., 2014). When I started my dissertation in the Edbauer lab, little was known 
about the role of arginine-rich DPR proteins in relation to neurodegeneration. At that time, only two 
groups had published their results on the mechanistic contribution of poly-GR/PR to disease pathology. 
Their studies revealed that the two DPR protein bind nucleoli, induce stress granule formation, impair 
mRNA splicing and disrupt rRNA processing in vitro (Kwon et al., 2014; Wen et al., 2014).  
Based on these findings, the major aim of my work was to further elucidate by which 
mechanisms poly-GR and poly-PR contribute to cellular toxicity and determine their relevance in 
C9orf72 patients. An extensive interactome study based on mass spectrometry in primary neurons and 
HEK293 cells should identify the major proteins sequestered by the arginine-rich DPR proteins. In 
parallel, the global effects of poly-GR/PR on the neuronal proteome should be monitored. A system 
level enrichment analysis of the protein networks should be used to prioritize specific interactors from 
key cellular compartments for individual detailed analysis using a variety of methods including 
validation of co-aggregation in patient tissue. Finally, specific interactors and common identified 
pathways should be tested for modulation of poly-GR and poly-PR toxicity.  
Since my aim was to reveal potential pathogenic disease mechanisms, the used models should 
resemble the disease context in C9orf72-ALS/FTD patients as closely as possible. Therefore, it was of 
great importance to conduct the interactome study as well as the subsequent validation experiments 
in primary hippocampal and cortical neurons. Validation of poly-GR/PR interactors directly in patient 
tissue was critical to connect cell culture models to human disease.  
Another aim was to address the importance of subcellular localization of poly-GR/PR toxicity as 
several groups reported poly-GR as well as poly-PR to be predominantly localized to the nucleolus in 
vitro, while both proteins are almost exclusively found in cytoplasmic inclusions in patient brains.  
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Taken together, the mechanisms of poly-GR and poly-PR toxicity should be investigated in vitro 
and subsequently be linked to C9orf72 disease pathogenesis in patients starting with an interactome 
study in primary neurons.  
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3. MATERIALS 
 
 Instruments, devices and equipment 
 General equipment 
Equipment Supplier 
scale BP3100S Sartorius 
Certomat BS-1 incubator B. Braun Biotech International 
developing machine Cawomat 2000 IR CaWo 
filter trap slot blot Hoefer Scientific Instruments 
forceps FST 
freezer (-20°C) Liebherr 
freezer (-80°C) HFU-T Series Hareus 
fridge Liebherr 
glassware VWR, Hirschmann 
incubator for bacteria Binder 
liquid Nitrogen tank Messer Griesheim 
microwave inverter Sharp 
MilliQ plus filtration system QPod Merck Millipore 
multichannel pipettes VWR 
multichannel pipettes - automated Rainin 
NanoPhotometerTM Implen 
pH meter Five Easy Mettler-Toledo 
pipette boy Brand 
pipettes Gilson, Rainin  
scanner V700 Photo Epson 
shaker Edmund Bühler 
Thermomixer® comfort Eppendorf 
vortex-Genie 2 Scientific Industries 
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 Centrifuges 
(a) Beckman Coulter Ultracentrifuge Optima XpN90 with SW28 rotor; (b) Heraeus Multifuge 3 SR with 
a swing-out rotor for Falcon Tubes and 96-well plates; (c) Heraeus Megafuge 16; (d) Heraeus Megafuge 
40R (e) Eppendorf Centrifuge 5427R for centrifugation of 1.5 and 2 mL reaction tubes at 4°C or RT; 
(f) Eppendorf Centrifuge 5417R for centrifugation of 1.5 and 2 mL reaction tubes at 4°C or RT.  
 Microscope equipment 
(a) BioTek Cytation 3 imaging reader; (b) Hund Wetzlar Light Microscope WilovertS Mikro; (c) Olympus 
CKX41 Fluorescent Microscope with (d) Olympus RFL-T Mercury Burner MSH-1030L; (e) Zeiss LSM 710 
Confocal Laser Scanning Microscope; with (f) LASOS RMC 7812 Z2 remote control; (g) Zeiss Illuminator 
HXP 120 V; (h) Zeiss Stage Controller XY CD MC 2008; (i) Zeiss Objective Plan Apochromat 40x/1.4 oil 
DIC; (j) Zeiss Objective Plan Apochromat 63x/1.4 oil DIC.  
 Devices for (qRT-)PCR experiments 
(a) Bio Rad PowerPac Basic Power Supply; (b) Bio Rad CFX384 TouchTM Real-Time PCR Detection 
System; (c) Eppendorf PCR thermal cycler nexus (gradient eco) (d) INTAS UV Transilluminator; 
(e) Mitsubishi P93D printer (f) peqlab and owl separation systems gel chambers and combs; (g) Rainin 
EDP3 Multichannel Pipette E3-8-20. 
 Cell culture  
(a) Agilent Seahorse XF96 extracellular flux analyzer; (b) Agilent Seahorse XF prep station; (c) GFL 
waterbath; (d) Heraeus Hera cell culture hood Safe2020; (e) Heraeus Hera incubator Safe Cell 150; 
(f) Heraeus Bunsen burner; (g) LifeTechnologies Countess II.  
 Protein biochemistry 
(a) Bio-Rad glass plates for electrophoresis gels; (b) Bio-Rad electrophoresis gel casting system; (c) Bio-
Rad Mini-PROTEAN Tetra Cell Electrophoresis system; (d) Bio-Rad Mini-PROTEAN Trans-Blot Transfer 
Cell; (e) Bio-Rad foam pads; (f) Branson Digital Sonifier 250; (g) Fuji X-ray films; (h) G. Kisker X-ray film 
chamber.  
 Mass spectrometry 
(a) Maisch GmbH Inhouse 1.9 µm C18 particle packed columns with 75µm inner diameter and 20 cm 
length; (b) Thermo Fisher Easy-nLC 1000 HPLC system; (c) Thermo Fisher Orbitrap Elite. 
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 Software 
(a) Adobe Systems Incorporated - Adobe Acrobat Pro; (b) Bio Rad – CFX Manager for qRT-PCR data 
analysis; (c) CLC bio – CLC Main Workbench for DNA, RNA, and protein analysis; (d) Ensemble online 
data base (http://www.ensembl.org/index.html); (e) Fiji for image processing; (f) Graphpad Software, 
Inc. – GraphPad PRISM for statistical analysis; (g) Microsoft Corporation – Microsoft Office 2016; 
(h) Primer 3 online tool for qPCR primer design (http://bioinfo.ut.ee/primer3/); (i) NCBI online data 
base (http://www.ncbi.nlm.nih.gov/); (j) Thomson Reuters - EndNote X8. 
 Services 
(a) DNA Sequencing: GATC Biotech; (b) Oligonucleotide Synthesis: Sigma-Aldrich. 
 Consumable supplies 
 General consumables 
equipment supplier 
Biosphere® Filtertips Sarstedt 
gloves (Latex) Semperit 
gloves (Nitrile) Meditrade 
Parafilm ‘M’ Pechiney Plastic Packaging 
pH indicator strips Merck Millipore 
Pipette Tips, UltrafineTM VWR 
scalpel Braun 
serological pipettes (2 mL, 5 mL, 10 mL, 25 mL) Sarstedt 
Tubes (1.5 mL, 2 mL) Sarstedt 
Tubes (15 mL, 50 mL) Sarstedt 
LoBind Tubes (1.5 mL) Eppendorf 
 Cell culture 
equipment supplier 
cell counting chambers Countess II Life Technologies 
cell culture dish (3.5 cm, 6 cm, 10 cm) Nunc 
cell culture plate (6 well, 12 well, 96 well) Nunc 
microscope cover glasses (20 mm) VWR 
PES membrane filter, 0.45 µm VWR 
syringe (50 mL) VWR 
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 Molecular biology 
equipment supplier 
FrameStar 384 4titude 
MicroAmp Optical 8-Tube strip Applied Biosystems 
Microseal® ‘B’ Adhesive Seal Bio Rad 
PCR Strip tubes VWR 
 Protein biochemistry 
equipment supplier 
0.2 μm cellulose acetate membrane GE Healthcare 
Blotting Paper Macherey-Nagel 
Immobilon-P membrane, PVDF, 0.45 µM Merck Millipore 
Novex™ 10-20% Tricine Protein Gels Thermo Fisher 
MaxiSorb 96-well plate Thermo Fisher 
 Chemicals and reagents 
 General consumables 
equipment supplier 
2-propanol Merck Millipore 
Boric acid Merck Millipore 
Brij® 35 Sigma-Aldrich 
citric acid Sigma-Aldrich 
dimethyl sulfoxide (DMSO) Roth 
ethanol Merck Millipore 
ethylenediaminetetraacetic acid (EDTA) USB 
fetal calf serum (FCS) Life Technologies 
fish gelatin Sigma-Aldrich 
formic acid Sigma-Aldrich 
gelatin Sigma-Aldrich 
Glycerole Biomol 
glycine Biomol 
Hepes BioMol 
KCl USB 
KH2PO4 Merck Millipore 
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methanol Merck Millipore 
MgCl2 Roth 
Na2[B4O5(OH)4] (Borax) Sigma-Aldrich 
Na2HPO4 Merck Millipore 
H2SO4 Merck Millipore 
Na2HPO4 Merck Millipore 
NaCl Merck Millipore 
paraformaldehyde (PFA) SERVA 
sodium citrate Sigma-Aldrich 
sodium dodecyl sulfate (SDS) Roth 
sucrose Sigma-Aldrich 
Sudan Black B Sigma-Aldrich 
Tris AppliChem 
Triton X-100 Merck Millipore 
Tryptone BD Bioscience 
Tween 20 Sigma-Aldrich 
Xylol Merck Millipore 
 Cell culture 
equipment supplier 
Bovine serum albumin (BSA) Sigma-Aldrich 
DMEM Glutamax Life Technologies 
L-Glutamate Sigma-Aldrich 
L-Glutamine Sigma-Aldrich 
Lipofectamine2000 Life Technologies 
Neurobasal Life Technologies 
Non-essential amino acids (NEAA) Life Technologies 
OptiMEM Life Technologies 
Penicillin/Streptomycin Life Technologies 
Poly-D-Lysine (PDL) Sigma-Aldrich 
Seahorse XF Assay-Medium agilent technologies 
Seahorse XF Calibrant agilent technologies 
tetracycline Sigma-Aldrich 
Trypsin (2.5%) Life Technologies 
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 Molecular biology 
equipment supplier 
1 kb Plus DNA Ladder Invitrogen 
4′,6-Diamidin-2-phenylindol (DAPI) Roche Applied Science 
Ampiciline Boehringer Ingelheim 
Antimycin Sigma-Aldrich 
Bromphenol blue Merck Millipore 
calf intestine alkaline phosphatase (CIP) NEB 
dNTP Mix, 10 mM  Thermo Scientific 
FCCP Sigma-Aldrich 
GelRedTM  Biotium 
Oligomycin Sigma-Aldrich 
Q5 DNA polymerase NEB 
Random Hexamer Primer Sigma-Aldrich 
restriction enzymes NEB 
RiboLock RNase Inhibitor Thermo Scientific 
Rotenone Sigma-Aldrich 
SsoFastTM Eva Green® Supermix Bio Rad 
T4 Ligase NEB 
Taq DNA polymerase Promega 
TO-PRO-3 Life Technologies 
UltraPureTM Agarose Life Technologies 
Proteinase K Sigma-Aldrich 
 Protein biochemistry 
equipment supplier 
ammonium persulfate Sigma-Aldrich 
Benzonase Sigma-Aldrich 
dithiothreitol (DTT) Sigma-Aldrich 
DNase Sigma-Aldrich 
Dynabeads™ Protein G invitrogen 
ECL plus Thermo Scientific 
enhanced chemiluminescence (ECL) Thermo Scientific 
i-Block Tropix 
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NaN3 Merck Millipore  
protease inhibitor cocktail Sigma-Aldrich 
SeeBlue Prestained Protein Ladder Plus 2 Life Technologies 
puromycin Merck Millipore 
tetramethylethylendiamin (TEMED) USB 
tricine Sigma-Aldrich 
β-mercaptoethanol Merck Millipore 
Acrylamid (37.5:1/40% (w/v)) BioRad 
3,3′,5,5′-Tetramethylbenzidine (TMB) Sigma-Aldrich 
GFP magnetic beads chromotek 
 
 Antibodies 
 Primary antibodies 
antigen supplier usage 
mouse α GFP Clonetech WB 
mouse α HA Sigma-Aldrich IF 
mouse α HA, clone R001 Elisabeth Kremmer WB, immunoassay 
mouse α MTCO1 abcam WB, IF 
mouse α MTCO2 abcam IF 
mouse α PR, clone 32B3 Elisabeth Kremmer WB, IF 
mouse α puromycin Merck Millipore WB 
mouse α RPL19 Santa Cruz Biotechnology WB, IF 
mouse α RPS25 Santa Cruz Biotechnology WB, IF 
mouse α RPS36A Santa Cruz Biotechnology WB, IF 
mouse α RPS6 Santa Cruz Biotechnology WB, IF 
mouse α TIAR Santa Cruz Biotechnology IF 
rabbit α BOP1 abcam WB 
rabbit α Calnexin Proteintech WB 
rabbit α Fibrillarin abcam IF 
rabbit α FMRP abcam IF 
rabbit α G3BP abcam IF 
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 Secondary antibodies 
 
  
rabbit α G3BP2 abcam IF 
rabbit α GFP, clone N38/8 Neuromab WB 
rabbit α GFP, clone N86/8 Neuromab IF, IP 
rabbit α GTPBP4 abcam IF 
rabbit α H4R3me2A abcam WB 
rabbit α MAGOHB abcam IF 
rabbit α mono methylated 
arginine 
Cell Signaling WB 
rabbit α MRPL19 abcam IF 
rabbit α MRPS9 abcam IF 
rabbit α NOP56 Atlas Antibodies IF 
rabbit α PES1 Thermo Fisher WB 
rabbit α PRMT1 abcam IF 
rabbit α STAU2 abcam IF 
rabbit α symmetric di-methyl 
arginine 
Cell Signaling WB 
rabbit α TRA2A abcam IF 
rabbit α WDR77 Atlas Antibodies IF 
rabbit α YBX1 abcam IF 
rat α GR, clone 7H1 Elisabeth Kremmer IF 
rat α GST, clone 6G9 Elisabeth Kremmer immunoassay 
antigen supplier label usage 
goat α mouse IgG Life Technologies Alexa488, 555 or 647 IF 
goat α rabbit IgG Life Technologies Alexa488, 555 or 647 IF 
goat α rat IgG Life Technologies Alexa488, 555 or 647 IF 
goat α mouse IgG Promega horse radish peroxidase 
(HRP) 
WB 
goat α rabbit IgG Promega HRP WB 
goat α rat IgG Merck Millipore HRP WB, ELISA 
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 Kits 
(a) Applied Biosystems TaqMan MicroRNA Reverse Transcription Kit; (b) DCS SuperVision 2 Kit 
(c) Macherey-Nagel Extract II Kit; (d) Macherey-Nagel NucleoBond®Xtra Midi; (e) Macherey-Nagel 
NucleoBond® Plasmid; (f) Macherey-Nagel NucleoSpin® Gel and PCR Cleanup; (g) Qiagen RNeasy Mini 
Kit; (h) Roche Cell Proliferation Kit II (XTT); (i) Promega CytoTox 96® Non-Radioactive Cytotoxicity 
(LDH);  
 Buffers 
Components of buffers were dissolved in MilliQ water unless stated otherwise.  
 Buffers for cell culture experiments 
equipment supplier 
borate buffer 40 mM boric acid 
10 mM sodium tetra borate 
adjusted to pH 8.5 
Coating solution for glass cover slips 1.5% PDL dissolved in borate buffer 
HEK293 and HeLa medium 1% Penicillin/Streptomycin 
1% NEAA 
10% FCS 
in DMEM Glutamax 
phosphate-buffered saline (PBS) 0.14 M NaCl 
10 mM Na2HPO4 
2.8 mM KH2PO4 
2.7 mM KCl 
adjusted to pH 7.4 
 Buffers for molecular biology experiments 
equipment supplier 
5x DNA loading buffer 50% Glycerol 
50 mM Na2EDTA 
0.05% Bromophenol blue 
adjusted to pH 8.0 
LB agar 1.5% agar 
1% Tryptone 
0.5% Yeast extract 
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86 mM NaCl 
lysogeny broth (LB) medium 1% Tryptone 
0.5% Yeast extract 
86 mM NaCl 
sodium borate buffer (SB) 5 mM Na2[B4O5(OH)4] 
adjusted to pH 8.0 with H3BO3 
immunoprecipitation lysis buffer 2% Triton X-100 
0.75 M NaCl 
1 mM KH2PO4 
3 mM Na2HPO4 
immunoprecipitation basic buffer 50 mM Tris-HCl pH 7.5 
150 mM NaCl 
5% glycerol 
 Buffers for biochemical experiments 
equipment supplier 
4x Lämmli sample buffer 4% SDS 
20% glycerol 
5% β-mercaptoethanol 
200 mM Na2HPO4 
blocking buffer 0.2% i-Block in TBSTx 
tricine gel running buffer 0.1 M Tris-HCl 
0.1 M Tricine 
0.1% SDS 
RIPA buffer 50 mM Tris-HCl 
150 mM NaCl 
2 mM EDTA 
1% NP-40 
0.1% SDS 
TBSTx 20 mM Tris 
0.14 M NaCl 
0.2% Triton X-100 
adjusted to pH 7.6 
tricine buffer 0.1 M Tris-HCl 
0.1 M Tricine 
MATERIALS 
47 
 
0.1% SDS 
transfer buffer 25 mM Tris 
0.2 M Glycine 
ribosome assay buffer 20 mM Hepes pH 7.4 
100 mM KOAc 
20 mM MgCl2 
2 mM DTT (add freshly) 
 Buffers for immunofluorescence and immunohistochemistry 
equipment supplier 
citrate buffer A 0.1 M citric acid 
citrate buffer B 0.1 M sodium citrate 
fixing solution 4% PFA 
0.15 mM NaOH 
0.13 mM NaH2PO4 
0.12 mM sucrose 
adjusted to pH 7.5 
immunohistochemistry blocking buffer 2% FCS dissolved in PBS 
immunohistochemistry wash buffer 0.05% Brij dissolved in PBS 
immunofluorescence blocking buffer 2% fetal bovine serum 
2% bovine serum albumin 
0.2% fish gelatin 
dissolve in PBS 
permeabilisation buffer 0.2% Triton-X-100 
50 mM NH4Cl 
dissolve in PBS 
 
 Bacteria strains and cell lines 
equipment supplier 
DH5α and Stbl3 E.coli competent cells Life Technologies 
HEK293-FT Life Technologies 
HeLa Life Technologies 
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 DNA oligonucleotides and plasmids 
 Primers for cloning 
name  sequence 
GFP-GR15/GR53 sense tcgagaggatccgccaccATGGTGAGCAAGGGC 
 antisense atactcgagttaTCTGCCTCGCCCCCGTCCCCGTCC, 
atactcgagttaCCTGCCTCGTCCGCGTCCCCTTCC, and 
atactcgagttaTCTGCCTCTGCCCCTGCCCCTGCC 
RFP-hTRA2A sense ATAggcgcgccTATGAGTGATGTGGAGGAAAACAACTTCGAGGGC 
 antisense tatgcggccgcTCAATAGCGTCTTGGGCTGTAGGAACGAGATC 
RFP-hTRA2B sense ATAggcgcgccTATGAGCGACAGCGGCGAGCAGAA 
 antisense tatgcggccgcTTAATAGCGACGAGGTGAGTATGATCGAGATCTGGAAC 
RFP-hSRSF1 iso1 sense ataggcgcgcctATGTCGGGAGGTGGTGTGAT 
 antisense gatcctgcaggTTATGTACGAGAGCGAGATCTGCT 
RFP-hSRSF10 sense ATAggcgcgccTATGTCCCGCTACCTGCGTCCC 
 antisense tatgcggccgcTCAGATCTTTCTTGAAGTGTAGTAAGCAGAACTGTAC 
RFP-hNPM1 sense ATAggcgcgccTATGGAAGATTCGATGGACATGGACATGAGCC 
 antisense tatgcggccgcTTAAAGAGACTTCCTCCACTGCCAGAGATCTTGAATA 
RFP-hNOP56 sense ATAggcgcgccTATGGTGCTGTTGCACGTGCTGTTTG 
 antisense tatgcggccgcCTAATCTTCCTGGGATGCTTTATGGAACTTTTTCTTC 
RFP-hSTAU1 sense ATAggcgcgccTATGAAACTTGGAAAAAAACCAATGTATAAGCCTGTTGA 
 antisense tatgcggccgcTCAGCACCTCCCACACACAGACATT 
RFP-hYBX1 sense ATAggcgcgccTATGAGCAGCGAGGCCGAGACCCAGC 
 antisense tatgcggccgcTTACTCAGCCCCGCCCTGCTCAGCC 
RFP-hBRIX1 sense ATAggcgcgccTATGGCGGCAACCAAGAGGAAACGG 
 antisense tatgcggccgcTTATTTTGTTTTCCCACTGTCCATCCTCTGTTTCATT 
RFP-hGTPBP4 sense ATAggcgcgccTATGGCACATTACAACTTCAAGAAAATTACGGTGGTGCC 
 antisense tatgcggccgcCTATCTCCTGTCCTTTTTACCAGCTTTCCTCTTCC 
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 qPCR primers 
target sense sequence antisense sequence 
18S rRNA GATGGTAGTCGCCGTGCC GCCTGCTGCCTTCCTTGG 
5.8S rRNA ACTCGGCTCGTGCGTC GCGACGCTCAGACAGG 
BOP1  AGAGAAGACCTCTGAGGAGCA TCATCTCTGGTCAGAGCACCTG 
PES1 CCTCCATGAACCCATCGTCAA ACTCGCTCTTCCCATAGGCT 
 
 Plasmids 
construct cloning strategy 
FhSynW GFP-GA50-GR50-myc Dieter Edbauer 
FhSynW GFP-GA50-PR50-myc Dieter Edbauer 
FhSynW GFP Dieter Edbauer 
FhSynW PR175-GFP NES Dieter Edbauer 
FhSynW-175xPR-GFP Dieter Edbauer 
FhSynW2 GFP-GR149 Dieter Edbauer 
FhSynW2 GFP-GR149 NES Dieter Edbauer 
FhSynW2 GFP-GR53 PCR from FhSynW2 GFP-GR149c  
BamHI/XhoI cloning into FhSynW2 GFP-GR149c 
FU2 HA-hMEK1 constitutive active Dieter Edbauer 
FU3a tagRFP-hBRIX1 PCR from ORF clone (Daniel Hornburg) 
AscI/NotI cloning into FU3a-tagRFP-T2 2b 
FU3a tagRFP-hEIF4A3 Dieter Edbauer 
FU3a tagRFP-hGTPBP4 PCR from ORF clone (Daniel Hornburg) 
AscI/NotI cloning into FU3a-tagRFP-T2 2b 
FU3a tagRFP-hNOP56 PCR from ORF clone (Daniel Hornburg) 
AscI/NotI cloning into FU3a-tagRFP-T2 2b 
FU3a tagRFP-hNPM1 PCR from ORF clone (Daniel Hornburg) 
AscI/NotI cloning into FU3a-tagRFP-T2 2b 
FU3a tagRFP-hSTAU1 PCR from ORF clone (Daniel Hornburg) 
AscI/NotI cloning into FU3a-tagRFP-T2 2b 
FU3a tagRFP-rStau2-LL Dieter Edbauer 
FU3a tagRFP-hYBX1 PCR from ORF clone (Daniel Hornburg) 
AscI/NotI cloning into FU3a-tagRFP-T2 2b 
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FU3a tagRFP-hSRSF1 iso1 PCR from cDNA 
AscI/SfbI cloning into FU3a-tagRFP-T2 2b 
FU3a tagRFP-hSRSF10  PCR from cDNA 
AscI/NotI cloning into FU3a-tagRFP-T2 2b 
FU3a tagRFP-hTRA2A PCR from ORF clone (Daniel Hornburg) 
AscI/NotI cloning into FU3a-tagRFP-T2 2b 
FU3a tagRFP-hTRA2B PCR from ORF clone (Daniel Hornburg) 
AscI/NotI cloning into FU3a-tagRFP-T2 2b 
FU3a tagRFP-hYBX1 PCR from ORF clone (Daniel Hornburg) 
AscI/NotI cloning into FU3a-tagRFP-T2 2b 
FU3a-H2B-mEGFP Dieter Edbauer 
FU3a-tagRFP-T2 2b  Dieter Edbauer 
FU3a-tagRFP-T2 n1  Dieter Edbauer 
pEF6 GFP  Dieter Edbauer 
pEF6 GFP-GR149 Dieter Edbauer 
pEF6 GFP-GR53 BamHI/EcoV cloning into pEF6 triple-tag control 
pEF6 triple-tag control Dieter Edbauer 
pEF6-175xPR-GFP Dieter Edbauer 
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4. METHODS 
 
 Molecular biology 
 Molecular cloning 
 Cloning strategy 
Complementary DNA (cDNA) sequences of interest were either excised with restriction enzymes or 
polymerase chain reaction (PCR) amplified from a plasmid template or prepared cDNA. In order to 
insert cDNA sequences into a desired vector, restriction sites were chosen according to available 
restriction sequences in the multiple cloning site of the acceptor vector. Therefore, PCR primers were 
designed with restriction sites attached to the original primer sequences.  
 Polymerase chain reaction  
For standard PCR reactions Taq, Pwo or the high fidelity Q5 polymerase were used according to the 
standard conditions given in the tables below. For optimization these protocols were modified with 
regard to annealing temperature.  
Table 1:Taq/Pwo polymerase PCR standard components and temperature profile 
components volume 
̴150 ng template DNA ~ 2 µL 
primer forward (10 µM) 0.2 µL 
primer reverse (10 µM) 0.2 µL 
dNTPs (10 mM each) 1 µL 
10x Taq Buffer 5 µL 
DNA Polymerase (5U/µL) 0.2 µL 
MilliQ water ad 50 µL 
 
 
  
 temperature time 
initial denaturation 94°C 2 min 
denaturation 94°C 30 sec 
annealing Tm(primer)-5°C 30 sec 
elongation 73°C 1 min/1kb 
final elongation 73°C 10 min 
36 cycles   
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Table 2: Q5 polymerase PCR standard components and temperature profile 
components volume 
̴50 ng template DNA ~ 2 µL 
primer forward (10 µM) 0.25 µL 
primer reverse (10 µM) 0.25 µL 
dNTPs (10 mM each) 1 µL 
10x Taq Buffer 10 µL 
DNA Polymerase (5U/µL) 0.5 µL 
MilliQ water ad 50 µL 
 
 Gel electrophoresis and isolation of DNA fragments 
In order to analyze and separate DNA fragments one dimensional agarose gel electrophoresis was 
performed. Gels containing 0.7% to 2% agarose in Sodium Borate (SB) buffer dependent on the 
expected DNA length were supplemented with GelRed (1:50,000) and subsequently loaded with DNA 
samples premixed with the respective amount of 5x DNA loading buffer. Gels were run at constant 
300 V. DNA fragments were visualized by transillumination with ultraviolet light and analyzed by 
comparison of fragments to the DNA ladder. Finally, the DNA of interest was purified with the 
NucleoSpin® Gel and PCR Cleanup Kit (Macherey-Nagel) according to the manufacturer’s instructions. 
 Digest of DNA by restriction endonucleases and dephosphorylation  
Typically, plasmids or PCR products were digested at 37°C for 1 h or overnight, respectively, in a 50 µL 
reaction with the respective endonucleases. The amount of enzyme, the buffer system and the 
conditions required for a complete digest were chosen according to the information provided by the 
manufacturer (NEB). To prevent self-ligation of plasmid backbones 5’ phosphoryl termini were 
removed by calf intestine phosphatase (CIP). In a typical reaction 1 unit phosphatase was used for 3 µg 
of vector DNA at 37°C for 1 h. Subsequently, processed plasmids or PCR fragments were purified by 
gel electrophoresis or on column (see 4.1.1.3). 
 Ligation  
A typical 20 µL ligation reaction comprised 3 µL vector backbone, 9 µL PCR product or plasmid 
fragment, 2 µL T4 DNA Ligase catalyzing the formation of a phosphodiester bond between 
5’ phosphorylated and 3’ hydroxylated termini, 2 µL reaction buffer and water. The reaction was 
incubated for 1 h at room temperature (RT).  
 temperature time 
initial denaturation 98°C 30 sec 
denaturation 98°C 30 sec 
annealing Tm(primer)-5°C 30 sec 
elongation 72°C 30 sec/1kb 
final elongation 72°C 2 min 
36 cycles   
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 Transformation  
The complete volume of the ligation reaction was used for transformation into chemically competent 
DH5α cells. First, 100 µL bacteria cells were thawed on ice and DNA was added gently. Afterwards, 
cells were incubated on ice for 20 min, heat shocked for 30 sec at 42°C and again incubated on ice for 
3 min. 400 µL antibiotic free LB medium was added prior to horizontal shaking (300 rpm) at 37°C for 
1 hour. Thereafter, each transformation reaction was plated on a prewarmed antibiotic selective agar 
plate and incubated overnight at 37°C. For all repeat containing and therefore recombination prone 
inserts the temperature was set to 30°C. 
 Plasmid preparation and determination of DNA concentration 
In order to inoculate a 4 mL culture (mini preparation) or 100 mL culture (midi preparation) single 
colonies were picked from agar plates using a sterile pipette tip and transferred to LB (antibiotic 
selective) medium. For further amplification the cultures were incubated overnight at 37°C (or 30°C 
for repeat containing DNA). The next day, cells were pelleted by centrifugation at 3000 g for 10 min at 
4°C and plasmid DNA was extracted using the NucleoSpin® Plasmid kit (Macherey-Nagel) for mini 
preparation or the NucleoBond®Xtra Midi kit (Macherey-Nagel) for midi preparation according to the 
manufacturer’s instructions. Finally, the DNA was eluted in MilliQ water and stored at -20°C. 
Concentrations were determined by measurement of absorbance at 260 nm (NanoPhotometerTM, 
Implen). 
 Sequencing 
In order to verify successful cloning, purified plasmids were sent to GATC Biotech for sequencing. 
Standard primers binding in the backbone were provided by the company.  
 Quantitative real time PCR (qRT-PCR) 
 RNA isolation  
Total RNA isolation including DNase treatment was performed using the RNeasy Mini Kit (Qiagen) 
according to the protocol provided by the manufacturer. Purified RNA was eluted in 40 µL RNase-free 
water. Also, RNase-free consumables and solutions were used during all isolation steps. 
Concentrations were measured on the NanoPhotometer at 260 nm. RNA samples were stored at -80°C. 
 cDNA synthesis 
In order to transcribe RNA into cDNA the protocol provided with the TaqMan MicroRNA Reverse 
Transcription Kit was followed. cDNA was typically synthesized from 50 ng RNA using random hexamer 
primers (N6) according to Table 3. For generation of a standard curve equal amounts of each RNA 
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sample were pooled and diluted to a 1:10, 1:100, 1:1000 and 1:10,000 ratio. Freshly prepared cDNA 
was subsequently used as template in the qRT-PCR reaction. 
Table 3: cDNA synthesis standard components and temperature profile 
components volume 
dNTPs (100 mM) 0.3 µL 
RNA (50 ng) 10 µL 
N6 primer (50 ng/µL) 0.2 µL 
RNase inhibitor 0.38 µL 
10x RT Buffer 3 µL 
MultiScribe™ Reverse 
Transcriptase (50 U/µL) 
2 µL 
RNse-free water ad 30 µL 
 
 Quantitative PCR primer design 
Primers for the qRT-PCR reaction were designed to bind in exon-intron border regions, span an intron 
larger than 1000 bases and show no to little off target effects. Furthermore, the optimal product size 
was set to be 80 to 100 base pairs with a primer melting temperature of optimally 60°C and a primer 
size of 20 bases. Therefore, mRNA sequences were taken from the NCBI database and analyzed for 
suitable primers using the Primer3 web tool (http://bioinfo.ut.ee/primer3/). 
 qRT-PCR 
For a single qRT-PCR reaction 2 µl of 1:5 diluted cDNA were used as a template. For each primer pair a 
SsoFast™ EvaGreen (Bio Rad) containing reaction mix according to Table 4 was prepared. The reaction 
was performed using the CFX384 Real-Time System (Bio Rad) with the temperature profile depicted in Table 4. Primer pair specificity was verified by a single peak in melting curve analysis from 60°C to 
95°C with increases of 0.5°C every 5 sec in advance. Each reaction was performed as triplicate. Mean 
relative mRNA expression values were calculated with the Δ-Δ-Ct using YWHAZ and GAPDH as 
housekeeping genes. 
 
 
 
 
temperature time 
4°C 5 min 
25°C 10 min 
48°C 30 min 
95°C 5 min 
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Table 4: qRT-PCR standard components and temperature profile 
components volume 
SsoFast™ EvaGreen 2.5 µL 
primer forward (20 µM) 0.125 µL 
primer reverse (20 µM) 0.125 µL 
RNase-free water 0.25 µL 
DNA Polymerase (5U/µL) 0.2 µL 
reaction volume 5 µL 
 
 Cell Biology 
 Maintenance of cells  
 Cultivation of Human Embryonic Kidney (HEK293-FT) and HeLa cells 
HEK293-FT and HeLa cells were cultivated in DMEM Glutamax medium supplemented with 10% FCS, 
1% Penicillin/Streptomycin (Pen/Strep) and 1% non-essential amino acids (NEAA) at 37°C and 5% CO2. 
At a confluency of 80%, cells were split in a ratio of 1:10. For passaging, cells were washed once with 
PBS, detached with 1 mL 0.05% Trypsin/EDTA and replated in new medium.  
 Cultivation of primary neurons 
Primary cortical and hippocampal neurons were cultured from embryonic day 19 Sprague-Dawley rats 
and cultivated in Neurobasal medium at 37°C and 5% CO2. For cortical neurons the medium was 
supplemented with 2% B27, 1% Pen/Strep and 0.25% glutamine, for hippocampal neurons 0.125% 
glutamate was additionally added. Neurons were either plated in plastic dishes or on cover slips 
treated with 65% nitric acid and sterilized at 200°C for 6h. 85,000 and 400,000 cells were seeded for 
hippocampal and cortical neurons, respectively. Typically, primary neurons were transduced or 
transfected at 7 days in vitro (DIV7). 
 PDL coating of cell culture dishes 
In order to avoid detachment of cells, both, plastic dishes and cover slip containing plastic dishes, were 
coated with 1.5% PDL in 0.1 M borate buffer for 4°h and washed with water three times before plating 
HEK293 or neuronal cells. For neurons a final equilibration step with Neurobasal medium followed. 
Dishes were kept in the cell culture incubator until cells were seeded.  
 temperature time 
initial denaturation 95°C 30 sec 
denaturation 95°C 5 sec 
annealing 60°C 5 sec 
elongation 95°C 10 sec 
50 cycles   
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 Transfection 
 Transfection of HEK293-FT and HeLa cells 
In order to introduce foreign DNA into HEK293-FT or HeLa cells, 200,000 cells per mL were seeded the 
day before transfection. The transfection mix for one well of a 12-well plate was set up as follows:  
component amount for 1 well in 12-well plate 
DNA in total 1 µg 
OptiMEM 125 µL 
combine with:  
Lipofectamin 2000 2.5 µL 
OptiMEM 125 µL 
 
For other plate formats the volumes were adjusted accordingly. After 20 min incubation time at RT, 
the mix was gently added into the cell culture medium and incubated for 48 h before cells were 
harvested for analysis.  
 Transfection of primary neurons 
Just as HEK293 cells, neurons were transfected with Lipofectamin 2000 according to the 
manufacturer’s instruction. The following table shows the setup of the neuronal transfection mix: 
component amount for 1 well in 12-well plate 
DNA in total 1.8 µg 
OptiMEM 100 µL 
combine with:  
Lipofectamin 2000 3.2 µL 
OptiMEM 100 µL 
 
During the 20 min incubation time of the transfection mix, hippocampal neurons on glass cover slips 
were removed from the original plate, dipped into warm Neurobasal medium and transferred into a 
new plastic dish containing prewarmed Neurobasal medium supplemented with 1% Pen/Strep and 
0.25% glutamine. Then, the transfection mix was added drop-wise into the new dish. 45 min later, 
cover slips were again removed, dipped in warm Neurobasal medium twice and transferred back into 
the original plate. Analysis followed three to five days after transfection.  
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 Usage of lentivirus 
 Lentivirus production 
In order to produce lentiviruses with high virus titer, low passage HEK293-FT cells were used for 
packaging. Per LTR vector, three 10 cm were plated with 5.5 million cells 24  before transfection with 
Lipofectamin 2000. Three essential constructs were needed to set up the transfection mix: pVSVg as 
envelope protein and psPAX as Gag-Pol-Rev containing plasmid which allows for the formation of the 
virus as well as the LTR vector harboring the construct of interest. The transfection mix was set up as 
follows:  
component amount for three 10 cm dishes 
LTR vector 18.6 µg 
pSPAX2 11 µg 
pVSVg 6.4 µg 
OptiMEM 4.5 mL 
combine with:  
Lipofectamin 2000 108 µL 
OptiMEM 4.5 mL 
 
Again, the mixture was incubated for 20 min. In the meantime, medium in the 10 cm dishes was 
changed to 5 mL OptiMEM supplemented with 10% FCS. Then, 3 mL of the transfection mix per dish 
were slowly added and incubated with the cells for 24 h. Thereafter, medium was exchanged to 10 mL 
DMEM Glutamax plus 10% FCS, 1% Pen/Strep, 1% NEAA and 1.3% BSA. 24 h later, the virus containing 
medium was collected, filtered through a sterile 0.45 µm PES membrane filter and centrifuged at 
66,000 g for 2 h at 4°C. The pellet was resuspended in 120 µL Neurobasal medium, aliquoted and 
stored at -80°C until usage.  
 Transduction 
In order to transduce neurons with lentivirus, 1 µL of virus preperation was added to one well of a 12-
well plate. For other plate formats the volume was adjusted accordingly. Cells were incubated for at 
least 7 days in case of DPR proteins to allow proper aggregate formation. 
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 Cell viability assays 
 XTT assay 
To assess cell viability, the 2,3-bis-(2-methoxy-4-nitro-5-sulfophenyl)-2H-tetrazolium-5-carboxanilide 
(XTT) assay from Roche was used according to the manufacturer’s instructions. For this purpose, cells 
were cultivated in 96-well plates and after 48 h 50 µL of the freshly thawed XTT labeling reagent mixed 
with the electron-coupling reagent were added. After 24 h absorption was measured 
spectrophotometrically at 480 nm with a plate reader.  
 LDH activity assay 
Toxicity assays in transduced primary cortical neurons (DIV7+14) and HEK293FT cells were performed 
in 96-well plates using the lactate dehydrogenase (LDH) cytotoxicity assay from Promega following the 
manufacturer’s protocol. Therefore, first, the whole cell supernatants were transferred into a new 
plate and the remaining cells were frozen for 30 min at -80°C in order to lyse them. Then, cells were 
thawed again and resuspended in 100 µL medium. In a new 96-well plate 50 µL of the cell supernatant 
as well as the cell suspension was added to 50 µL of the substrate mix. After 10 to 20 min incubation 
at RT in the dark, the enzymatic reaction was stopped and absorption was measured at 490 nm 
wavelength. To calculate relative toxicity, first the mean background value was subtracted. Then the 
experimental LDH release was divided by the maximum LDH release and further normalized to the 
respective control.  
 Cell respiration assay 
Cellular respiration was measured on the Seahorse XF96 extracellular flux analyzer (Agilent). The day 
before the assay, primary neurons were plated in PDL-coated 96-well Seahorse assay plates. One hour 
before cell respiration measurements started, cells were washed and the growth medium was 
exchanged with pre-warmed XF assay medium supplemented with 10 mM pyruvate and 10 mM 
glucose using the Seahorse XF prep station. The cells were then incubated at 37°C without CO2 for at 
least 45 min. Oxygen consumption rates (OCR) were recorded at baseline and after Oligomycin, FCCP 
and a mixture of antimycin A and rotenone addition through the injector ports. Oligomycin (1 µM 
diluted in assay medium) injection allowed for calculation of ATP-linked OCR and the OCR due to 
proton leak. The maximal respiration was determined after adding FCCP (0.75 µM). The OCR 
independent of complex IV could be measured after Rotenone and antimycin A (10 μM each) injection. 
The analyzer was set to obtain three data points per respiratory stadium including 4 min of mixing and 
4 min of measurement.  
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 Protein biochemistry 
 Immunoblotting 
 Cell lysate sample preparation 
HEK293-FT cells growing in a 12-well plastic dish were harvested in 1x PBS and centrifuged at 800 g for 
5 min. The cell pellet was resuspended in 300 µL RIPA buffer supplemented with protease inhibitor 
cocktail (1:500) and incubated for 20 min on ice. Afterwards, the lysate was centrifuged at 17,000 g for 
15 min at 4°C. However, when cells were harboring DPR proteins the lysate was only centrifuged at 
1,000 g for 10 min. Finally, 4x Laemmli sample buffer was added to the supernatant in a 1:4 ratio and 
samples were boiled at 95°C for 5 min.  
In order to prepare lysate from neurons, cells were directly harvested in 180 µL 2x Laemmli 
sample buffer per well.  
 SDS-polyacrylamide gel electrophoresis (SDS-PAGE) 
In order to separate proteins by their molecular masses, SDS-PAGE was performed. Therefore, lysate 
samples were run under denaturizing conditions using discontinuous ready-to-use 10-20% Tris-Tricine 
polyacrylamide gels from Novex. Gels were loaded with 10 to 20 µL of lysate samples and 
electrophoresis was carried out in tricine buffer with a voltage of 80 V until the dye front reached the 
stacking gel. Afterwards, the gel was run at 120 V. For comparison of molecular weights, the SeeBlue 
Protein marker was run side by side to the samples.  
 Immunoblotting and immunodetection 
Previously separated proteins were blotted on an isopropanol activated polyvinylidene difluoride 
(PVDF) membrane at a constant current of 400 mA for 75 min using a wet blotting chamber. 
Subsequently, the membrane was blocked in 0.2% i-Block in TBSTx for 1 h at RT in order to reduce non-
specific binding sites and afterwards incubated in primary antibody solution at 200 rpm and 4°C 
overnight. The next day, five washing steps with TBSTx followed. Then, the membrane was incubated 
for 1 h at RT with an HRP coupled secondary antibody appropriate for the species of the first antibody 
used and washed another five times. For detection of the protein of interest, the membrane was 
incubated with the chemiluminescence substrate ECL for 2 min. Directly afterwards, an X-ray film was 
exposed to the membrane in complete darkness and developed on an X-ray film processor.  
 SUnSET assay 
In order to monitor total protein synthesis a Surface sensing of translation (SUnSET) assay was 
performed. Therefore, primary cortical neurons were treated with 10 µg/mL puromycin for 10 min at 
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37°C and 5% CO2 in order to allow puromycin, as structural analogue of aminoacyl-transfer RNA, to 
incorporate into the newly synthesized peptide chains. Afterwards, cells were lysed and 
immunoblotted as described above and protein synthesis was analyzed by detection with a puromycin 
specific antibody.  
 Immunoprecipitation of GFP-tagged poly-GR and poly-PR aggregates 
In order to analyze the whole proteome as well as the interacting proteins of GFP-(GR)149, (PR)175-GFP 
or GFP in infected cortical neurons (DIV7+8) and transfected HEK293FT cells quadruplicates of 
immunoprecipitation samples were prepared. Cells were harvested in 1 mL IP lysis buffer substituted 
with Benzonase (67 U/mL) per 10 cm dish. Lysates were rotated for 45 min at 4°C. For whole proteome 
analysis 10% of the samples were kept while the remaining lysate was centrifuged at 1000 g for 5 min 
at 4°C. In the meantime, 10 µg of GFP antibody were incubated with 50 µL Protein-G Dynabeads. 
Afterwards, lysate supernatant was united with the beads and incubated for 3 h at 4°C. Three washing 
steps in 1 mL IP basic buffer followed. 80% of the sample was used for further sample preparation for 
mass spectrometry analysis. 20% of the beads was boiled in 4x Laemmli sample buffer at 95°C in order 
to release the protein from the antibody and the resulting samples were run on a gel followed by 
immunoblotting.  
 Ribosome binding assay 
For investigation of the binding capacity of a protein of interest (antigen) to a specific other target 
protein, in this case the ribosome, immunoassays were carried out. Importantly, all assay steps 
including blocking and washing, were performed with ribosome assay buffer (RB) in order to keep the 
Mg2+ concentration at 20 mM thereby guaranteeing an intact ribosome. Also, if not indicated 
otherwise, each incubation step was carried out on a horizontal shaker at 220 rpm for 1 h at RT. First, 
MaxiSorb 96-well plates were coated with 100 µL of 80S yeast ribosome (5-500 ng/well) at 4°C 
overnight. The next day, plates were washed three times with RB, blocked with 300 µL 1% BSA in RB 
and washed again. Then, the antigen (0.1-10 µg/well) was added for 1 h at RT, plates were washed 
three times and incubation with a primary antibody detecting the antigen started. After three more 
washing steps the plates were incubated with an HRP coupled secondary antibody. Thereafter, plates 
were washed again and incubated with 100 µL 3,3′,5,5′-Tetramethylbenzidine (TMB), a liquid substrate 
for HRP, for 5 min in the dark. Finally, the reaction was stopped with 2 M sulfuric acid and absorption 
was measured at 450 nm or 630 nm on a plate reader.  
 Chromatin immunoprecipitation (ChIP) from HEK293 cells 
In order to elucidate the binding of proteins of interest to certain chromatin regions, ChIP experiments 
were performed with the MAGnify Chromatin Immunoprecipitation System kit (Life Technologies). For 
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all reaction steps Lo-bind tubes were used. 1 million HEK293-FT cells served as starting material. The 
chromatin binding protein Histone 2B (H2B) was used as positive control. In a final step the eluted DNA 
binding to the protein of interest was amplified by PCR with specific primers prior to analysis by gel 
electrophoresis. 
 Crosslinking 
Cells were harvested from 6-well plates in 5 mL medium and centrifuged 5 min at 200 g. After 
resuspension of the pellet in PBS, cells were counted and diluted to 1 million cells in 500 µL PBS. 13.5 µL 
37% Formaldehyde was added and incubated for 10 min prior to the addition of 57 µL 1.25 M glycine 
and 5 min incubation in order to stop the reaction. Afterwards, the solution was centrifuged at 2800 g 
for 10 min at 4°C. Then, the pellet was washed with cold PBS and centrifuged again.  
 Cell lysis and chromatin shearing 
The pellet was taken up in 50 µL PI containing lysis buffer (1:200) per 1 million cells, vortexed and 
incubated on ice for 10 min. 300 µL dilution buffer was added prior to sonication. The following 
sonication protocol was chosen: 30% amplitude with 0.6 sec duty cycle and 4 cycles of 30 sec pulse 
with 1 min pause. Thereafter, a centrifugation step of 20,000 g for 5 min at 4°C followed. In order to 
verify chromatin shearing into 200 base pair long fragments, 10 µL of the supernatant was incubated 
with 1 µL proteinase K at 55°C for 20 min and run on a 1.5% agarose gel. The rest of the supernatant 
was split into three aliquots with 100 µL each, 10% of the samples were kept as input.  
 Immunoprecipitation 
To each sample 10 µL antibody precoupled Dynabeads were added and incubated on a rotator for 2 h 
at 4°C. For GFP-tagged proteins GFP-Trap®_M beads (chromotek) were used. Afterwards, beads were 
separated from the solution by a magnet, the supernatant was removed, and the beads were washed 
three times with 100 µL IP Buffer 1 and two times with IP Buffer 2.  
 Reverse crosslinking and DNA isolation 
In order to separate proteins from DNA, 53 µL or 43 µL Reverse Crosslinking Buffer supplemented with 
Proteinase K (1 µL per sample) were added to IP or input samples, respectively, and incubated for 
15 min at 55°C. Thereafter IP sample supernatants were harvested. Finally, all samples were incubated 
for 15 min at 65°C. DNA was isolated using DNA-binding magnetic beads. Therefore, 20 µL beads 
together with 50 µL DNA purification buffer were added to each sample and incubated for 5 min at RT. 
Then, beads were washed two times with 150 µL DNA wash buffer prior to incubation for 5 min at 55°C 
with 150 µL DNA elution buffer. The eluted DNA was separated from the beads and transferred into a 
new tube and stored at -20°C.  
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 Imaging 
 Immunofluorescent stainings in patient tissue  
The tissue was first de-paraffinated and rehydrated by incubating the tissue slides in xylene for 20 min 
and subsequently rinsing them 10x in 100% ethanol twice, once in 96% ethanol and finally twice in 
70% ethanol. To retrieve the antigen, slides were boiled four times 5 min in citrate buffer pH 6.0 using 
a microwave and cooled down for 20 min. Blocking in inhibiting endogenous peroxidase was 
performed with 5% H2O2 in methanol for 15 min prior to a brief rinse with deionized water. After 
sections were washed in PBS/0.05% Brij35, blocking with 2% fetal calf serum in PBS for 5 min followed. 
Thereafter, primary antibody solution was applied over night at 4°C. The next day, the tissue was 
washed twice in PBS/0.05% Brij35 prior to incubation with Alexa-coupled secondary antibodies (1:500 
in blocking buffer) for 1 h at RT in the dark. Thereafter, the brain sections were washed again, stained 
with DAPI (1:5000 in blocking buffer) 15 min and washed twice in 0.05% Brij35 in PBS and twice in PBS 
only. The tissue was treated with Sudan Black B for 1 min at RT, rinsed in PBS and mounted with 
Fluoromount Aqueous mounting medium.  
 Immunofluorescent stainings in cell culture 
For immunostainings in cell culture, hippocampal neurons, HEK293-FT or HeLa cells were grown on 
PDL coated glass cover slips. All incubation steps were performed in a wet chamber in the dark. First, 
cells were fixed with 4% paraformaldehyde for 15 min and the nuclei were subsequently permeabilized 
by incubation with permeabilization buffer for 5 min. After three washing steps using PBS, the cover 
slips were blocked in blocking solution for 30 min and then incubated in primary antibody solution 
(blocking buffer diluted 1:10 in water containing the primary antibody) at RT for 1 h. Next, they were 
again washed with PBS and incubated in Alexa-coupled secondary antibody solution (1:400 in blocking 
buffer diluted 1:10 in water) for 1 h. Finally, the cells on cover slips were treated with DAPI or TO-PRO-
3 (1:5000 in PBS) for 15 min in order to stain the nuclei and mounted on a glass microscope slides using 
Vectashield mounting medium.  
 Image acquisition 
Single plane images from immunofluorescent stainings were acquired with the laser scanning 
microscope LSM 710 system from Carl Zeiss together with the ZEN 2010 software. Plan-Apochromat 
40x and 63x oil objectives were used. For colocalization experiments the pinhole was set to 1 Airy Unit 
for the longest wavelength and adjusted for the others accordingly. The scanning speed was chosen 
according to the quality of the staining. In general, the scanning speed was much lower for patient 
tissue stainings and additionally, it was averaged over 2 or 4 images allowing for better quality. Images 
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were acquired at 1024 x 1024 pixels. In order to allow meaningful comparison between groups, all 
samples of one experiment were imaged with the same settings.  
 Image analysis  
All images were processed with the ImageJ software. When required, brightness and contrast were 
adapted by lower fixed grey value for thresholding the signal. For retaining comparability, same 
thresholds were applied for images of one channel. Whenever possible, images were analyzed blinded 
to the experimental conditions. Counting of aggregates and cells was done without software image 
analysis programs.  
 Statistical analysis 
Statistical analysis was conducted with the GraphPad Prism software. Depending on the experimental 
setting and distribution of the data points the appropriate test including post-test was performed. 
Initially, it was tested for normal distribution. Mostly, multiple data groups should be compared to a 
control group. Here, the one-way ANOVA was used for normally distributed data points, whereas for 
non-normal distributed data, the Kruskal Wallis test was used. These tests are specified in the figure 
legends. Statistical significance was indicated as p-value as follows: * p<0.05, ** p<0.01, *** p<0.001. 
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5. RESULTS  
Since the discovery that the (GGGGCC)n repeat expansion within the first intron of C9orf72 in ALS/FTD 
patients is translated, DPR proteins have come into the focus of researchers. At the beginning of my 
PhD, the relative contribution of the two arginine-rich DPR species poly-GR and poly-PR to 
neurodegeneration was just starting to emerge. Besides impairment of splicing and disruption of rRNA 
processing only little was known. In order to address the role of poly-GR and poly-PR in ALS/FTD 
disease pathogenesis, my aim was to elucidate the mechanisms underlying DPR toxicity by analysis of 
an extensive interactome study in different cell culture systems. Importantly, the validation of poly-
GR/PR interactors was aimed to be extended to patient tissue.  
In order to express the two DPR species in different cell types, I used ATG-initiated synthetic 
poly-GR and poly-PR constructs during the whole study. The repeat sequences were harboring 
alternative codons preventing RNA based toxicity and reducing genomic repeat instability. The poly-
GR sequence was C-terminally tagged with GFP containing 149 repeats resulting in GFP-(GR)149, while 
poly-PR was tagged on the N-terminus and comprised 175 repeats resulting in (PR)175-GFP. A GFP-only 
construct served as negative control in all experiments.  
 Subcellular localization and toxicity of poly-GR and poly-PR  
I first analyzed general characteristics of poly-GR as well as poly-PR in two cell culture systems. For this 
purpose, I expressed GFP-(GR)149 and (PR)175-GFP in HEK293 cells and primary rat neurons and studied 
localization as well as toxicity.  
 Poly-GR and poly-PR localization differs between cell types 
Consistent with previous results (Schludi et al., 2015b), in transfected HEK293 cells, GFP-(GR)149 was 
found in both nucleolus and cytoplasm while (PR)175-GFP mainly localized to the nucleolus. Surprisingly, 
in contrast to previous studies, lentiviral expression of GFP-(GR)149 in primary neurons resulted in 
predominantly diffuse cytoplasmic localization and only little nucleolar expression suggesting different 
poly-GR interacting proteins in neurons and HEK293 cells may affect its subcellular localization. (PR)175-
GFP was mostly localized to the nucleolus as in HEK293 cells (Figure 5-1A and B).  
Although the repeat length of poly-GR and poly-PR with 149 and 175 repeats, respectively, is 
considerably longer compared to previous studies, it is probably still shorter than in patients. Since 
poly-GR and poly-PR are found in the cytoplasm in patients and aberrant localization potentially alters 
the downstream toxic effects, I attempted to relocalize poly-GR and poly-PR to the cytoplasm in our 
cell culture system. Thus, I fused the constructs to a nuclear export signal (NES) from p53 
(MFRELNEALELK) or (GA)50, which by itself forms large cytoplasmic aggregates. Surprisingly, fusion with 
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(GA)50 only led to even bigger nucleolar aggregates and also the NES failed to form poly-GR and poly-
PR inclusions in the cytoplasm (Figure 5-1C). 
 
 
 
 
 Nucleolar poly-GR and poly-PR show significant toxicity in vitro 
As reported in previous studies, poly-GR and poly-PR are toxic in various cell culture systems. Also in 
my hands, expression of both, (PR)175-GFP and GFP-(GR)149, showed growth impairment of HEK293 cells 
in an XTT proliferation assay. This test is measuring the activity of the succinate-tetrazolium reductase 
system which belongs to the respiratory chain of mitochondria and is only active in metabolically intact 
cells (Figure 5-2A). Next, active cell death was measured by an LDH colorimetric assay, detecting the 
presence of the LDH enzyme in the culture medium being released from cells where membrane 
integrity is compromised. However, (PR)175-GFP and GFP-(GR)149 expression in HEK293 cells did not lead 
to active cell death (Figure 5-2B). In neurons, surprisingly only nucleolar (PR)175-GFP but not 
cytoplasmic GFP-(GR)149 induced significant neuronal loss (Figure 5-2C) leading to the hypothesis that 
only nucleolar localization may be driving the poly-GR/PR toxicity observed in vitro. This would be in 
line with previous studies in which poly-GR was exclusively localized to the nucleolus and was 
notoriously toxic compared to the cytoplasmic GFP-(GR)149 in this study. To further validate this 
hypothesis, I also performed a toxicity assay in GFP-(GA)50-(GR)50 and GFP-(GA)50-(PR)50 expressing 
neurons, which harbor big nucleolar inclusions with dense fluorescence signal. Here, GFP-(GA)50-(GR)50 
and GFP-(GA)50-(PR)50 transduced neurons displayed even higher toxicity as measured by LDH release 
assay than (PR)175-GFP transduction (Figure 5-2D).  
Figure 5-1: Poly-GR and poly-PR show nucleolar and cytoplasmic expression in HEK293 cells and neurons.  
(A, B) GFP, GFP-(GR)149 or (PR)175-GFP were transduced or transfected in primary rat neurons and HEK293 cells, respectively. 
(A) Images show a single confocal plane depicting GFP fluorescence and anti-fibrillarin (red) staining to visualize nucleoli in cells 
stained with DAPI (blue). Scale bar denotes 20 µm. (B) Quantitative analysis of GFP-(GR)149 or (PR)175-GFP colocalization with 
fibrillarin-labeled nucleoli, n=17 for GFP-(GR)149, n=13 for (PR)175-GFP images in neurons and n=6 for GFP-(GR)149, n=6 for 
(PR)175-GFP images in HEK cells from two independent experiments, mean ± SEM is shown. (C) Images show GFP fluorescence 
of a single confocal plane of GFP-(GA)50-(GR)50, GFP-(GA)50-(PR)50, GFP-(GR)149-NES or (PR)175-GFP-NES expressing primary 
hippocampal neurons. Nuclei are visualized with DAPI. Scale bar denotes 20 µm. 
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Figure 5-2: Nucleolar poly-GR and poly-PR show significant toxicity in HEK293 cells and neurons.  
(A, B) GFP, GFP-(GR)149 or (PR)175-GFP were expressed in HEK293 cells. (A) 3 days after transfection cell viability was measured 
by XTT assay. GFP-(GR)149 and (PR)175-GFP showed significantly reduced cell growth compared to GFP control (12 replicates 
from 2 independent experiments, box plot is shown with 25th percentile, median and 75th percentile and whiskers 
representing minimum and maximum, *** denotes p<0.001 in one-way ANOVA with Dunnett's post-test). (B) LDH release 
assay detects no significant cell death upon expression of (PR)175-GFP and GFP-(GR)149 compared to GFP control (n=2 
independent experiments with 6 replicates each, box plot is shown, n.s. denotes not significant in one-way ANOVA with 
Dunnett's post-test). (C, D) Primary cortical rat neurons were infected with indicated constructs. (C) LDH release assay detects 
significant toxic effect upon (PR)175-GFP, but not GFP-(GR)149 expression compared to GFP control. (18 replicates from 3 
independent experiments, box plot is shown, *** denotes p<0.001 in one-way ANOVA with Dunnett's post-test). (D) LDH 
release assay reveals toxic effect comparable to (PR)175-GFP upon expression of nucleolar GFP-(GA)50-(GR)50 and GFP-(GA)50-
(PR)50 (12 replicates from 2 independent experiments, box plot is shown, *** denotes p<0.001 in one-way ANOVA with 
Dunnett's post-test). 
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 GFP-(GR)149 and (PR)175-GFP bind DNA 
Besides localization and toxicity, I also investigated the capacity of GFP-(GR)149 and (PR)175-GFP to bind 
negatively charged DNA as it is known that the positively charged arginine residues within the two DPR 
protein species have the ability to bind negatively charged RNA (Lipfert et al., 2014). Therefore, I isolated 
crosslinked DNA from HEK293 cells expressing poly-GR/-PR, and GFP as negative control and performed 
chromatin immunoprecipitation (ChIP) experiments with three replicates each. Histone 2B as DNA-binding 
protein served as positive control. After the last purification step, the DNA was amplified with primers 
specific for Presenilin 2 exon 7 and visualized on an agarose gel. The intensity of the PCR products shows that 
in comparison to the GFP control, GFP-(GR)149 and (PR)175-GFP have a higher binding capacity to DNA 
suggesting that the positively charged residues of arginine bind to the negatively charged phosphate group of 
the DNA ( 
 
Figure 5-3). As expected, the positive control H2B had the highest binding capacity.  
 
 
Figure 5-3: Poly-GR and poly-PR bind DNA in HEK293 cells. 
ChIP assay performed with DNA extracted from cell lysates of GFP-(GR)149, (PR)175-GFP, GFP or H2B-GFP expressing HEK293 
cells 3 days after transfection. Histone 2B served as positive control and GFP as negative control. DNA was amplified with 
primers specific for Presenilin 2 exon 7 and visualized on an agarose gel. Note that in comparison to the GFP control, GFP-
(GR)149 and (PR)175-GFP have a higher DNA binding capacity. 
 
Overall, the two DPR species analyzed in this study show both cytoplasmic and nucleolar localization 
upon expression in HEK293 cells and primary rat neurons. In HEK293 cells, both bind to DNA. 
Importantly, expression of nucleolar GFP-(GR)149 and (PR)175-GFP is accompanied by cellular toxicity in 
vitro, while cytoplasmic poly-GR is not. 
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 Poly-GR/PR preferentially interact with RNA-binding proteins 
The main focus of this work was to identify the mechanisms driving poly-GR/PR toxicity in cellular 
models and ultimately in C9orf72-ALS/FTD. In order to understand the physiological and functional 
consequences of poly-GR/PR expression in ALS/FTD patients, my first approach was to set up a 
proteome study in cell culture. Therefore, I first conducted an immunoprecipitation (IP) experiment 
using a GFP antibody in order to pull down GFP-(GR)149, (PR)175-GFP or GFP from transduced cortical 
neurons (DIV7+8) and transfected HEK293FT cells. To reduce indirect RNA-mediated interactions, the 
lysates were treated with benzonase before IP. Immunoblotting validated the enrichment of poly-GR 
and poly-PR as well as the GFP control in the IP samples (Figure 5-4A and B). In a second step, label-
free quantitative liquid chromatography-tandem mass spectrometry (LC-MS/MS) was performed in 
collaboration with Daniel Hornburg and Jakob Bader from the Max-Planck Institute for Neurobiology. 
That way it was possible to identify a plethora of poly-GR/PR interacting proteins. In order to analyze 
differences in global protein expression between poly-GR/PR and GFP expressing cells, additionally, 
whole proteome analysis was performed from the neuronal extracts.  
 
Figure 5-4: Poly-GR and poly-PR can be immunoprecipitated from neuron and HEK293 cell lysates.  
Primary cortical rat neurons (DIV7+8) (A) and HEK293 cells (B) expressing GFP, GFP-(GR)149 or (PR)175-GFP were subjected to 
anti-GFP immunoprecipitation. Immunoblotting with a GFP specific antibody confirms pull-down of GFP, GFP-(GR)149 as well as 
(PR)175-GFP in the GFP-IP lanes. 
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 Poly-GR/PR predominantly interact with ribosomes in primary neurons 
In primary cortical neurons, we discovered in total close to 600 proteins binding to GFP-(GR)149 and 
(PR)175-GFP, but not the GFP control. In detail, we found 89 proteins significantly enriched in poly-GR 
expressing neurons and 104 in poly-PR expressing neurons, of which 39 were shared interactors 
mostly associated with stress granules and the ribosome (Figure 5-5A and Table S1/  
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Table S2). Among the poly-GR and poly-PR interacting proteins CCDC40, a dynein regulator, as well as 
C1QBP, a multifunctional protein involved in protein synthesis, splicing and apoptosis, were found to 
show the highest enrichment (Figure 5-5B). Moreover, analysis of interactors showed significant 
enrichment in proteins containing low complexity domains (LCD) (Figure 5-5C) in poly-GR and poly-PR 
expressing neurons, which is consistent with previous observations (Lee et al., 2016a; Lin et al., 2016). 
In line with the role of LCD containing proteins in assembly of membrane-less organelles, ~60% of the 
enriched proteins were annotated as RNA-binding (Gerstberger et al., 2014). They can be clustered 
into components of the nucleolus and stress granules, with interactors such as NPM1, STAU2, and 
YBX1, as well as proteins involved in splicing and methylation, like PRMT1/5, WDR77, and SRSF 
proteins. Furthermore, functional classification analysis revealed that the most abundant class of 
interacting proteins were ribosomal subunits. About 30% of them were identified as mitochondrial 
ribosomal proteins that are required for translation of the 13 subunits of respiratory chain complexes.  
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Figure 5-5: Poly-GR/PR predominantly interact with ribosomes in primary neurons.  
(A, B, C) Quantitative proteomic analysis of GFP immunoprecipitations from cortical neurons expressing GFP, GFP-
(GR)149 or (PR)175-GFP (DIV7+8). (A) Graph showing proteins with significant enrichment in poly-GR and pol-PR 
interactomes compared to GFP control. Interactors were manually grouped into functional categories. Note that the 
ribosome is the class with most interactors. Orthologs of proteins in italics were also found in the poly-GR/PR 
interactomes from HEK293 cells. (B) Proportion of low complexity regions (IUPred-L) of all proteins identified in the 
neuronal interactome analysis, the poly-GR interactome and the poly-GR interactome, ** denotes p < 0.01 in Mann-
Whitney-Wilcoxon test. (C) Volcano plots show interacting proteins plotted as log2 fold change versus the −log10 of 
the P-value. Grey line indicates significance cut-off. Enriched protein families are color coded: cytoplasmic ribosome 
(blue), mitochondrial ribosome (red), stress granules (brown) (Jain et al., 2016) and methylosome (green). The top 
enriched proteins (sorted by fold-change) and the proteins analyzed in this study are labeled with gene names. Filled 
circles indicate proteins significantly altered in HEK293 cells. 
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 Mitochondrial ribosomal proteins are the most abundant interactors in the poly-GR/PR 
interactome of HEK293 cells 
In order to compare the neuronal interactome of GFP-(GR)149 and (PR)175-GFP with an additional 
cellular system, I analyzed the poly-GR/PR interactome in HEK293 cells. Here, 394 proteins were 
associated with poly-GR and 50 were identified being enriched in poly-PR (Figure 5-6 and Table 
S3/Table S4). The two DPR species had 49 interactors in common while CD2AP was the only protein 
exclusively interacting with poly-PR (Figure 5-7A). Classification revealed that poly-GR associates with 
methyltransferases, such as PRMT1 and PRMT5, and numerous proteins from the 80S ribosome. In 
addition, both, poly-GR and poly-PR interactors were related to splicing with DDX/DHX and SRSF 
proteins being examples for RNA helicases and RNA splicing factors. Also stress granule associated 
proteins were enriched in both DPR interactomes with STAU1 being among them (Figure 5-5A proteins 
marked in italics). With ~15% of poly-GR interactors and ~67% of poly-PR interactors, mitochondrial 
ribosomal proteins were the most represented interactors. Moreover, about 80% of the interacting 
proteins were annotated as RNA-binding proteins, similar to the interactors of the neuronal 
interactome.  
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Figure 5-6: Mitochondrial ribosomal proteins are the most abundant interactors in the poly-GR/PR interactome of HEK293 cells.  
Quantitative proteomic analysis of GFP immunoprecipitations from HEK293 cells transduced with GFP, GFP-(GR)149 or (PR)175-GFP. 
Volcano plots show all significantly enriched interactors. The data for all proteins are plotted as log2 fold change versus the −log10 of 
the P-value. Grey line indicates significance cut-off. Enriched protein families are color coded: cytoplasmic ribosome (blue), 
mitochondrial ribosome (red), stress granules (brown) (Jain et al., 2016) and methylosome (green). The top enriched proteins (sorted 
by fold-change) and the proteins analyzed in this study are labeled with gene names. Filled circles indicate proteins significantly 
altered also in neurons.  
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 The interactomes of poly-GR/PR identify overlapping interactors in the two cell culture 
systems 
Figure 5-7: Poly-GR and poly-PR interact with similar RNA-binding proteins in neurons and HEK293 cells. 
(A, B) Comparison of poly-GR/PR interactomes of HEK293 cells and neurons expressing GFP, GFP-(GR)149 or (PR)175-GFP. 
(A) Venn diagram directly comparing individual interactors of poly-GR and poly-PR between cell types. (B) 2D analysis of gene 
ontology terms (GOMF, GOCC, GOCC, GOPB, KEGG, Uniprot Keywords) and stress granule proteins (Jain et al., 2016) for 
proteins identified in the poly-GR and poly-PR interactome in primary neurons and HEK293 cells (Fig. 5.5B and 5.6). Dots with 
nearly identical position and annotation were removed for clarity. Related terms from the main enriched protein families are 
color coded: ribosome (blue), nucleolus and stress granules (purple)(Jain et al., 2016), methylosome (green), splicing (yellow) 
and others (black). Annotation terms with a Benjamini-Hochberg FDR (q-value) smaller than 0.1 and comprising at least six 
proteins quantified by mass spectrometry are shown. 1D annotation scores close to 1 indicate strongest enrichment over the 
GFP control, scores close to 0 depict no enrichment and scores close to -1 strongest depletion. The analysis was performed in 
the Perseus software (Tyanova et al., 2016). 
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To elucidate whether primary rat neurons and human HEK293 cells show similar interactors which can 
be grouped into parallel pathways, I compared their interactomes directly. Detailed analysis revealed 
that neurons and HEK293 cells have 33 proteins in common in GFP-(GR)149 immunoprecipitates, such 
as NCL, C1QBP, and PRMT5. The poly-PR interactomes from both cell types on the other hand only 
share 11 identical proteins mostly being ribosomal subunits from mitochondria (C1QBP, MRPL3, 
MRPL17, MRPL22, MRPL27, MRPL28, MRPL41, MRPS30, MRPS9, SRSF10, YBX1) (compare Figure 5-5B 
with Figure 5-6 and Figure 5-7A). All four interactomes share C1QBP, MRPL3, MRPL28, and YBX1. When 
comparing gene ontology (GO) terms enriched in poly-GR interactors of the two cell types it becomes 
clear that there is a high selectivity for proteins associated with the nucleolus, ribosomes, the 
spliceosome, stress granules, and the methylosome. On the other hand, poly-PR interactors were 
mostly enriched in proteins connected to the U1 and U4 snRNP, the exon junction complex and the 
large ribosomal subunit from mitochondria (Figure 5-7B).  
Taken together, the poly-GR and poly-PR interactomes of primary rat neurons and human HEK293 cells 
revealed RNA-binding proteins as the most abundant interactors. In line with this finding, functional 
classification analysis showed that these interactors were associated with the cytosolic and 
mitochondrial ribosome, the nucleolus, the spliceosome and stress granules.  
 
 Whole proteome analysis of poly-PR expressing cells shows 
reduction of ribosomal proteins 
 
Although the analysis of the GFP-(GR)149 and (PR)175-GFP interactomes could already give new insights 
into the variety of interactors associated with poly-GR/PR, I was also interested in the changes on 
global protein levels in poly-GR/PR expressing cells. Therefore, we additionally analyzed global protein 
expression using quantitative LC-MS/MS in primary cortical neurons transduced with GFP-(GR)149, 
(PR)175-GFP and GFP. In poly-GR transduced neurons the expression of individual proteins was not 
obviously affected. After correction for multiple comparison only CSPG4 and NIFK were statistically 
different. In contrast, (PR)175-GFP expression significantly altered expression of numerous proteins 
compared to the GFP control (Figure 5-8A). Here, reduction of protein expression was very prominent 
and enrichment analysis revealed that especially cytosolic ribosome protein levels were reduced which 
was accompanied by a strong downregulation of synaptic and axonal proteins (Figure 5-8B). 
Interestingly, at the same time, expression of proteins associated with ribosomal biogenesis, such as 
BOP1 and PES1 were upregulated suggesting a compensatory effect. Also, proteins of the nucleolus 
and mitochondria were found to be slightly increased. Expression of stress granule components was 
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neither altered in (PR)175-GFP expressing nor in GFP-(GR)149 expressing neurons. Finally, GO annotation 
analysis showed a slight decrease in ribosomal proteins also in poly-GR transduced neurons (Figure 
5-8B). 
Overall, these observations suggest that poly-PR expression leads to the loss of ribosomal proteins 
which might directly affect global protein expression in neurons. Furthermore, the striking effect of 
nucleolar poly-PR, but not cytoplasmic poly-GR, on the whole neuronal proteome strongly supports 
the toxic effect of only (PR)175-GFP in neurons.  
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Figure 5-8: Poly-PR expression alters the whole proteome in neurons.  
(A) Volcano plot showing individual proteins quantified in whole proteome of GFP-(GR)149 and (PR)175-GFP transduced primary 
cortical neurons from the same mass spectrometry samples used for the interactome studies in Figures 5.5 to 5.7. The data 
for all proteins identified in whole cell lysates are plotted as log2 fold change versus the −log10 of the P-value. Significantly 
altered proteins (q-value <5%) are highlighted as black dots. Interactors significantly enriched (q-value <5%) are shown in red. 
Transparent black and red dots denote proteins that are not significantly changed. (B) 1D annotation enrichment analysis for 
comparison of gene ontology terms of respective proteome. GOMF, GOCC, GOCC, GOPB, KEGG, Uniprot Keywords, stress 
granule proteins (Jain et al., 2016) and proteins enriched in the neuronal poly-GR/PR interactome are shown. Annotations 
indicated in color or black are Benjamini-Hochberg FDR significant (q-value <5%). The analysis was performed in the Perseus 
software. 
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 Functional analysis of poly-GR/PR interactors reveals multiple 
pathways to be involved in C9orf72-associated toxicity 
Even though the analysis of the GFP-(GR)149 and (PR)175-GFP interactomes in primary neurons and 
HEK293 cells already revealed possible mechanisms involved in DPR toxicity, my aim was to further 
elucidate the connection of poly-GR/PR with the underlying pathways and validate interacting proteins 
involved. Thus, the following functional analysis focuses on the proteins associated with methylation, 
splicing, mitochondria, the nucleolus, stress granules and ribosomes as suggested by enrichment 
analysis of the interactome of both poly-GR and poly-PR. In order to functionally confirm putative poly-
GR/PR interacting proteins and their connection to C9orf72 pathogenesis, the major method was to 
co-express RFP-tagged interactors together with GFP-(GR)149, (PR)175-GFP or control GFP in neurons 
and HEK293 cells and study their effect on the localization of the DPR proteins and vice versa. 
Additionally, various other methods such as qRT-PCR, toxicity assays, immunoblotting and 
immunofluorescent stainings in cell culture and patient tissue were used. 
 Effects of poly-GR and poly-PR on methylation and splicing 
 Expression of various splicing factors leads to diffused nuclear poly-PR  
First, I tested the splicing factors SRSF1, SRSF10, TRA2A and TRA2B which we identified as interactors 
in both GFP-(GR)149 and (PR)175-GFP expressing HEK293 cells, but not in neurons. As expected, in 
HEK293 cells, all RFP-tagged interacting proteins involved in splicing localized to the nucleus. 
Compared to the GFP control, co-expression of GFP-(GR)149 did not lead to obvious changes in poly-GR 
or in RFP-SRSF1/SRFS10/TRA2A/TRA2B expression or localization. In contrast, all four interactors 
recruited otherwise nucleolar poly-PR into the remaining parts of the nucleus thereby leading to a 
diffuse expression pattern and colocalization with the respective splicing factor (Figure 5-9A). An 
explanation for changed (PR)175-GFP localization might be the spatial proximity of the DPR protein with 
the splicing factors within the nucleus compared to more cytoplasmic poly-GR. Thus, SRSF1, SRSF10, 
TRA2A and TRA2B, which are representing the group of proteins involved in splicing, could be validated 
as interacting proteins in poly-PR expressing HEK293 cells.  
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 Poly-GR does not affect methylation in neurons 
To assess the role of the methylosome, which was suggested to be potentially altered in GFP-(GR)149 
expressing cells, I had a closer look at methylation in primary neurons. Therefore, I conducted western 
blot analysis using antibodies detecting Histone H4 asymmetric di-methylation, general mono-
methylation and symmetric di-methylation of arginines. In cortical neurons transduced with GFP-
(GR)149, the methylation pattern and methylation intensity were indistinguishable from the one in the 
GFP control. Thus, interaction of poly-GR with PRMT5/WDR77 may reflect arginine-methylation of 
poly-GR itself. In contrast, (PR)175-GFP expressing cells showed a general reduction of methylated 
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Figure 5-9: Expression of splicing factors alter poly-PR 
distribution while poly-PR expression alters arginine 
methylation patterns.  
(A) HEK293 cells co-expressing GFP, GFP-(GR)149 or 
(PR)175-GFP and RFP tagged splicing factors. Single plane 
images were obtained on a confocal microscope. Left 
columns show GFP fluorescence and right columns show 
merge of GFP, RFP-tagged proteins and nuclear DAPI 
staining (blue). Scale bar denotes 20 µm. Note that poly-
PR shows diffuse nuclear localization upon expression of 
splicing factors. (B) Primary rat cortical neurons (DIV6+7) 
were transduced with GFP, GFP-(GR)149 or (PR)175-GFP. 
Immunoblots show reduced methylation in poly-PR 
expressing neurons detected with antibodies specific for 
histone methylation as well as general single and di-
methylation. Calnexin was used as loading control. 
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proteins (Figure 5-9B) which is probably a secondary effect of overall reduction of protein expression 
already revealed by whole proteome analysis.  
 Mitochondria are stressed upon poly-GR/PR expression 
 Poly-GR and poly-PR do not alter the mitochondrial ribosome 
Given the wide-spread interaction of the mitochondrial ribosome with both poly-GR and poly-PR, I 
next analyzed if expression of GFP-(GR)149 or (PR)175-GFP alters localization or distribution of subunits 
of the mitochondrial ribosome in HEK293 cells as well as in neurons. Immunofluorescence stainings 
showed that, as expected, MRPL19 and MRPS9 localize to the cytoplasm in a dot-like manner in cells 
expressing the GFP control. Also upon transfection or transduction of GFP-(GR)149 or (PR)175-GFP, the 
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Figure 5-10: The mitochondrial ribosome is not altered upon poly-GR or poly-PR expression in neurons. 
(A, B) Hippocampal and cortical rat neurons transduced with GFP, GFP-(GR)149 or (PR)175-GFP lentivirus (DIV6+7). 
(A) Immunofluorescent stainings of components of the small (MRPS9) and large (MRPL19) ribosomal subunits of mitochondria. 
Single confocal planes are shown. Left columns visualize mitochondrial ribosomal proteins and right columns show merge of 
GFP, MRP (red) and nuclear DAPI staining (blue). Scale bar denotes 20 µm. (B) Immunoblots show no changes in MRPS9 
expression in poly-GR or poly-PR expressing neurons. Calnexin was used as loading control. 
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distribution pattern, as well as the expression levels of the endogenous proteins of the small ribosomal 
subunits of mitochondria, remained unchanged (Figure 5-10A). In addition, immunoblotting analysis 
showed that MRPS9 protein levels were not significantly altered in cortical neurons upon poly-GR and 
poly-PR transduction (Figure 5-10B) confirming the observations from immunofluorescence.  
 Poly-PR transduced neurons show respiratory deficits  
Although poly-GR and poly-PR did not seem to have an effect on localization and expression levels of 
the mitochondrial ribosome, I was curious whether the extensive interaction of the two DPR proteins 
with MRPS/L proteins identified in the MS analysis is affecting mitochondria directly. As previous 
studies only reported oxidative stress without showing effects on mitochondrial morphology or 
respiration, I assessed subcellular localization and checked for mitochondrial integrity. I first stained 
HeLa cells and hippocampal neurons using antibodies specific for the mitochondrial proteins MTCO2 
and MTCO1, two cytochrome c oxidase components of the respiratory chain, respectively. GFP 
expressing HeLa cells maintained healthy mitochondria membranes and showed mitochondria-specific 
tubular, cytoplasmic MTCO2 staining. Interestingly, upon transfection with GFP-(GR)149 and also 
(PR)175-GFP, mitochondrial morphology was changed to a string-like, hyper-fused distribution (Figure 
5-11A) indicating mitochondrial stress. In hippocampal neurons transduced with GFP or GFP-(GR)149, 
MTCO1 showed a dot-like mitochondrial pattern. This pattern remained unchanged upon expression 
of (PR)175-GFP, but overall MTCO1 signal was reduced (Figure 5-11A) suggesting that poly-PR toxicity 
may be associated with loss of mitochondria. 
This strong downregulation of the mitochondria related MTCO1 protein detected in 
immunofluorescence stainings was also validated by immunoblotting experiments. Here, MTCO1 
expression levels were significantly reduced in poly-PR transduced cortical neurons, while poly-GR 
expressing neurons showed similar MTCO1 levels as the GFP control (Figure 5-11B).  
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In order to elucidate whether this downregulation of the cytochrome c subunit, which 
catalyzes the reduction of oxygen to water, has a direct effect on mitochondrial respiration, I measured 
oxygen consumption rates (OCR) using the Seahorse analyzer. Quantification of cellular respiration in 
GFP-(GR)149 and GFP expressing neurons showed the typical OCR pattern. (PR)175-GFP expressing 
neurons, however, displayed reduced basal respiration accompanied by reduced maximal respiration 
upon uncoupling with FCCP, resulting in an overall significant lower respiratory capacity (Figure 5-11C).  
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Figure 5-11: Mitochondria are stressed especially in poly-PR expressing cells. 
(A, B, C) HeLa cells, hippocampal and cortical rat neurons (DIV6+7) were transfected or transduced with GFP, GFP-(GR)149 or 
(PR)175-GFP. (A) Immunofluorescent stainings of subunits 1 and 2 of the mitochondrial cytochrome c complex of the inner 
mitochondrial membrane in HeLa cells and hippocampal neurons. Left columns show single confocal planes of MTCO2 or 
MTCO1 stainings and right columns show merge of GFP, the cytochrome c complex (red) and DAPI marking nuclei (blue). Scale 
bar denotes 20 µm. (B) Immunoblot shows reduction of MTCO1 levels in cortical neurons expressing (PR)175-GFP. Calnexin was 
used as loading control. (C) Mitochondrial respiration was quantified in hippocampal and cortical neurons in real-time using 
the Seahorse analyzer. The oxygen consumption rate (OCR) was normalized to total protein concentration. After recording 
basal respiration, oligomycin (final concentration 1 μM) was added to inhibit ATP synthase (proton leak). Thereafter injection 
of FCCP followed to measure maximal respiration and antimycin A/rotenone was added to calculate non-mitochondrial oxygen 
consumption. Mean ± SEM is shown. (6 replicates from 1 experiment, * denotes p<0.05, ** denotes p<0.01 and *** denotes 
p<0.001 in two-way ANOVA, only shown for significant data points in poly-PR expressing neurons.) (D) Immunofluorescent 
staining of MTCO1 in C9orf72 patient cortex and control. DAPI stains nuclei in blue. Single confocal planes are shown. Scale bar 
depicts 20 µm. 
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Lastly, I wanted to assess the role of mitochondria in C9orf72 patients. Therefore, I probed 
brain slices from patients with an MTCO1 specific antibody. Immunofluorescence stainings showed 
that MTCO1 distribution was unchanged in C9orf72 patient compared to healthy control. 
Furthermore, MTCO1 did not co-aggregate with poly-GR (Figure 5-11D).  
Although the interactome of poly-GR and poly-PR shows extensive interaction of the two DPR species 
with mitochondrial ribosomal subunits, the analysis in vitro reveals no clear role of the mitochondrial 
ribosome in disease pathogenesis so far. However, mitochondria themselves seem to be stressed upon 
poly-GR and poly-PR expression showing changed morphology in HeLa cells and respiratory deficits in 
primary neurons. In C9orf72 patients, there is no evidence for altered mitochondrial morphology. In 
accordance to the stress phenotype of the mitochondria observed in these experiments, also Lopez-
Gonzalez and colleagues found increased mitochondrial reactive oxygen species (ROS) in patient 
derived iPSC neurons (Lopez-Gonzalez et al., 2016). Nevertheless, together with the findings in this 
work, that study is the only one making involvement of mitochondria a subject of discussion in poly-
GR/PR mediated toxicity although mitochondrial ribosomal proteins were associated with the two 
arginine-rich DPR proteins in previous proteome and interactome studies (Lopez-Gonzalez et al., 2016; 
Yin et al., 2017; Zhang et al., 2018b). Thus, it remains to be elucidated whether stress in this cellular 
compartment is indeed involved in a pathogenic mechanism.  
 Poly-PR expression alters nucleolar structure 
Next, I examined the nucleolar proteins NOP56 and NPM1, which we identified as poly-PR/GR 
interacting proteins in both HEK293 cells and neurons, respectively. In HEK293 cells, expression of RFP-
NOP56 and RFP-NPM1 resulted in colocalization with GFP-(GR)149 and (PR)175-GFP in the nucleolus as 
expected, but had no effect on localization or expression of either DPR protein (Figure 5-12A). In 
hippocampal neurons, however, expression of RFP-NPM1 surprisingly shifted otherwise cytoplasmic 
GFP-(GR)149 into the nucleolus showing colocalization in nearly every cell (Figure 5-12B and D). In 
contrast, in RFP-NOP56 transduced neurons, poly-GR was not affected and remained in the cytosol 
similar to cells with RFP expression (Figure 5-12B and D). Furthermore, RFP-NOP56 co-expression did 
not change (PR)175-GFP localization in neurons. Interestingly, vice versa, (PR)175-GFP expression altered 
the distribution of RFP-NOP56 within the nucleolus compared to GFP or GFP-(GR)149 co-transfected 
cells (Figure 5-12C close-up). While RFP-NOP56 would typically be evenly distributed in the nucleolus, 
expression of poly-PR led to the formation of a granular pattern with granules surrounding the PR 
aggregate. This result is in line with the specific interaction of poly-PR with NOP56 in neurons (Figure 
5-5A).  
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Figure 5-12: Nucleolar interactors colocalize with poly-GR/PR in HEK293 cells and neurons.  
(A-D) HEK293 cells and hippocampal neurons (DIV6+7) co-expressing GFP, GFP-(GR)149 or (PR)175-GFP and the RFP-tagged 
nucleolar interacting proteins NPM1 and NOP56. Single focal planes were analyzed. RFP was used as negative control. Scale 
bars denote 20 µm. (A, B, C) Left columns show GFP fluorescence and columns labeled with ‘merge’ show merge of GFP, RFP-
tagged proteins and nuclear DAPI staining (blue). (A) Poly-GR and poly-PR colocalize with RFP-NPM1 and RFP-NOP56 in nucleoli 
in HEK293 cells (red arrows). White arrows indicate poly-GR/PR granules occasionally seen the cytoplasm. (B) RFP-NPM1 is 
localizing to nucleolar poly-PR in hippocampal neurons. Note that NPM1 expression recruits poly-GR into the nucleolus (white 
arrow). (C) Poly-PR expression in neurons results in altered RFP-NOP56 distribution (RFP-NOP56 channel and close-up). 
(D) Percentage of neurons with poly-GR localized to the nucleolus in NPM1- and NOP56-expressing neurons compared to the 
RFP control (RFP: n=9; RFP-NPM1: n=11; RFP-NOP56: n=10 images (40x objective) from 3 independent experiments, mean ± 
SEM, *** denotes p<0.001 in one-way ANOVA with Dunnett's post-test). 
To further validate that poly-PR expression has an influence on nucleolar structure, I analyzed 
the nucleolar markers proteins fibrillarin and GTPBP4 in hippocampal neurons by 
immunofluorescence. Also here, the nucleolar disorganization was clearly visible in (PR)175-GFP 
expressing neurons. Cells transduced with GFP-(GR)149 and GFP showed a ring-like or even distribution 
of fibrillarin as well as GTPBP4, whereas poly-PR expression resulted in granule-like dots within the 
nucleolus (Figure 5-13).  
Overall, these findings suggest that the nucleolus, which emerged from the enrichment analysis of 
both interactomes, is indeed a cellular compartment affected by DPR protein expression in vitro. This 
is underlined by the observations that the interaction of poly-GR/PR with co-expressed nucleolar 
proteins has sufficient affinity to alter the subcellular distribution of either binding partner and that 
especially poly-PR has direct effect on nucleolar structure also on an endogenous level in vitro. 
 
Figure 5-13: Poly-PR expressing neurons show altered nucleolar distribution in hippocampal neurons. 
Hippocampal rat neurons (DIV6+7) were infected with GFP, GFP-(GR)149 or (PR)175-GFP. Single confocal planes of 
immunofluorescent stainings of the nucleolar marker proteins fibrillarin and GTPBP4 were analyzed. Left columns show GFP 
fluorescence, middle columns visualize stainings of fibrillarin/GTPBP4 and right columns show merge of GFP, nucleoli (red) and 
DAPI marks nuclei (blue). Scale bar denotes 20 µm. Note that poly-PR expression results in disruption of the nucleolus. 
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 Cytoplasmic poly-GR/PR clusters resemble stress granules  
 Poly-GR/PR forms large granule-like structures in the cytoplasm 
As various proteins linked to stress granules were found to interact with poly-GR/PR in both HEK293 
cells and neurons, I again conducted co-expression experiments to elucidate their role in DPR protein 
toxicity. Therefore, I expressed the interactors RFP-STAU1, RFP-STAU2, RFP-YBX1, and RFP-EIF4A3 
together with GFP-(GR)149, (PR)175-GFP or a GFP control in HEK293 cells and neurons. Under RFP control 
conditions, transfection of both poly-GR and -PR occasionally resulted not only in nucleolar 
aggregation, but also formation of small cytoplasmic granules in HEK293 cells (white arrows in Figure 
5-12A). Interestingly, upon co-expression of RFP-STAU1/STAU2 and RFP-YBX1, these cytoplasmic 
granules were significantly increased in number, size, and intensity. Of note, not only poly-GR/PR were 
rerouted to the cytoplasm, but also the stress granule associated proteins themselves clustered into 
the large cytoplasmic inclusions leading to colocalization of the two DPR species and 
STAU1/STAU2/YBX1 (white arrows in Figure 5-14A). Among the tested stress granule components only 
EIF4A3, identified in the poly-PR interactome, did not alter cytoplasmic poly-GR/PR proteins. 
Quantitative analysis confirmed that the GFP-(GR)149 and (PR)175-GFP inclusions in the cytoplasm are 
increased in number and also the average size upon expression of RFP-STAU1, RFP-STAU2 and RFP-
YBX1, but not RFP-EIF4A3 (Figure 5-14B).  
Next, I repeated this experiment in primary hippocampal neurons to elucidate whether dense 
cytoplasmic poly-GR or -PR granules can also be detected in this cellular system. To allow higher 
expression levels I co-transfected GFP-(GR)149, (PR)175-GFP or a GFP control with RFP-STAU1/STAU2 and 
RFP-YBX1. While transfection of (PR)175-GFP resulted in high toxicity (compared to the lower expression 
in transduced neurons) and probably killed all poly-PR expressing neurons, poly-GR transfected 
neurons showed similar colocalization with the stress granule associated proteins in the cytoplasm as 
seen in HEK293 cells. Also here, the even cytoplasmic distribution was disrupted and resulted in 
granule like inclusions (Figure 5-14C). In transduced neurons, expression levels were presumably too 
low to affect poly-GR/PR distribution (data not shown). 
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 The large cytoplasmic poly-GR/PR granules are G3BP1 positive 
To assess the nature of these cytoplasmic poly-GR/PR clusters detected in both HEK293 cells and 
neurons, I analyzed classical stress granule markers G3BP1, TIAR and FMRP in HEK293 cells co-
transfected with GFP-(GR)149, (PR)175-GFP or a GFP control and RFP-STAU1 or RFP-YBX1 by 
immunofluorescence. Strikingly, all three markers colocalized with the poly-GR/PR granules in RFP-
STAU1 and RFP-YBX1 transfected HEK293 cells indicating that the large cytoplasmic inclusions 
represent bona fide stress granules (white arrows in Figure 5-15A and B, FMRP not shown, YBX1 
transfected cells not shown). In addition, also an antibody against YBX1 itself nicely detected the 
granules (data not shown). However, the less frequent small cytoplasmic poly-GR/PR inclusions formed 
in RFP control conditions were also predominantly G3BP1, TIAR and FMRP-positive suggesting that 
expression of the RFP-tagged stress granule associated proteins enhances the formation of stress 
granules by boosting the process existing under basal conditions.  
  
Figure 5-14: STAU1/2 and YBX1 recruit poly-GR/PR into large cytoplasmic granules.  
HEK293 cells and primary cortical neurons co-expressing GFP, GFP-(GR)149 or (PR)175-GFP and RFP-tagged interactors related 
to stress granules. (A) Single confocal planes of immunofluorescence images of HEK293 cells showing co-expression of RFP-
STAU1/2, RFP-YBX1 or RFP-EIF4A3 together with the two DPR proteins or GFP are shown. Left columns visualize GFP 
fluorescence, right columns show merge of GFP, RFP-tagged proteins and nuclear DAPI staining (blue). Scale bar denotes 
20 µm. Note that STAU1/2 and YBX1 reroute poly-GR and -PR into large cytoplasmic granules (white arrows). (B) Quantifications 
of cytoplasmic poly-GR/PR structures seen in (A). Left bar graph represents percentage of cytoplasmic granules out of all 
analyzed granules in both, nucleolus and cytoplasm in poly-GR (red bars) and poly-PR (blue bars). RFP served as control 
(GR/RFP: n=16; PR/RFP: n=14; GR/RFP-STAU1: n=19; PR/RFP-STAU1: n=20; GR/RFP-STAU2: n=10; PR/RFP-STAU2: n=8; GR/RFP-
YBX1: n=14; PR/RFP-YBX1: n=14; GR/RFP-EIF4A3: n=6; PR/RFP-EIF4A3: n=6 images (40x) from two independent experiments). 
Cytoplasmic granule size is visualized by the right bar graph (GR/RFP: n=130; PR/RFP: n=132; GR/RFP-STAU1: n=104; PR/RFP-
STAU1: n=132; GR/RFP-STAU2: n=123; PR/RFP-STAU2: n=65; GR/RFP-YBX1: n=119; PR/RFP-YBX1: n=53; GR/RFP-EIF4A3: n=93; 
PR/RFP-EIF4A3: n=71 aggregates from two independent experiments). Mean ± SEM is shown, *** denotes p<0.001 and ** 
denotes p<0.01 in one-way ANOVA with Dunnett's post-test. (C) Immunofluorescence images of neurons (DIV7+3) co-
transfected with RFP-STAU1, RFP-STAU2 or RFP-YBX1 and GFP-(GR)149 or GFP. Single focal planes are shown. Top rows show 
GFP signal, middle rows visualize RFP fluorescence of stress granule proteins or RFP control and bottom rows show merged 
signals including DAPI marking nuclei (blue). Note that the largely homogenous poly-GR pattern in the RFP control is largely 
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Figure 5-15: Cytoplasmic poly-GR/PR granules are identified as stress granules in HEK293.  
HEK293 cells were co-transfected with GFP, GFP-(GR)149 or (PR)175-GFP and RFP-STAU1. Immunofluorescence images show colocalization 
of cytoplasmic poly-GR/PR with the stress granule markers (A) G3BP1 and (B) TIAR in HEK293 cells co-transfected with RFP-STAU1. Left 
three columns show individual channels as indicated. Right columns visualize merge with additional nuclear DAPI staining in white. Arrows 
indicate cytoplasmic inclusions co-labeled with G3BP1 or TIAR. Single confocal planes were taken. Scale bar depicts 20 µm. 
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 STAU2 but no other SG proteins are found in poly-GR aggregates in C9orf72 patient brain 
In order to elucidate whether stress granules also play a role in FTD/ALS patients, I additionally probed 
FTD patient brains with C9orf72 repeat expansion and healthy control brains with two different stress 
granule markers and antibodies detecting the poly-GR/PR interacting proteins YBX1 and STAU2. As 
expected, the C9orf72 FTD case showed widespread poly-GR and sparse poly-PR cytoplasmic inclusions 
in the frontal cortex. Cytoplasmic G3BP2 and nuclear TIAR did not show convincing colocalization with 
aggregates stained with a poly-GR antibody. Also, the interactor YBX1 could not be discovered in 
cytoplasmic poly-GR inclusions. Only STAU2 colocalized with approximately 25% of the poly-GR 
aggregates in the frontal cortex of two C9orf72 patients (Figure 5-16A).  
 
In conclusion, although poly-GR and poly-PR interact with various stress granule related proteins and 
are recruited into stress granules upon expression of STAU1/2 and YBX1, classical stress granule 
markers are not labeling the poly-GR inclusions in patient brains. Here, only STAU2 was convincingly 
co-aggregating with poly-GR. These findings indicate that a more transient interaction exists between 
stress granule proteins and the two DPR proteins in C9orf72 patients. 
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Figure 5-16: STAU2 colocalizes with poly-GR 
aggregates in C9orf72 patient brain. 
C9orf72 patients and a healthy controls were 
analyzed in immunofluorescence images of frontal 
cortex. Stress granule components TIAR, G3BP2, 
YBX1 and STAU2 were stained in red while poly-GR 
was labeled in green. Merge shows additional DAPI 
staining (blue) marking nuclei. Arrows point to poly-
GR aggregates. Single confocal planes were taken. 
Scale bar depicts 20 µm. 
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 Poly-GR and poly-PR bind the cytosolic ribosome and inhibit translation 
 Ribosomal proteins are absent from cytoplasmic stress granule-like inclusions 
Next, I wondered whether the poly-GR/PR cytoplasmic stress granule-like inclusions found upon 
STAU1/2 and YBX1 expression are also recruiting parts of the ribosome, as ribosomal proteins were 
the most prominent interactors of poly-GR and poly-PR in both primary neurons and HEK293 cells. 
Therefore, I stained HEK293 cells co-expressing poly-GR/PR and RFP-STAU1, as representative 
example, with an antibody directed against the 40S ribosomal protein RPS6. As expected, the small 
ribosomal subunit was diffusely distributed throughout the cytoplasm in control RFP cells independent 
of GFP or poly-GR/PR expression (Figure 5-17 lower image). Co-expression of the stress granule 
component RFP-STAU1 with poly-GR/PR did not change the localization of RPS6 and only modest 
amounts of RPS6 were detected in cytoplasmic poly-GR/PR inclusions (Figure 5-17 upper image). 
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Figure 5-17: RPS6 does not label large 
cytoplasmic poly-GR/PR inclusions in vitro.  
HEK293 co-expressing GFP, GFP-(GR)149 or 
(PR)175-GFP and RFP-STAU1 were imaged on 
a confocal microscope. Endogenous staining 
of the ribosomal subunit RPS6 was analyzed. 
Left three columns show individual channels 
as indicated. Right columns visualize merge 
with additional nuclear DAPI staining in 
white. Scale bar depicts 20 µm. Note that the 
large cytoplasmic poly-GR/PR granules 
induced by STAU1 expression are not clearly 
stained with RPS6 when comparing 
intensities to the cytoplasm. 
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 Poly-PR expression reduces ribosomal proteins in neurons 
In order to validate and investigate individual poly-GR/PR interactors I so far mainly used co-expression 
of RFP-tagged proteins, but tagging of ribosomal proteins without affecting their function is difficult. 
Therefore, I first analyzed expression of endogenous ribosomal proteins in immunoblotting 
experiments. Strikingly, primary cortical neurons transduced with (PR)175-GFP showed significant 
reduction of RPS6, RPL19, and RPL36A levels compared to the GFP control, while GFP-(GR)149 
expression had no overt effect (Figure 5-18A). This finding was confirmed by quantification of the 
respective immunoblots (Figure 5-18B).  
To further study the effects of the two DPR proteins on the cytosolic ribosome, I additionally 
examined the localization of ribosomal subunits in neurons expressing GFP-(GR)149 and (PR)175-GFP 
using immunofluorescence stainings. As expected, RPS6 as well as RPL19 diffusely localized to the 
cytoplasm in control GFP conditions. While expression of GFP-(GR)149 had no effect on the localization 
or the expression level of the two ribosomal subunits, expression of poly-PR was causing a more 
disordered and granular pattern of RPS6. In line with the findings from the immunoblotting 
experiments, poly-PR strongly reduced RPL19 staining intensity (Figure 5-19A).  
To examine the role of cytosolic ribosomes in vivo, I performed immunofluorescence stainings 
of ribosomal proteins in FTD patient brains harboring the C9orf72 repeat and controls. In contrast to 
the results from neuronal cell culture, immunofluorescence analysis of RPS6 and RPL19 in C9orf72 
patients did not reveal differences in protein levels compared to healthy controls (Figure 5-19B).  
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Figure 5-18: Subunits of the cytoplasmic ribosome are reduced upon poly-PR expression in neurons. 
(A) Cortical rat neurons were transduced with GFP, GFP-(GR)149 or (PR)175-GFP lentiviral constructs (DIV6+7) and analyzed on 
immunoblots. Poly-PR expressing neurons show reduction of several ribosomal subunits compared to GFP and poly-GR. 
Calnexin was used as loading control. (B) Quantification of RPS6 signal normalized to Calnexin (n=6 from 3 independent 
experiments, mean ± SEM, ** denotes p<0.01 in one-way ANOVA with Dunnett's post-test), RPL19 signal normalized to 
Calnexin (n=6 from 3 independent experiments, mean ± SEM, *** denotes p<0.001 in Kruskal-Wallis test with Dunn’s post-
test) and RPL36A signal normalized to Calnexin (n=6 from 3 independent experiments, mean ± SEM, ** denotes p<0.01 in 
Kruskal-Wallis test with Dunn’s post-test). 
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Thus, especially poly-PR expression results in an overall reduction of the cytosolic ribosome which 
could be validated on protein level by immunoblotting and immunofluorescence stainings in primary 
neurons, but not in neurons bearing poly-GR/PR inclusions in C9orf72 patient brains.  
 
A
B
D
AP
I
R
P
m
er
ge
CTRL C9orf72 CTRL C9orf72
RPS6 RPL19
GFP GFP-GR149 PR175-GFP
G
FP
R
P
m
er
ge
RPS6
GFP GFP-GR149 PR175-GFP
RPL19
Figure 5-19: The cytosolic ribosome is not reduced in C9orf72 patient brain.  
(A) Hippocampal primary neurons (DIV6+7) were infected with GFP, GFP-(GR)149 or (PR)175-GFP lentiviral constructs. Single 
focal images of immunofluorescence stainings of the ribosomal subunits S6 and L19 were analyzed. Upper rows show GFP 
fluorescence, middle rows visualize ribosomal proteins (RP) in red and in merge DAPI marks nuclei (blue) additionally. 
Compare ordered RPS6 staining in GFP and poly-GR with unstructured RPS signal in poly-PR. Also, note that RPL19 signal is 
reduced in poly-PR expressing neurons. Scale bar denotes 20 µm. (B) Immunofluorescence stainings of RPS6 and RPL19 in 
C9orf72 patient cortex and healthy control. DAPI stains nuclei in blue. Single confocal planes are shown. Scale bar depicts 
50 µm. 
RESULTS 
93 
 
 Ribosomal subunits are found in poly-GR/PR inclusions in patients 
Although the reduction of ribosomal proteins could not be validated in patient tissue, interestingly, I 
noticed that RPS6, RPL19 as well as RPS25 and RPL36A showed condensed spots within the cytoplasm 
which colocalized with poly-GR inclusions in double immunofluorescent stainings. In contrast, 
ribosomal subunits were evenly distributed in healthy controls (Figure 5-20A and B). Quantification 
revealed that strikingly about one-third of cytoplasmic poly-GR inclusions in the cortex were positive 
for ribosomal proteins (Figure 5-20C and D). This enrichment of ribosomal proteins was less in poly-PR 
aggregates (Figure 5-20A) and the low number of aggregates did not allow reliable quantification. 
Overall, this observation suggests that the ribosome is not only affected by poly-GR/PR in vitro, but 
also plays a significant role in C9orf72 patients. 
Figure 5-20: Ribosomal proteins co-aggregate with poly-GR and -PR in C9orf72 patient brain.  
Confocal images of immunofluorescent stainings of (A) RPS6, RPL19, (B) RPS25 and RPL36 in C9orf72 patient cortex and healthy control. 
Note that ribosomal proteins are sequestered into poly-GR/PR inclusions. DAPI marks nuclei in blue. Single confocal planes are shown. 
Scale bar depicts 20 µm. (C, D) Quantitative analysis of colocalization of ribosomal proteins with poly-GR aggregates (n=3 sections with 
100 poly-GR aggregates counted each from C9orf72 cortex, mean ± SEM is shown). 
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 Translation is impaired by poly-PR in primary neurons  
Next, I was curious whether the reduction of ribosomal proteins detected in vitro would also affect 
translation. This would be in line with the proteomics finding that in poly-PR expressing neurons 
hundreds of proteins, including the ribosome itself, were downregulated. To verify this hypothesis, I 
performed a so-called ‘surface sensing of translation’ (SUnSET) assay, which measures puromycin 
incorporation into newly synthesized proteins using a puromycin specific antibody. Immunoblotting 
showed that translation was substantially reduced in neurons expressing (PR)175-GFP after 10 min and 
20 min of puromycin incubation compared to the GFP control and poly-GR (Figure 5-21A). This 
significant reduction in protein expression was quantified in Figure 5-21B. Hence, the loss of ribosomal 
subunits led to an overall translational repression suggesting that poly-PR expression leads to a 
reduction of functional/assembled ribosomes.  
 
 rRNA processing is not changed in DPR expressing cells 
The observations that poly-PR expression disrupts nucleolar structure and reduces translation in 
neurons imply that rRNA processing might also be impaired. To test this, I performed quantitative PCR 
on RNA extracted from GFP-(GR)149, (PR)175-GFP and GFP transduced neurons. The primers I used 
covered the 18S and 5.8S rRNA. Primers specific for the whole unprocessed 45S rRNA and the 28S part 
only resulted in melting curves with multiple maxima or irregular standard curves making them 
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Figure 5-21: Poly-PR expression in neurons inhibits translation.  
(A) Cortical rat neurons were transduced with GFP, GFP-(GR)149 or (PR)175-GFP lentiviral constructs (DIV6+7) and incubated with 
1 µM puromycin (puro) for 0, 10 and 20 min prior to sample preparation in order to quantify global translation. Immunoblot 
of SUnSET assay shows that poly-PR expressing neurons have less puromycin incorporated in newly synthesized proteins 
compared to poly-GR and GFP control. (B) Quantification of RPS6 signal normalized to Calnexin (n=3, mean ± SEM, Kruskal-
Wallis test with Dunn’s post-test, not significant) and puromycin signal normalized to Calnexin (n=6, mean ± SEM, one-way 
ANOVA with Dunnett's post-test, *** denotes p<0.001). 
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impracticable for analysis (Figure 5-22A). Relative expression levels of 18S and 5.8S rRNA revealed that 
none of the tested rRNA fragments was significantly altered upon poly-GR or poly-PR expression in 
primary neurons (Figure 5-22B) suggesting that aberrant rRNA processing is not the major pathway 
driving impaired translation under physiological conditions.  
Figure 5-22: Reduction in ribosomal proteins is independent of rRNA maturation, but may trigger ribosomal biogenesis.  
(A)  Schematic of rRNA primer binding sites depicted in grey. (B-D) Cortical rat neurons were transduced with GFP, GFP-(GR)149 
or (PR)175-GFP lentiviral constructs (DIV6+7). (B) Analysis of quantitative RT-PCR showing rRNA levels of the 18S and 5.8S 
fragments relative to PGK (n=4 from 2 individual experiments, mean ± SEM, one-way ANOVA with Dunnett's post-test). 
(C) Immunoblots of neuronal lysates were exposed to antibodies specific for BOP1 and PES1. Calnexin was used as a control. 
Note that the 83 kDa BOP1 protein is increased upon poly-PR expression. The 71 kDa large isoform 2 of BOP1 is marked with 
asterisks. All other bands are unspecific. (D) qRT-PCR analysis visualizing mRNA levels of the ribosome biogenensis proteins 
BOP1 and PES1 relative to PGK (n=4 from 2 individual experiments, mean ± SEM, one-way ANOVA with Dunnett's post-test). 
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GO term analysis of differentially expressed proteins in the whole proteome of poly-PR 
transduced primary cortical neurons showed upregulation of proteins involved in ribosome biogenesis, 
including NSA2, RRP1, BRIX1, NOC2L, WDR75 and TSR1 suggesting neurons may trigger a 
compensatory response to evade cell death (Figure 5-8C). BOP1 and PES1, two of the three proteins 
of the PeBoW complex involved in processing the 28S and 5.8S rRNA and subsequent maturation of 
the large 60S ribosomal subunit were significantly upregulated in the proteome analysis. WDR12 was 
not altered in the proteome. To validate this finding, I analyzed expression levels by immunoblotting 
experiment and qPCR in GFP-(GR)149, (PR)175-GFP and GFP transduced neurons. Here, the 83 kDa large 
BOP1 protein was indeed upregulated in poly-PR expressing cells, but the small increase in mRNA levels 
did not reach significance (Figure 5-22C and D). This modest effect, however, is in line with 1.66-fold 
enrichment of BOP1 in neurons expressing poly-PR. Although PES1 was also enriched at the same level 
in the mass spectrometry analysis of poly-PR expressing neurons, it did not show elevated protein or 
mRNA levels (Figure 5-22C and D).  
 NPM1 has no rescue effect, but MEK1 does 
The next step was to determine whether boosting translation would prevent neuronal death in poly-
PR expressing neurons. Thus, I first tested whether expression of poly-GR or poly-PR interactors is able 
to reverse the translational impairment seen in (PR)175-GFP transduced neurons. As the nucleolus is 
the major compartment associated with ribosome biogenesis, I first tested interactors which are 
nucleolar and linked to ribosomes, namely NOP56, NPM1, GTPBP4 and BRIX1. NOP56 and GTPBP are 
involved in the assembly of the 60S ribosomal subunit, NPM1 is chaperoning ribosomal proteins, and 
BRIX1 also functions in biogenesis of the 60S ribosomal subunit. However, co-expression of poly-PR 
with the four nucleolar proteins did not restore translation efficiency in the SUnSET assay compared 
to the poly-PR/RFP control (Figure 5-23A).  
The next step was to test whether expression of proteins other than poly-GR/PR interactors 
could rescue impaired ribosome biogenesis. Therefore, I chose MEK1, the main activator of the 
MAPK/ERK/S6K pathway which boosts translation by phosphorylation of RPS6. The effect on 
translation of the constitutive active form (S218D and S222D mutations) of MEK1 in GFP-(GR)149, 
(PR)175-GFP and GFP transduced neurons was again analyzed by the SUnSET assay as before. Here, 
expression of MEK1 resulted in increased puromycin signal in poly-GR as well as in poly-PR and GFP 
expressing neurons compared to the empty vector control. Notably, in poly-PR expressing neurons the 
puromycin signal was restored to control levels (Figure 5-23B) and similarly, also RPS6 levels were 
almost restored suggesting that poly-PR toxicity induced by impaired protein synthesis could be 
rescued by overexpression of MEK1. To substantiate this hypothesis, I performed an LDH toxicity assay 
in neurons (DIV7+14) in the same experimental settings. Here, MEK1 expression slightly inhibited basal 
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cell death in GFP and (non-significantly) also in poly-GR expressing neurons. This is not surprising as 
MEK1 positively regulates ERK1/2 which activate anti-apoptotic proteins (Lu and Xu, 2006). Strikingly, 
MEK1 overexpression reduced cell death induced by poly-PR expression nearly to GFP control levels 
suggesting impaired translation contributes to cell death.  
Taken together, MEK1, a key regulator of translation and cell growth, was able to reverse poly-PR 
induced translational impairment and toxicity in neurons, while overexpression of poly-GR/PR 
interacting proteins associated with ribosome biogenesis had no effect.  
Figure 5-23: Reduction of ribosomal proteins can only be rescued by the constitutive active form of MEK1. 
(A, B) Cortical rat neurons were co-transduced with GFP, GFP-(GR)149 or (PR)175-GFP lentiviral constructs and RFP tagged rescue 
constructs (DIV6+7). (A) Immunoblots of SUnSET assays in neurons expressing poly-GR/PR and ctrl or nucleolar RFP-
NOP56/NPM1/GTPBP4/BRIX1 detecting newly synthesized proteins by puromycin incorporation. Calnexin was used as a 
control. (B)  SUnSET assay in poly-GR/PR and ctrl/MEK1 transduced neurons. Purocmycin, RPS6 and Calnexin immunoblots are 
shown. Note elevated RPS6 and translation levels in MEK1 expressing neurons. (C) LDH release assay detects significant 
reduction in cell death upon expression of MEK1 in neurons (DIV7+14) transduced with (PR)175-GFP compared to (PR)175-GFP 
only control (n=2 independent experiments with 6 replicates each, mean ± SEM, *** denotes p<0.001 in one-way ANOVA with 
Dunnett's post-test). 
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 PR and GR proteins/peptides bind to the yeast ribosome 
To further elucidate the connection between the ribosome and poly-GR/poly-PR, I tested whether the 
two DPR species directly interact with ribosomes. In a first experiment, I coated 96-well plates with 
500 ng of the purified 80S yeast ribosome and then added recombinant GR25-GST, PR25-GST or GST 
protein in a concentration series. Finally, I detected the interaction with an antibody specific for GST. 
A secondary antibody together with 3,3′,5,5′-Tetramethylbenzidine (TMB) led to a reaction product 
that was read at 450 nm or 630 nm. At 100 ng, GR25-GST bound the ribosome specifically compared to 
the GST control. The higher the amount of protein was, the more protein was binding (Figure 5-24A). 
I speculated this signal may be due to residual RNA co-purified with GST from E. coli. In order to obviate 
this, I repeated the ribosome binding assay with chemically synthesized DPR peptides harboring 20 
repeats and an HA tag to exclude RNA contamination. Strikingly, the GR20-HA peptide also significantly 
bound to the yeast ribosome in all three tested concentrations compared to the HA control peptide. 
At the highest concentration (10 µg) PR20-HA binding did not reach significance, although there was a 
small trend towards elevated binding capacity (Figure 5-24B). This experiment suggests that poly-GR 
and possibly also poly-PR induce toxicity by effectively binding to the ribosome and thereby preventing 
it from performing its normal function.  
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Figure 5-24: Purified poly-GR/PR bind to the yeast ribosome.  
Increasing amounts of purified (A) GR25-GST/PR25-GST/GST or (B) GR20-HA/PR20-HA/HA protein were incubated with 500 ng 
purified 80S yeast ribosome in an immunoassay. Binding of proteins to the ribosome was detected by HRP-labeled secondary 
antibody which was bound by 3,3′,5,5′-Tetramethylbenzidine (TMB) leading to a reaction product that was read at 450 nm or 
630 nm. Bar graphs depict absolute absorbance signal. Note that especially poly-GR binds the yeast ribosome significantly 
compared to the GFP control. (n=4 replicates for GST assay and n=2 for HA assay, mean ± SEM, *** denotes p<0.001, ** 
denotes p<0.01, * denotes p<0.05 in one-way ANOVA with Dunnett's post-test). 
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 Most poly-GR and poly-PR interactors are not enriched in DPR inclusions in C9orf72 
patients 
After extensive testing of interesting interacting proteins identified in the poly-GR and poly-PR 
interactomes in vitro, it was particularly important to elucidate whether these poly-PR/GR interactors 
would also be altered in C9orf72 patient brain.  
Therefore, I analyzed the distribution of several other poly-GR/PR interactors in C9orf72 patients and 
controls by immunofluorescence. Apart from the experiments shown above, I tested antibodies for 22 
Figure 5-25: Several tested interactors do not colocalize with poly-GR in C9Orf72 patient brain.  
Immunofluorescence stainings of the frontal cortex of a C9orf72 patient and a healthy control case to analyze colocalization of 
poly-GR with the interacting proteins GTPBP4, NOP56, PRMT1, WDR77, MAGOHB and TRA2A. 
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additional proteins, among which 6 showed convincing staining of endogenous protein distribution. 
However, I could not detect co-aggregation of the nucleolar proteins GTPBP4 or NOP56, PRMT1 or 
WDR77, two proteins involved in methylation, or the splicing factors MAGOHB or TRA2A with poly-GR 
in the cortex of C9orf72 patients (Figure 5-25B and 4.4.1). 
Summing up, among the ~30 tested poly-GR/PR interacting proteins, STAU2 and subunits of the 
cytosolic ribosome are relevant co-aggregating proteins in C9orf72 patients in this study. 
 Nucleolar poly-GR shows poly-PR characteristics in neurons 
 Rerouting poly-GR into the nucleolus disrupts nucleolar architecture 
As described before, basic characterization of GFP-(GR)149 and (PR)175-GFP showed that both DPR 
species are impairing cell growth in HEK293 cells and that only (PR)175-GFP is toxic in primary rat 
neurons (Figure 5-1A and B). In HEK293 cells, GFP-(GR)149 and (PR)175-GFP localize to the nucleolus, 
while in neurons only (PR)175-GFP expression resulted in nucleolar localization (Figure 5-2A and B). 
Given these findings, I wondered whether the absence of GFP-(GR)149 from the nucleolus in primary 
neurons, despite a significant overlap of interacting proteins with (PR)175-GFP, might explain lack of 
toxicity. Therefore, my aim was to shift diffuse cytoplasmic localization of GFP-(GR)149 into the 
nucleolus and investigate the outcome of this relocalization in neurons. Since other groups reported 
toxicity for shorter poly-GR repeat constructs, I truncated the GFP-(GR)149 construct. A poly-GR version 
with 53 repeats showed diffuse cytoplasmic localization as well as strong localization to the nucleolus 
in 77.5% of GFP-(GR)53 transduced neurons (Figure 5-26A). Additionally, I analyzed nucleolar 
organization itself using immunofluorescence stainings of fibrillarin. While in GFP-(GR)149 and GFP 
expressing neurons most nucleoli showed homogeneous distribution of the nucleolar marker, 
interestingly, GFP-(GR)53 expression resulted mostly in a ring-like fibrillarin staining and occasionally in 
a granular pattern. This disrupted nucleolar organization was even more pronounced in (PR)175-GFP 
expressing neurons as described above (compare Figure 5-13A and Figure 5-26A and B). Moreover, 
acute toxicity was significantly induced upon GFP-(GR)53 expression although not as strong as in 
neurons transduced with (PR)175-GFP (Figure 5-26C).  
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Figure 5-26: Nucleolar poly-GR53 disrupts nucleolar structure and inhibits translation.  
Primary rat neurons were transduced with GFP, GFP-(GR)53, GFP-(GR)149 or (PR)175-GFP lentiviral constructs. (A) Confocal 
images show immunofluorescence staining of fibrillarin in hippocampal neurons. Left two columns visualize GFP signal and 
fibrillarin staining (red) in various DPR species as indicated. Right column shows merge depicting nuclei with DAPI staining in 
blue additionally. Scale bar denotes 20 µm. (B) Classification and quantification of fibrillarin distribution within the nucleolus 
from (A) n= 6 to 16 images were analyzed. (C) LDH release assay detects significant cell death upon lentiviral expression of 
(PR)175-GFP and GFP-(GR)53, but not GFP-(GR)149 compared to GFP control in primary rat neurons (DIV7+14) (n=3 individual 
experiments with 6 replicates each, box plot is shown with 25th percentile, median and 75th percentile and whiskers 
representing minimum and maximum, *** denotes p<0.001 and ** denotes p<0.01 in one-way ANOVA with Dunnett's post-
test). (D) Immunoblot showing SUnSET assay in GFP-(GR)53, GFP-(GR)149, (PR)175-GFP or GFP-expressing primary cortical 
neurons (DIV6+7). Cortical neurons were exposed to 1 µM puromycin (puro) for 10 min or not treated (nt). Note the reduced 
synthesis of proteins indicated by puromycin signal in neurons expressing GFP-(GR)53 and (PR)175-GFP. (E) Quantification of 
puromycin signal normalized to Calnexin (n=6 from 3 independent experiments, mean ± SEM, *** denotes p<0.001 and ** 
denotes p<0.01 in one-way ANOVA with Dunnett's post-test). 
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 Nucleolar poly-GR impairs ribosome biogenesis 
The effects of nucleolar GFP-(GR)53 on nucleolar structure and toxicity in primary neurons are 
comparable to the effects seen in (PR)175-GFP neurons suggesting that other poly-PR specific 
deficiencies might also be found in poly-GR53 expressing cells. To test this hypothesis, I conducted 
another SUnSET assay and analyzed expression levels of the small ribosomal subunit with an antibody 
specific to RPS6. Lentiviral expression of GFP-(GR)53 indeed significantly reduced protein synthesis as 
well as RPS6 levels similar to (PR)175-GFP, while GFP-(GR)149 had no effect (Figure 5-26D and E).  
Thus, nucleolar localization of poly-GR/PR may be required for the toxicity observed in vitro.  
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6. DISCUSSION AND OUTLOOK 
 
In this study, I analyzed the interactomes of poly-GR and poly-PR in transduced rat cortical neurons 
and transfected HEK293 cells using GFP-(GR)149 and (PR)175-GFP immunoprecipitation. In both cell lines, 
poly-GR and poly-PR interact with RNA-binding proteins including numerous components of stress 
granules, the nucleolus, and the ribosome. Interestingly, overexpression of the interactors STAU1, 
STAU2, and YBX1 reroutes poly-GR and poly-PR into large stress granule-like structures. In addition, 
NPM1 overexpression leads to relocalization of poly-GR into the nucleolus. Strikingly, expression of 
poly-PR disrupts nucleolar organization, reduces levels of ribosomal subunits and impairs translation 
in vitro. The latter effects are dependent on nucleolar localization of poly-GR and poly-PR. Most 
importantly, ribosomal proteins are present in cytoplasmic DPR inclusions in C9orf72-ALS/FTD patient 
brains suggesting that sequestration of ribosomes may chronically affect protein synthesis even in 
absence of nucleolar localization.  
Compared to several competing reports, my data most accurately reflects the patient situation 
for several reasons. First, the constructs I used in this work are significantly longer than in all other 
studies and thus, better replicate the situation in patients, which typically harbor hundreds of repeats. 
While I used poly-GR and poly-PR containing 149 and 175 repeats, respectively, previous groups report 
expression of only 80 repeats or less (Lee et al., 2016a; Lopez-Gonzalez et al., 2016). Second, as other 
studies also administered 20-mer or 30-mer poly-GR and poly-PR peptides at high concentrations, my 
experiments more precisely mirror the low abundance of poly-GR/PR expression in patients 
(Boeynaems et al., 2017; Kanekura et al., 2016; Lin et al., 2016; Yin et al., 2017). Third, GFP-(GR)149 
almost exclusively localized to the cytoplasm in neurons, as observed in patient brains, arguing that 
other groups with nucleolar poly-GR expression possibly study in vitro artifacts. The increased toxicity 
of truncated poly-GR constructs with nucleolar localization also in my hands strongly support this 
concern. Finally, I performed my experiments and validated the findings in primary cortical neurons, 
while most other groups studied poly-GR/poly-PR mainly in non-neuronal cell lines. Thus, the system I 
used in this work is the most physiologically accurate among all competing studies. On top of this, only 
I extended my validation efforts to patient brains, representing the most important validation step.  
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 Poly-GR and poly-PR interactomes 
 
The interactomes of GFP-(GR)149 and (PR)175-GFP identified numerous RNA-binding proteins enriched 
in splicing factors, stress granule, and nucleolar components as well as in the mitochondrial and 
cytoplasmic ribosome in neurons and HEK293 cells. These results are consistent with previous 
interactome studies which reveal similar poly-GR/PR associated cellular pathways and protein groups 
to be enriched independent of cell type (Boeynaems et al., 2017; Kanekura et al., 2016; Lee et al., 
2016a; Lin et al., 2016; Lopez-Gonzalez et al., 2016). Thus, the poly-GR and poly-PR interactomes of my 
work, which were performed under physiological conditions, support previous interactome data and 
indicate that the cellular components and biological processes found might be indeed disease relevant.  
Regarding the DPR proteins individually, enrichment analysis revealed that poly-GR expressing 
cells show a high selectivity for ribosomes, stress granules, and the methylosome. The poly-PR 
interactomes from HEK293 cells and neurons are most enriched in proteins connected to the U1 and 
U4 snRNP consistent with reported effects of poly-PR on splicing (Kwon et al., 2014). Nonetheless, 
poly-GR and poly-PR overall share a large set of interacting proteins. This interesting observation was 
made throughout all other interactome studies in which up to 40% of interactors were overlapping 
(Lee et al., 2016a). This may reflect the preferential binding of both poly-GR and poly-PR to LCD 
containing proteins. 
 In the following, especially the difference in poly-GR and poly-PR toxicity in my neuron model 
and possible toxic mechanism emerging from the interactomes and my validation experiments will be 
discussed.  
 Poly-GR and poly-PR toxicity depends on subcellular localization 
In this study, (PR)175-GFP localized to the nucleolus resulting in impairment of cell growth as well as 
toxicity in both HEK293 cells and neurons, respectively. Expression of nucleolar GFP-(GR)175 led to less 
proliferation in HEK293 cells. In neurons, however, cytoplasmic GFP-(GR)149 caused no cell death within 
14 days. Thus, these data strongly indicate that mainly nucleolar localization is triggering the acute 
poly-GR/PR mediated toxicity observed in many in vitro systems. I designed several DPR protein 
constructs to enhance or reduce nucleolar localization of poly-GR/PR, but all variants either promoted 
nucleolar localization or had no effect. All DPR variants with enhanced nucleolar expression, like GFP-
(GR)53, GFP-(GA)50-(GR)50 and GFP-(GA)50-(PR)50, caused toxicity in an LDH assay. Strikingly, their 
expression additionally resulted in reduced RPS6 levels and impaired protein synthesis just as in (PR)175-
GFP transduced neurons (Figure 5-26 and data not shown) providing evidence that also toxic 
mechanisms are mediated by nucleolar localization alone.  
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Nearly every study analyzing individual DPR proteins reports poly-PR to be almost exclusively 
localized within the nucleolus independent of cell type or expression system, whereas poly-GR is 
typically found both in the nucleolus and the cytoplasm (Kramer et al., 2018; Kwon et al., 2014; Lee et 
al., 2016a; Tao et al., 2015; Wen et al., 2014; Yamakawa et al., 2015; Zhang et al., 2018b). However, 
C9orf72-ALS/FTD post mortem brains do not display any evidence for nucleolar poly-PR or other DPR 
species. Most DPR inclusions are cytoplasmic and most nuclear DPR inclusions are para-nucleolar 
(Schludi et al., 2015a). Thus, I propose that acute poly-GR/PR toxicity seen in many model systems is 
mainly due to aberrant nucleolar localization. A reason for nucleolar localization in cellular models 
might be that unphysiologically high DPR amounts more likely lead to relocalization as the effect of 
poly-GR and poly-PR mimicking the nuclear localization signals (NLS) is more prominent. Therefore, the 
data deriving from in vitro experiments in which DPR proteins localize to the nucleolus likely 
exaggerate the patient situation or might even be artifacts. Nonetheless, it cannot be excluded that 
during the ALS/FTD time course, poly-GR and poly-PR temporarily localize to the nucleolus triggering 
some of the effects seen in cell culture models. 
Regarding the interactome studies of this work, the overlap in poly-GR and poly-PR interactors 
in neurons is striking despite differential toxicity as measured by LDH release assays and evident from 
the whole proteome data (see below). A reason for this discrepancy might be that a small percentage 
of GFP-(GR)175 transduced neurons additionally showed nucleolar localization - enough to detect 
interactors by mass spectrometry but too little to induce significant neuronal death. It would be 
interesting to compare the interactomes of purely nucleolar to purely cytoplasmic poly-GR, but we 
were not able to generate such constructs so far. 
To understand the toxicity exclusive to poly-PR, I analyzed the proteins which selectively 
interact with poly-PR, e.g. CD2AP. However, the analysis did not lead to a clear mechanism of toxicity 
due to these interactors. My data is most consistent with nucleolar localization as the main driver of 
poly-PR mediated toxicity in vitro. Poly-PR expression results in dramatic down-regulation of numerous 
proteins in neurons. In fact, gene ontology analysis reveals that especially the expression of ribosomal 
subunits is significantly reduced. This finding suggests that poly-PR mediated reduction of ribosome 
numbers directly affects global protein translation leading to reduced expression of hundreds of 
proteins, including axonal and synaptic proteins, and finally cell death. Comparable calnexin levels and 
therefore total cell numbers between poly-PR and control expressing cells validate this. Poly-GR 
expressing neurons do not show alterations in global protein expression which is consistent with the 
observation that poly-GR expression does not lead to cellular toxicity in this system. In HEK293 cells, 
high-level expression of poly-GR and poly-PR through transient transfection inhibit cell growth to a 
similar extent. It would be interesting to see whether poly-PR has the ability to reduce global protein 
levels in this cell system although there is no active cell death detected. If so, nucleolar poly-GR 
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expression might result in comparable effects. Eventually, however, the strict distinction between 
poly-GR and poly-PR toxicity might not be relevant for C9orf72 pathogenesis as poly-PR almost 
completely co-aggregates with poly-GR and the other DPR proteins in C9orf72-mediated ALS/FTD 
brains (Mori et al., 2013a).  
 No evidence for nucleocytoplasmic transport deficits in the interactomes of poly-GR/PR 
In recent studies, disruption of the nuclear pore complex and nucleocytoplasmic transport has 
emerged as a cellular mechanism underlying C9orf72-mediated toxicity. Not only have different 
genetic modifier screens identified numerous proteins linked to the nuclear pore to be enhancers or 
suppressors of C9orf72-associated toxicity, but also have interactome studies shown various NPC, 
import and export proteins to interact with poly-GR and -PR (Boeynaems et al., 2016; Freibaum et al., 
2015; Jovicic et al., 2015; Lee et al., 2016a; Lin et al., 2016; Zhang et al., 2015). However, our mass 
spectrometry-based proteome studies in poly-GR/PR bearing cells could not detect components of the 
nuclear pore interacting with these two DPR protein species similar to other reports (Kanekura et al., 
2016; Lopez-Gonzalez et al., 2016). Also, the transcriptome profile of poly-(GR)100 expressing mice did 
not identify any NPC-associated transcript to be altered (Zhang et al., 2018a). Poly-GA expression, 
however, leads to a transport deficit particularly of TDP-43 leading to enhanced cytoplasmic 
localization. This effect was not significant in poly-GR and poly-PR expressing neurons (Khosravi et al., 
2017). Thus, my data provide no evidence supporting dysfunctional nucleocytoplasmic transport due 
to poly-GR/PR and therefore I suggest that poly-PR/GR toxicity is mostly triggered by other 
mechanisms.  
 Poly-GR/PR and their link to nucleoli and stress granules  
My interactome study could convincingly show that a large set of nucleolar and stress granules 
components are binding partners of poly-GR and poly-PR which is consistent with other reports 
(Boeynaems et al., 2017; Lee et al., 2016a; Tao et al., 2015). Lee, Boeynaems, and colleagues support 
these physical interactions by reporting impaired NPM1, NCL and G3BP1 dynamics upon expression of 
poly-(GR)50 and poly-(PR)50 (Boeynaems et al., 2017; Lee et al., 2016a). In contrast, my validation efforts 
concentrated on the impact of interactors on poly-GR/PR expression, aggregation as well as 
localization and most importantly, their alterations in C9orf72 patient brain.  
Co-expression of nucleolar candidates and poly-GR/PR in primary neurons showed that NPM1 
recruits otherwise predominantly cytosolic GFP-(GR)149 into the nucleolus, whereas NOP56 had no 
such effect. Higher endogenous NPM1 levels in HEK293 cells compared to primary neurons may 
contribute to the differential localization of poly-GR in both cell types. The other way around, poly-PR 
strikingly altered the distribution of NOP56 and other nucleolar proteins. This observation was 
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confirmed in other reports in which NCL displayed disrupted distribution in patient-derived 
lymphoblasts as well as iPS motor neurons. Also in hippocampal neurons expressing poly-PR, the 
majority of nucleoli appeared fragmented (Haeusler et al., 2014; Schludi et al., 2015a). Disorganization 
of the nucleolus likely reflects functional impairment. And indeed, numerous proteins associated with 
the nucleolus were found to modulate poly-GR and poly-PR toxicity in a modifier screen in flies (Lee et 
al., 2016a). Since super-resolution microscopy revealed that poly-GR/PR localize to the outer 
subregions of the nucleolus where ribosome assembly takes place, specifically this step of ribosome 
biogenesis might be affected (Lee et al., 2016a). Also the interference of poly-GR/PR with NOP56 and 
NPM1, observed in this study, most likely leads to impaired biogenesis of ribosomes as the two 
nucleolar proteins play a role in assembly of the 60S subunit and chaperoning ribosomal subunits 
(Hayano et al., 2003; Maggi et al., 2008). Hence, my observations provide first evidence that poly-GR 
and poly-PR toxicity may ultimately emerge from impaired translation mediated by nucleolar 
dysfunction. To gain deeper insight into the role of the nucleolus in C9orf72-mediated ALS/FTD, 
detailed nucleolar organization would be worth investigating to find the connection between this 
compartment and translation inhibition. Importantly, in C9orf72 patient post mortem brains, DPR 
protein inclusions do not localize to the nucleolus (Schludi et al., 2015a; Vatsavayai et al., 2016). 
However, larger nucleoli have been reported in poly-GR expressing neurons (Mizielinska et al., 2017) 
suggesting that the effects of poly-GR/PR on the nucleolus observed in vitro are of a more subtle nature 
in patients.  
 I showed that co-expression of the stress granule components STAU1, STAU2, and YBX1 leads 
to striking colocalization with poly-GR and poly-PR in large cytoplasmic granules. Since the two DPR 
proteins already form small cytoplasmic inclusions in control situations (Figure 5-14) in HEK293 cells, 
it is likely that expression of STAU1, STAU2, and YBX1 promotes expansion of these structures. I 
propose that these inclusions are stress granules since they are positive for G3BP1, YBX1 as well as 
STAU1 (Figure 5-15), all representing proteins found in this cellular compartment (Jain et al., 2016; 
Thomas et al., 2009). In line with my findings, several other groups made similar observations linking 
stress granules to poly-GR and poly-PR: In poly-(PR)100 expressing HeLa cells, aggregated cytoplasmic 
poly-PR could be co-stained with the stress granule marker protein G3BP. Zhang et al. additionally 
show that both poly-GR and poly-PR significantly induce the formation of SGs compared to controls 
(Boeynaems et al., 2017; Zhang et al., 2018b). Also, poly-PR preferentially interacts with proteins 
localized to stress granules (Boeynaems et al., 2017; Lee et al., 2016a) and several SG associated 
proteins like YBX1 and Ataxin2 are altered upon poly-PR expression in cell culture (Boeynaems et al., 
2017). Moreover, numerous proteins linked to stress granules were found to be enhancers or 
suppressors of poly-GR/PR50 toxicity in a Drosophila in vivo screen. Summarizing, my observations 
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together with other studies clearly suggest a significant role of stress granules in cellular and animal 
models. 
There are many ways how co-expression of the DPR proteins with stress granule components 
might lead to enhanced stress granule formation. STAU1, for example, functions in dissolution of the 
latter by stabilization of polysomes (Thomas et al., 2009). It is possible that after recruitment to the 
stress granules, STAU1 is sequestered by poly-GR and poly-PR. The interaction with the two DPR 
species might prevent STAU1 from performing its normal function which ultimately leads to 
accumulation of STAU1 and expansion of the inclusions. However, it is not clear whether these stress 
granule proteins are recruited into the granule-like poly-GR/PR clusters or vice versa.  
Overall, it is also possible that poly-GR and poly-PR disrupt stress granule protein function 
through liquid-liquid phase separation. Several groups could validate these relations by showing 
disturbed dynamics of nucleolar and stress granule components such as NPM1, NCL, and G3BP1. In 
addition, poly-GR and poly-PR changed phase transition of FUS, NPM1, TIA1, hnRNPA1 or intermediate 
filaments (Boeynaems et al., 2017; Lee et al., 2016a; Lin et al., 2016). Moreover, (PR)30 increased β-
sheet content in FUS droplets over time (Boeynaems et al., 2017). Consequently, poly-GR/PR may 
interfere with liquid-liquid phase separation by enhancing the formation of amyloid-like structures. 
Since poly-GR and poly-PR preferentially bind to intrinsically disordered proteins, disturbed phase 
transition might impair formation and function of membrane-less organelles as another toxic 
mechanism in C9orf72-ALS/FTD. 
Interestingly, G3BP1 knockdown strongly enhanced poly-GR toxicity in an RNAi screen in flies 
(Lee et al., 2016a). Since G3BP1 is required for SG formation, this observation, in turn, indicates that 
the appearance of SGs upon poly-GR/PR expression might be protective. However, it is known that 
stress granules occur upon cellular stress and typically contain mRNA as well as 40S ribosomal subunits 
(Buchan and Parker, 2009) which are kept in an inactive state. Therefore, it is conceivable that DPR 
induced formation of SGs alone or the sequestration of key components of translation via DPR proteins 
lead to stalled protein synthesis. Thus, SG formation might still be harmful to the cell. This hypothesis 
is in line with a study from Zhang and colleagues showing colocalization of the small ribosomal subunit 
RPS6 and poly-GR100 in eIF3η-positive cytoplasmic inclusions (Zhang et al., 2018b). How arginine-rich 
DPR proteins are further connected to translational inhibition is discussed in the following chapter.  
Although the data of my interactome study are consistent with other reports uncovering 
numerous stress granule constituents to bind to poly-GR and poly-PR (Lee et al., 2016a; Lin et al., 2016; 
Lopez-Gonzalez et al., 2016), I could not detect classical stress granule markers in poly-GR aggregates 
in C9orf72 patient brains. Similarly, Zhang et al. observed cytoplasmic TIA-1 co-aggregation with poly-
GR inclusions in C9orf72 repeat expressing mice but failed to show such results in patients (Zhang et 
al., 2018b). Among the non-ribosomal interactors I tested, only STAU2 colocalized with poly-GR in the 
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frontal cortex of C9orf72 patient brain, suggesting that STAU2 binding may be involved in poly-GR 
aggregation in vivo.  
Taken together, the observations made in terms of both the nucleolus and stress granules upon poly-
GR/PR expression raise the possibility that the two DPR proteins indirectly affect ribosomal biogenesis 
or function by interacting with proteins within the two compartments.  
 Poly-PR toxicity is linked to impaired translation 
Kwon and colleagues provided the first evidence that poly-GR and poly-PR interfere with ribosome 
biogenesis by showing that some of the 45S rRNA processing products were strongly reduced upon 
administration of 30 µM GR20 or PR20 peptide to U2OS cells. In particular, the 5.8S rRNA was decreased 
by 70% (Kwon et al., 2014). However, upon transduction of poly-GR or poly-PR in primary rat neurons, 
I could not observe such an effect. There might be two explanations why poly-GR/PR expressing 
neurons do not show impaired rRNA maturation. First, the conditions found in my cellular system are 
in contrast to the non-physiologically conditions in which poly-GR or poly-PR peptides are added in 
high molecular concentrations localize predominantly to the nucleolus- potentially leading to spurious 
effects. Second, in primary neurons transduced with poly-PR, two components of the PeBoW complex, 
BOP1 and PES1, are upregulated as shown by MS. These two proteins are known to be associated with 
rRNA splicing and the assembly of the large ribosomal subunit. In fact, it was shown that depletion of 
BOP1 or PES1 leads to inhibition of 36S pre-rRNA processing and therefore, the maturation of the 
downstream rRNA fragments (Rohrmoser et al., 2007). Thus, the upregulation of BOP1 and PES1 in 
neurons might boost rRNA processing preventing reduction of 5.8S rRNA as seen in U2OS cells in Kwon 
et al. Together, these data suggest that impairment of rRNA synthesis is not the main mechanism 
underlying poly-GR and poly-PR toxicity in neurons. 
In this work, I show significantly decreased protein synthesis in a SUnSET assay in poly-PR 
transduced primary neurons. These findings are confirmed in in vitro translation assays monitoring 
incorporation of S35 as well as puromycin into newly synthesized proteins following expression of poly-
PR and poly-GR in NSC-34 cells, astrocytes and HeLa cells (Kanekura et al., 2016; Lee et al., 2016a). As 
the poly-PR construct used in this study is highly toxic to neurons, in contrast to poly-GR, and its 
expression results in diminished protein translation, one can conclude that impaired protein synthesis 
is a major mechanism by which poly-PR drives toxicity. Kanekura and colleagues provide evidence that 
this effect is not caused by changed phosphorylation of the translation initiation factors, as cells 
treated with (PR)20 did not show altered levels of phospho-eIF4B, phospho-eIF4E or phospho-eIF4G. 
Thus, distinct pathways need to be involved. Kanekura et al. further suggest that direct binding of 
(PR)20 to mRNA might block access of translation factors (Kanekura et al., 2016). However, in my 
experiments, only nucleolar poly-(GR)53 and poly-PR show strong reduction of protein synthesis 
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compared to the cytoplasmic poly-(GR)149. Considering the cytoplasm being the compartment where 
mature mRNA is located, these observations argue against Kanekura et al.’s hypothesis.  
Interestingly, I found that the cytosolic ribosome is the top hit in gene enrichment analysis of 
the interactomes, which is also true for all other interactome studies elucidating the binding partners 
of poly-GR and poly-PR (Tao et al. 2015; Lopez-Gonzalez et al. 2016; Kanekura et al. 2016; Lee et al. 
2016; Boeynaems et al. 2017). Subsequently, I confirmed direct interaction between the ribosome and 
the two DPR species by a ribosome binding assay with purified (PR)15/(GR)15 and yeast ribosomes. 
Binding was also observed with synthetic peptides encoding poly-GR/PR, confirming that the 
interaction of DPR proteins with the ribosome is independent of poly-GR/PR bound RNA. However, I 
cannot exclude that the peptides bound yeast rRNA. Most importantly, I found that small and large 
subunits of the ribosome colocalize with 30% of poly-GR/PR in the cortex of C9orf72-FTD/ALS patient 
brains. This finding provides strong support for the in vivo relevance of poly-GR/PR impaired 
translation. It suggests that cytoplasmic poly-GR and poly-PR chronically impair protein synthesis even 
in absence of nucleolar localization. At the same time, Zhang and colleagues independently reported 
colocalization of cytoplasmic poly-GR to RPS6, RPL21 and the translation initiation factor eIF3η in 
transgenic mouse cortex and C9orf72-ALS/FTD brain (Zhang et al. 2018). Thus, in C9orf72-ALS/FTD, 
poly-GR/PR may lead to milder translational inhibition and slower neurodegeneration than in the acute 
cellular models.  
I can only speculate whether poly-GR/PR mediated toxicity emerges from impaired ribosome 
biogenesis or the loss of active ribosomes which might even differ in vitro and in vivo. On the one hand, 
my study provides strong evidence for the inhibition of ribosome biogenesis: ribosomal protein levels 
are reduced, ribosome biogenesis factors are interactors of poly-GR/PR and the structure as well as 
dynamics of the ribosome assembly associated nucleolus is disturbed. On the other hand, the neuronal 
interactome of poly-GR indicates that the entire ribosome is assembled, suggesting that the existing 
ribosomes may not be functional. It has previously been shown that comprised function of amino acyl 
tRNA synthetases (ARS) leads to repression of protein synthesis and neurodegeneration (Latour et al., 
2010; Lee et al., 2006; Storkebaum, 2016). Thus, it is also possible, that poly-GR and poly-PR 
dysfunctionalize the ribosome by affecting these amino acid transferases. For the future, it would be 
rewarding investigate direct interaction of poly-GR/PR with ribosomes using electron microscopy 
experiments in order to clarify these hypotheses. Identifying the exact binding site of the DPR proteins 
on the ribosome would shed light on the interference. It is possible that poly-GR/PR are blocking the 
sites important for the assembly of the ribosome with the mRNA or that the two DPR species are 
binding to the E, P or A site which are for example needed for ARS docking and subsequent maturation 
of the polypeptide chain. In this scenario, poly-GR/PR would impair ribosome activity. However, the 
two DPR protein species might only bind the ribosomal subunits at multiple sites and thus, hinder 
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ribosome assembly. Regardless, both scenarios would lead to the same outcome, namely less 
translation.  
Analysis of the whole proteome of poly-PR cell lysates suggests that neurons try to compensate 
for this translational repression through upregulation of ribosome biogenesis factors such as NSA2, 
RRP1, BRIX1, NOC2L, WDR77, TSR and as mentioned earlier also BOP1 and PES1. This effect could be 
validated in immunoblotting experiments for BOP1, but not PES1. Quantitative PCR experiments only 
showed non-significant trends. The reason for this might be that this method is not sensitive enough 
and that subtle effects can only be seen by mass spectrometry which allows detection of analytes at 
concentrations in the attomolar range (Annesley et al., 2009). 
Although neurons transduced with poly-PR appeared to counteract translational repression, 
poly-PR still reduced net ribosomal protein expression and caused pronounced cellular toxicity. 
Therefore, I hypothesized that the overexpression of poly-GR/PR interactors involved in ribosome 
biogenesis, which might be sequestered by the DPR proteins and thereby prevented from performing 
their regular function, should boost protein synthesis and reduce poly-PR mediated toxicity. However, 
expression of neither of the nucleolar proteins NOP56, NPM1, GTBP4, and BRIX1 could obviate 
neuronal death. NOP56 is participating in rRNA methylation, NPM1 is a ribosomal chaperone 
facilitating interactions between ribosomal proteins and rRNA and GTPBP4 as well as BRIX1 are 
involved in the biogenesis of the 60S subunit. Despite covering several pathways of ribosome 
biogenesis, none of the proteins alone was sufficient to restore reduced translation. Possibly, the 
combination of more ribosome biogenesis factors would be more effective. In a previous study in 
yeast, overexpression of the ribosome biogenesis factors NOB1 (human ortholog: NOB1) and STM1 
(no human ortholog) suppressed poly-PR toxicity (Jovicic et al., 2015).  
Thus, I overexpressed constitutively active MEK1 as an upstream regulator of translation. It is 
one of the main components of the MAPK/ERK pathway. It is activated by RAF and further 
phosphorylates its many downstream targets, thereby promoting cell growth and proliferation 
(McCubrey et al., 2007). By indirect phosphorylation of eIF4E and RPS6, MEK1 triggers translation 
initiation. Therefore, overexpression of the constitutive active form of MEK1 represents a more general 
approach to enhance protein synthesis. Indeed, MEK1 not only rescued translational repression but 
also prevented cellular toxicity in poly-PR expressing neurons. Furthermore, RPS6 protein expression 
was elevated upon MEK1 transduction. These findings suggest that inhibition of protein synthesis is 
connected to RPS6 levels as well as neuronal death, and that restoration of translation be 
neuroprotective.  
However, MEK1 is a protein known to have carcinogenic properties as it can drive ERK1/ERK2 
activation and lead to inappropriate cell proliferation and survival, precluding its therapeutic utility in 
patients. Alternatively, it might be advantageous to block the interaction of poly-GR and poly-PR with 
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the ribosome directly. Again, the exact binding site determined by electron microscopy might help for 
further elucidation of therapeutic strategies.  
Overall, this study proposes direct binding of poly-GR and poly-PR proteins to the ribosome, disturbed 
nucleolar organization and accompanied ribosomal biogenesis as the most relevant toxic mechanisms 
of the two examined DPR protein species. Although the processes occurring in vitro represent a very 
acute situation, my co-aggregation data in C9orf72-FTD/ALS patients suggests a similar mechanism 
may contribute to human pathogenesis. As DPR proteins are present long before symptom onset and 
brain atrophy, these processes might trigger toxicity less obtrusively. It is unquestionable that the 
ribosome is physiologically significant as patients show colocalization of all tested ribosomal subunits 
with 30% of poly-GR aggregates. The next important step will be to directly show translation repression 
in patient tissue due to poly-GR/PR. 
 The role of poly-GR and poly-PR toxicity in disease 
 Translation centered model of poly-GR and poly-PR mediated neurodegeneration 
The discovery of five DPR proteins species translated from the C9orf72 repeat expansion had major 
impact on ALS and FTD research. Extensive studies investigated the mechanisms by which the two DPR 
proteins poly-GR and poly-PR trigger neurodegeneration. The present study convincingly shows that 
the nucleolus, stress granules, and protein synthesis are the main targets of poly-GR/PR. These results 
emerged from proteomic analysis as well as validation experiments in vitro and, in contrast to most 
other groups, post mortem brains. From my data, I propose the following model for poly-GR/PR related 
ALS/FTD pathomechanisms (Figure 6-1).  
 Poly-GR and poly-PR toxicity could inhibit protein translation by interfering with three parallel 
cellular pathways. RAN translation of the C9orf72 repeat leads to formation of cytoplasmic poly-GR 
and poly-PR inclusions. These protein aggregates are causing cellular stress, thereby triggering the 
assembly of stress granules. Colocalization of poly-GR/PR with the membrane-less compartments 
impairs stress granule dynamics and disassembly. SGs are made from RNA and RNA-binding proteins 
and keep the messenger ribonucleoproteins in stalled translation pre-initiation complexes in order to 
protect them from harmful conditions. Consequently, the accumulation of SGs reduces overall protein 
synthesis. (Figure 6-1A). A parallel toxic mechanism is initiated by poly-GR/PR mediated sequestration 
of ribosomal subunits. I hypothesize that direct binding of the two DPR protein species to ribosomal 
proteins leads to a lack of ribosome components at the site where ribosome assembly takes place, 
namely the nucleolus. Additionally, poly-GR/PR might also bind whole ribosomes. As a result, fewer 
ribosomes are available finally causing impaired ribosomal assembly and subsequently, less 
translation. The sequestration of key factors associated with ribosome biogenesis might support this 
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mechanism of toxicity (Figure 6-1B). Furthermore, the interference of poly-GR and poly-PR with the 
nucleolus might pose a more direct link to reduced protein synthesis. In this situation, disorganization 
of the nucleolus, possibly emerging from binding to nucleolar proteins, would lead to nucleolar 
dysfunction (Figure 6-1C). As ribosome assembly occurs within the outer layers of the nucleolus, again, 
ribosome biogenesis is likely to be altered. Ultimately, all three pathways impair translation. 
 
 
Figure 6-1: Schematic model of poly-GR/PR induced toxicity in C9orf72-ALS/FTD  
The two arginine-rich DPR protein species poly-GR and poly-PR (glycine depicted in blue, proline in violet and arginine in red) 
are found in the cytoplasm of C9orf72-patient neurons and initiate three potential toxic pathways: (A) Stress-induced assembly 
of stress granules might lead to co-aggregation of poly-GR/PR and stress granule proteins. (B) Sequestration of ribosomal 
subunits (depicted as two grey ovals) in the cytoplasm potentially results in a lack of ribosomes in the nucleolus. (C) Poly-GR/PR 
bind nucleolar components leading to dysfunction of the nucleolus (grey circle in blue background (nucleus)). Ultimately, all 
three mechanisms comprise translation.  
 
 Concluding remarks and future directions 
This work importantly contributes to the understanding of pathological mechanisms underlying 
C9orf72-associated ALS/FTD. My data is consistent with parallel reports by other groups showing the 
association of poly-GR/PR with stress granules, the nucleolus and, most importantly, inhibition of 
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protein translation. It is the first study successfully validating poly-GR/PR interacting proteins in patient 
tissue and highlights the importance of the ribosome in disease pathogenesis. Furthermore, this work 
represents the first interactome study performed in neurons and thereby reflects the patient situation 
most accurately.  
Since neither individual poly-GR expression nor C9orf72 knockout in mice is sufficient to mimic 
all features of ALS/FTD, synergistic effects of the C9orf72-associated pathomechanisms are most likely. 
For example, the other DPR proteins may contribute to toxicity. Notably, poly-GA and poly-GP are the 
most abundant DPR species in ALS/FTD brains harboring the C9orf72 repeat and although poly-PR was 
shown to be the most toxic one in vitro, it is extremely rare (Schludi et al., 2015a). An explanation for 
this disconnect might be that rapid poly-PR-induced neurodegeneration may preclude its detection. 
However, RAN-translation of the anti-sense strand seems to be less efficient than from the sense 
strand as the inert poly-PA is also low abundance (Mori et al., 2013a; Mori et al., 2013c). Analysis of a 
poly-PR mouse model could be rewarding. In contrast, poly-GA toxicity, comprising nucleocytoplasmic 
transport (Khosravi et al., 2017) and proteasome function (Guo et al., 2018; May et al., 2014), seems 
to be slower. Furthermore, the repeat RNA itself is known to bind to several RNA-binding proteins, but 
a clear loss-of-function of any of these proteins has not been reported. Moreover, C9orf72 
haploinsufficiency, particularly in immune cells, might play a crucial role.  
As besides DPR protein pathology, post mortem C9orf72 ALS/FTD patient brains harbor 
characteristic cytoplasmic TDP-43 inclusions, additional pathomechanisms leading to 
neurodegeneration exist. Strikingly, the regional distribution of TDP-43 inclusions strongly correlates 
with neurodegeneration and the clinical phenotype (ALS vs. FTD). In contrast, DPR protein inclusions 
are also present in several non-degenerating brain regions (Mackenzie et al., 2013). This disconnect 
between DPR protein pathology (as well as RNA foci and reduced C9orf72 expression) and TDP-43 
pathology is the main open question in C9orf72-ALS/FTD research. Previous findings suggest that DPR 
proteins precede TDP-43 inclusions in cellular models as well as patient brains: Occasionally, poly-GA 
is surrounded by phosphorylated TDP-43 and C9orf72 patients who died of other conditions before 
reaching end stage of ALS/FTD show abundant DPR pathology while TDP-43 aggregates are rare 
(Mackenzie et al., 2013; Nonaka et al., 2018; Vatsavayai et al., 2016). And the finding that poly-GA 
partially reroutes nuclear TDP-43 into cytoplasmic granules in primary neurons and HeLa cells 
additionally supports a causal role of DPR proteins in TDP-43 pathology (Khosravi et al., 2017). In the 
end, neuronal death in C9orf72 mediated ALS/FTD likely results from the interplay of the two types of 
pathological inclusions and various toxic mechanisms. Thus, the relative contribution of the DPR 
proteins, particularly of poly-GR and poly-PR, and the synergistic effects remain to be defined. 
Ultimately, only a drug targeting specific DPR protein species, other pathological inclusions, RNA-
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toxicity or C9orf72 haploinsufficiency in patients can tell which pathway is most critical for C9orf72-
ALS/FTD pathogenesis. 
Taken together, my work provides strong evidence that poly-GR and poly-PR contribute to 
disease pathogenesis by direct binding of the ribosome in C9orf72-ALS/FTD patients probably leading 
to chronic toxicity, which may ultimately trigger a second disease stage with TDP-43 pathology 
(Edbauer and Haass, 2016). In cellular models, nucleolar poly-GR/PR reduce expression of ribosomal 
proteins as well as overall protein synthesis. Boosting translation and expression of ribosomal proteins 
using MEK1 overexpression rescued cellular toxicity in vitro. Hence, restoring chronically impaired 
translation, ribosome biogenesis or related pathways could serve as a novel therapeutic strategy in 
patients. Since overactivation of the MEK1/MAPK pathways would likely promote cancer, inhibiting 
the interaction of poly-GR and poly-PR with ribosomes might be a less harmful therapeutic strategy. 
As mentioned earlier, electron microscopy of ribosomes could help discover specific poly-GR binding 
sites, thereby unraveling the mode of action leading to rational drug design.  
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7. APPENDIX 
 Supplementary Tables  
Table S1: Proteins enriched in the neuronal interactome, T-test difference poly-GR vs GFP 
 
  
Welch's T-test  
s0=1, fdr=5% 
PR-enriched? protein ID protein name 
Difference LFQ 
intensity 
pGR_LFQ 
intensity GFP 
   
11.21805954 PR-enriched O35796 C1qbp 
10.14376736 PR-enriched Q4QR85;Q7TPI7 Wdr77 
9.776339531 
 
D4A0E8 Prmt5 
7.359214306 
 
A0A0G2JUV5;M0RBW5 Ccdc40 
6.141866207 
 
F1LRU1;Q9JIL3-2 Ilf3 
5.795619965 
 
P13383;Q5U328 Ncl 
5.287992477 PR-enriched F1M403 Ube2o 
5.082045078 PR-enriched B5DF95;A0A0G2K782 Zc2hc1a 
4.955165863 PR-enriched A0A0G2K9I8 Prmt1 
4.936328411 PR-enriched G3V7R1;O08587 Nup50 
4.934625626 PR-enriched Q4V898 Rbmx 
4.810759544 PR-enriched D3ZXH7 Alyref 
4.55553627 PR-enriched P15865 Hist1h1e 
4.25990057 PR-enriched P62961;F1LPL7 Ybx1 
4.255776405 PR-enriched P21707;P29101 Syt1 
4.249275684 PR-enriched D3ZBN0 Hist1h1b 
4.193473339 
 
P84586;A0A0G2K8K9 Rbmxrtl 
4.117208958 
 
D3ZXF9 Mrpl12 
3.950805664 PR-enriched P43278 H1f0 
3.944224834 PR-enriched P55770;H7C5X3 Nhp2l1 
3.841823101 
 
F1LNK0;P15146 Map2 
3.822192192 
 
A0A0G2JY73;D4A554 Eif4g3 
3.754371643 
 
P61314;D3ZXA2 Rpl15 
3.735926628 PR-enriched Q6AY68 Aurkaip1 
3.627151489 
 
P19944;A0A0G2K4Q1 Rplp1 
3.609757423 PR-enriched Q63827;F1LM54 Fgfr1 
3.590438366 
 
A0A0G2K1R5;F1LR80 Camkv 
3.587795258 PR-enriched D3ZVA5 Fbll1 
3.582002163 
 
D3ZIF0 Zfp512 
3.532605171 
 
P02401;D4A4D5 Rplp2 
APPENDIX 
117 
 
Table S2: Proteins enriched in the neuronal interactome, T-test difference poly-PR vs GFP 
Welch's T-test  
s0=1, fdr=5% 
GR-enriched? protein ID protein name 
Difference LFQ 
intensity 
pPR_LFQ 
intensity GFP 
   
8.999781132 GR-enriched A0A0G2JUV5;M0RBW5 Ccdc40 
8.753255844 GR-enriched O35796 C1qbp 
5.80452919 
 
Q925Q9;Q925Q9-2 Sh3kbp1 
5.536819935 GR-enriched P15865 Hist1h1e 
5.257129669 GR-enriched D3ZXF9 Mrpl12 
5.249002934 GR-enriched P19139 Csnk2a1 
5.138173103 GR-enriched F1LRJ2;A0A0G2K2M9 Srrm2 
4.720638752 GR-enriched D3ZBN0 Hist1h1b 
4.530203819 GR-enriched P43278 H1f0 
4.521471024 
 
P04218 Cd200 
4.518064976 
 
Q27W01 Rbm8a 
4.401230335 GR-enriched P55770;H7C5X3 Nhp2l1 
4.318847179 
 
Q5M7V8;F1M3X4 Thrap3 
4.27340889 GR-enriched P62961;F1LPL7 Ybx1 
4.254295826 
 
M0R907;M0R8M3 Snrpd3 
4.130423546 GR-enriched Q68SB1-2;Q68SB1 Stau2 
4.084741592 GR-enriched D4A3K5 Hist1h1a 
4.065413952 GR-enriched P13383;Q5U328 Ncl 
4.05639267 GR-enriched Q4V898 Rbmx 
3.973850727 
 
D3ZTW8 Mrpl27 
3.90845108 
 
Q5BJX1;D3ZH23 Mrpl41 
3.899531841 
 
B5DES0;M0R8K2 Snrpd2 
3.853073597 
 
P63170;A0A0G2JU43 Dynll1 
3.726355076 
 
D3ZFQ8 Cyc1 
3.698761463 GR-enriched P84586;A0A0G2K8K9 Rbmxrtl;Rbmxl1 
3.552656651 GR-enriched D3ZJY1 Mrpl28 
3.538584709 GR-enriched M0R7B4 LOC684828 
3.514945984 GR-enriched A0A0G2K654;P06349 
3.481257439 
 
D3ZGM1;A0A0G2JU15 Ptcd3 
3.480280876 
 
Q3B8Q2 Eif4a3 
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Table S3: Proteins enriched in the HEK293 cell interactome, T-test difference poly-GR vs GFP 
Welch's T-test  
s0=1, fdr=5% 
PR-enriched? protein ID protein name 
Difference LFQ 
intensity 
pGR_LFQ 
intensity GFP 
   
9.33267212 
 
O14744;O14744-2 PRMT5 
8.64189434 PR-enriched Q9HCE1;Q5JR04 MOV10 
7.17884731 
 
Q9BQA1;H0Y711 WDR77 
7.06018829 PR-enriched Q5T653;C9IY40 MRPL2 
6.6750226 PR-enriched Q07021 C1QBP 
6.49605656 PR-enriched Q96A35;X6RJ73 MRPL24 
6.41339779 PR-enriched P09001;H0Y9G6 MRPL3 
6.40069199 PR-enriched Q9H9J2 MRPL44 
6.36713791 PR-enriched Q8IXM3 MRPL41 
6.28270912 PR-enriched Q9P015;E5RIZ4 MRPL15 
6.27818775 PR-enriched Q9BYD2;Q5SZR1 MRPL9 
6.26837015 PR-enriched Q9BYD3;K7ES61 MRPL4 
6.13568354 PR-enriched Q9NRX2;E9PKV2 MRPL17 
5.85481071 PR-enriched Q8N5N7;Q8N5N7-2 MRPL50 
5.8260293 PR-enriched Q9BZE1;S4R369 MRPL37 
5.76797581 PR-enriched Q9NYK5;Q9NYK5-2 MRPL39 
5.74533319 PR-enriched Q13405;H0YDP7 MRPL49 
5.69108677 
 
Q7L2E3-2;Q7L2E3 DHX30 
5.67733049 PR-enriched Q96DV4;Q96DV4-2 MRPL38 
5.66948223 PR-enriched Q9BYD6;H0Y8N7 MRPL1 
5.61673355 PR-enriched Q8N983-4;Q8N983 MRPL43 
5.57176733 PR-enriched O95793;O95793-2 STAU1 
5.52799082 PR-enriched Q9Y2S7;B4DEM9 POLDIP2 
5.51922655 PR-enriched Q9NP92;A0A087WV52 MRPS30 
5.42335987 PR-enriched Q16540;A6NJD9 MRPL23 
5.2685895 PR-enriched Q8TAE8 GADD45GIP1 
5.20731497 PR-enriched Q96GQ7;B7Z6D5 DDX27 
5.19266939 
 
O15234;J3KSY7 CASC3 
5.16271877 PR-enriched Q13084;A2IDC6 MRPL28 
5.14378309 
 
Q14690;S4R3Q4 PDCD11 
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Table S4: Proteins enriched in the HEK293 cell interactome, T-test difference poly-PR vs GFP 
Welch's T-test  
s0=1, fdr=5% 
GR-enriched? protein ID protein name 
Difference LFQ 
intensity 
pPR_LFQ 
intensity GFP 
   
5.06309128 GR-enriched Q5T653;C9IY40 MRPL2 
4.91249514 GR-enriched Q07021 C1QBP 
4.88959026 GR-enriched P09001;H0Y9G6 MRPL3 
4.80967426 GR-enriched Q9H9J2 MRPL44 
4.66591167 GR-enriched Q9BYD3;K7ES61 MRPL4 
4.63696957 GR-enriched Q96A35;X6RJ73 MRPL24 
4.50121355 GR-enriched Q8IXM3 MRPL41 
4.29837513 
 
Q9Y5K6 CD2AP 
4.23110867 GR-enriched Q9BYD2;Q5SZR1 MRPL9 
4.0637455 GR-enriched Q13405;H0YDP7 MRPL49 
3.97548103 GR-enriched Q9BYD6;H0Y8N7 MRPL1 
3.65711308 GR-enriched Q9NYK5;Q9NYK5-2 MRPL39 
3.64774752 GR-enriched Q16540;A6NJD9 MRPL23 
3.41399431 GR-enriched Q9P015;E5RIZ4 MRPL15 
3.25861359 GR-enriched Q9NRX2;E9PKV2 MRPL17 
3.19250822 GR-enriched Q9H0U6 MRPL18 
3.18459654 GR-enriched Q8N983-4;Q8N983 MRPL43 
3.18127441 GR-enriched Q9BRJ2;A0A087X2D5 MRPL45 
3.16544533 GR-enriched Q96DV4;Q96DV4-2 MRPL38 
3.04626703 GR-enriched Q8TAE8 GADD45GIP1 
3.01187754 GR-enriched Q9BYD1;E5RJI7 MRPL13 
3.01071358 GR-enriched Q9NWU5;E7ESL0 MRPL22 
2.97999954 GR-enriched Q9BZE1;S4R369 MRPL37 
2.95969963 GR-enriched P68431 HIST1H3A 
2.91059303 GR-enriched Q13084;A2IDC6 MRPL28 
2.8484726 GR-enriched Q9P0M9;D6RAN8 MRPL27 
2.80497026 GR-enriched Q9NP92;A0A087WV52 MRPS30 
2.65388632 GR-enriched Q8N5N7;Q8N5N7-2 MRPL50 
2.62585402 GR-enriched Q14197;J3KS15 ICT1 
2.62239504 GR-enriched Q9HD33;Q9HD33-2 MRPL47 
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 Table of Abbreviations 
abbreviation explanation 
°C degree Celsius 
µg micro gram 
µL micro liter 
µM micro molar 
A adenine 
AA amino acid 
ALS Amyotrophic Lateral Sclerosis 
ARS amino acyl tRNA synthetase 
ASO antisense oligo nucleotide 
ATP adenosine tri-phosphate 
BAC bacterial artificial chromosome 
BOP1 block of proliferation 1 
bp base pairs 
bp base pairs 
BSA bovine serum albumin 
bvFTD Behavioral FTD 
C cytosine 
c concentration 
C1QBP Complement 1q binding protein 
C9orf72 Chromosome 9 open reading frame 72 
Cas CRISPR associated 
CCDC40 Coiled-coil domain containing 40 
CD2AP CD2 associated protein 
cDNA complementary deoxyribonucleic acid 
ChIP chromatin immunoprecipitation 
CHMP2b Charged multivesicular body protein 2b 
CIP calf intestine phosphatase 
CLP1 Cleavage And Polyadenylation Factor 1 
cm centi meter 
CMT Charcot Marie Tooth (disease) 
CNS central nervous system 
COX16 cyclooxygenase 16 
CRISPR clustered regulatory intersperse short 
palindromic repeats 
CSF cerebrospinal fluid 
DAPI 4′,6-Diamidin-2-phenylindol 
DBA Diamond Backfan Anemia  
dd double destilled 
DENN Differentially expressed in normal and 
neoplastic cells 
DFC dense fibrillar compartment 
DIV days in vitro 
DNA deoxyribonucleic acid 
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dNTP deoxyribonucleotides 
DPR Dipeptide repeat 
DTT dithiothreitol 
EAAT2 excitatory amino acid transporter 2 
EDTA Ethylenediaminetetraacetic acid 
eIF eukaryotic initiation factor 
ELISA enzyme-linked immunosorbent assay 
ER Endoplasmic Reticulum  
ERK extracellular signal-regulated kinase 
FC fibrillar core 
FCCP Mesoxalonitrile  
4-trifluoromethoxyphenylhydrazone 
FCS fetal calf serum 
fig. Figure 
FMRP fragile X mental retardation protein 
FTD Frontotemporal Dementia 
FUS Fused in sarcoma 
G guanine 
G3BP Ras GTPase-activating protein-binding protein 1 
GA glycine-alanine 
GADD45A DNA damage inducible 45A 
GAPDH glycerinaldehyd-3-phosphat-dehydrogenase  
GC granular compartment 
GDP Guanosine di-phosphate 
GEF Guanosine exchange factor 
GFP green fluorescent protein 
GO gene ontology 
GP glycine-proline 
GR glycine-arginine 
GRN progranulin 
GTP Guanosine tri-phosphate 
GTPBP4 GTP binding protein 4 
h hour 
HA hemaglutinin tag 
HEK human embryonic kidney 
hnRNP heterogeneous nuclear ribonucleoprotein 
HRP horseradish peroxidase 
IF immunofluorescence 
IgG immunoglobulin G 
iPSC induced pluripotent stem cell 
IP immunoprecipitation 
kb kilo base pairs 
kDa kilo Dalton 
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KEOPS-EKC Endopeptidase and Other Proteins of small Size 
(KEOPS)/Endopeptidase-like and Kinase 
associated to transcribed Chromatin 
KO knock out 
L  liter 
LB lysogeny broth 
LCD low complexity domain 
LC-MS/MS liquid chromatography mass spectrometry 
LDH lactate dehydrogenase 
LLPS liquid liquid phase separation 
M molarity (mol/L)  
mA milli ampere 
MAGOHB mago nashi 
MAPT Microtubule-associated protein Tau 
MBNL1 muscleblind-like protein 1 
MEK1 mitogen-activated protein kinase kinase 
(MAP2K) 
min minute(s) 
mL milli liter 
mm milli meter 
mRNA messenger RNA 
MRPL mitochondrial ribosomal protein large subunit 
MRPS mitochondrial ribosomal protein small subunit 
MTCO1 mitochondrially encoded Cytochrome C oxidase 
I 
n quantity 
NACA nascent polypeptide-associated complex 
subunit alpha 
NCL nucleolin 
NEAA non-essential amino acid 
NES nuclear export sequence 
ng nano gram 
NLS nuclear localization signal 
nm nano meter 
NOC2L nucleolar complex protein 2 homolog 
NOP56 NucleOlar protein of 56.8 kDa 
NP-40 Nonidet-P40, nonylphenylpolyethylenglycol 
NPC nuclear pore complex 
NPM1 nucleophosmin 1 
NSC34 Neuroblastoma hybrid cell line 34 
nt nucleotides 
Nup nucleoporin 
OCR oxygen consumption rate 
OPT optineurin 
p probability value 
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PA proline-alanine 
PAGE poly-acrylamide gel electrophoresis 
PBS phosphate buffered saline 
PCH Pontocerebellar Hypoplasia 
PCR polymerase chain reaction 
PES1 Pescadillo homolog 
pH measure of the activity of the solvated hydrogen 
ion 
PNFA Progressive non-fluent aphasia 
pNFH phosphorylated neurofilament heavy chain 
Pom121 nuclear pore membrane protein 121 kDa 
PPA Primary progressive aphasia 
PR proline-arginine 
PRMT protein arginine methyltransferase 
Pur-a purine-riche element binding alpha 
qRT-PCR quantitative real time polymerase chain 
reaction 
Rab Ras-related in brain 
Ran RAs-related nuclear  
RanGAP GTPase-activating protein 
RBP RNA binding protein  
RCC1 regulator of chromosome condensation 1 
RNA ribonucleic acid 
ROS reactive oxygen species 
RPL ribosomal protein large subunit 
rpm revolution per minute 
RPS ribosomal protein small subunit 
rRNA ribosomal RNA 
RRP1 ribosomal RNA processing protein 1 
RT room temperature 
SCA8 Spinocerebellar ataxia type 8 
SDS sodium dodecyl sulfate 
sec second(s) 
SF3 splicing factor 3 
SG stress granule 
SMCR8 Smith-Magenis syndrome chromosomal region 
candidate gene 8 
SNRPB2 U2 small nuclear ribonucleoprotein B 
SOD1 Superoxide dismutase 1 
SQSTM1 Sequestome 1 
SRSF Serine and arginine rich splicing factors  
STAU Staufen 
SUnSET surface sensing of translation 
T thymidine 
TAR Transactive response 
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TCOF1 treacle ribosome biogenesis factor 1 
TDP Tar DNA binding protein 
TEMED N,N,N',N'-tetramethylethylenediamine 
TIA1 T-cell-restricted intracellular antigen-1 
TIMM9 translocase of the inner mitochondrial 
membrane 
TMP 3,3‘,5,5‘ tetramethylbenzidine 
TMX2 thioredoxin protein 2 
TNPO1 transportin 1 
TRA2 transformer 2 protein 
TREM2 Triggered receptor expressed on myeloid cells 
tRNA transfer RNA 
TSEN tRNA splicing endonuclease 
UBQLN Ubiquilin 
ULK1 Unc51-like kinase 
UPS Ubiquitin proteasome system 
UV ultraviolet  
V  volt 
V Volt 
VCP Valosin-containing protein 
WB  western blot 
WDR WD repeat domain 
wt wild type 
YBX1 Y-box binding protein 1 
YWHAZ Tyrosine 3-Monooxygenase/Tryptophan 5-
Monooxygenase Activation Protein Zeta 
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